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The poly (adenosine-diphosphate (ADP) ribose) polymerase (PARP) family of enzymes has 
been of interest to researchers and clinicians for over fifty years, especially the first member of 
the family, PARP1. This enzyme has become a target for cancer therapeutics due the reliance 
of highly proliferating cells on PARP1 for genomic maintenance. In the coming age of 
individualized medicine, however, highly specific therapeutic agents like PARP inhibitors are in 
need of similarly highly specific companion diagnostic agents. These kind of agents have been 
made possible with the quickly progressing field of molecular imaging. Specifically, positron 
emission tomography (PET) has enabled the clinician to observe functional information about 
patients at a whole body level, and non-invasively. Our goal was to develop and validate an 18F-
labeled PARP-targeted molecular imaging agent with the ultimate goal of translation to the 
clinical setting. To that end, we have developed [18F]PARPi and tested it in animal models of 
many different kinds of disease. Over and over again, we see that [18F]PARPi uptake clearly 
and specifically reveals information about PARP1 expression and therapeutic target 
engagement. This information could serve a crucial role in patient stratification and treatment 
monitoring where PARP targeted therapeutics are being considered. In addition, PARP targeted 
PET imaging provides a new diagnostic and prognostic tool for diseases that currently lack good 
options for this purpose. In summary, these investigations serve as preclinical validation of 
! v!
[18F]PARPi, and serve as the basis for future preclinical and clinical exploration of the 
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The poly (adenosine-diphosphate (ADP) ribose) polymerase (PARP) group of proteins is a 17 
member family of enzymes that share a similar catalytic domain1. PARP biology and PARP 
inhibitor technology has been widely studied and it is beyond the scope of this chapter to 
present a thorough review of the literature on this topic, about which an entire book of reviews 
has been written2. However, it is essential to present at least a brief overview of the PARP 
biology to understand the potential utility and limitations of PARP imaging agents, as well as the 
structural requirements of these agents. 
The PARP family of enzymes, sometimes referred to as ADP-ribosyltransferases (ARTs), plays 
many roles in the DNA repair process (Figure 1.1.1). The first enzyme discovered in this family,
 




















PARP1, is the most studied, but there is an increasing interest in other members of this family3,4. 
Only 6 members are thought to actually produce poly (ADP-ribose) (PAR) chains, and only 3 
PARPs (PARP1, PARP2, and PARP3) can bind to DNA. Interestingly, knockout mice can 
survive in the absence of PARP1 or PARP2, but not when both are deleted5. The same has 
been shown for PARP5A and PARP5B (also referred to as the tankyrase enzymes, TNKS1 and 
TNKS2)6. PARP1 is overexpressed (expression raised above that in the healthy cells of the 
analogous organ, e.g. breast cancer compared to normal breast tissue) in many cancer types, 
but the same has not been found for other PARP enzymes, including PARP27. Therefore, 
PARP1 is most relevant member of the PARP family for imaging applications and was the focus 
of all studies described in this work. 
1.2: PARP1 in the DNA Repair Response 
 
Figure 1.2.1.  Biological function of PARP1. PARP1 detects and binds to sites of DNA damage. 
PAR chain formation causes the unwinding of DNA from the histones and also recruits other 
DNA damage repair proteins to the damage site. Modified and reprinted from Ferraris. J Med 
Chem, 2010. 
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DNA endures thousands of lesions everyday from sources such as ionizing radiation and 
ultraviolet light and also through the normal process of proliferation. There are many proteins 
involved in the DNA damage response (DDR) with a wide range of functions that together serve 
to repair the DNA so that the cells can remain viable and functional (Figure 1.1.1). PARP1 has 
been shown to be especially important with concern to single strand breaks (SSBs) by being a 
critical factor in base excision repair (BER)8,9, although it also plays a role in other repair 
pathways such as homologous recombination repair (HR)10, non-homologous end joining 
(NHEJ)11 and nucleotide excision repair (NER)12. One major mechanism by which PARP1 aids 
in DNA repair is through the nicotinamide adenine dinucleotide (NAD) dependent ADP-
ribosylation of the histones or other chromatin proteins. The negatively charged polymers relax 
the tertiary structure of the chromatin which causes the DNA to unwind and allows other DNA 
repair factors access to the damage site13,14 (Figure 1.2.1). 
In addition to histone ribosylation, PARP1 aides in recruitment of other DNA factors through the 
high affinity of these factors to either PARP1 itself (e.g. TDP115) or to the PAR chains it creates 
(e.g. XRCC116). The subsequent dissociation of PARP1 from the DNA is also important to the 
repair process, without which other repair factors cannot access the damage site17. This is 
especially relevant to a recently discovered mechanism of PARP inhibitor induced cell killing, 
called PARP trapping18, which will elaborated upon in section 1.7 below. 
1.3: Two Enzymatic Conformations 
PARP1 is a 1014 amino acid, 113 kDa enzyme that can be thought of as consisting of seven 
discrete domains. Three zinc finger domains (Zn1-3) are responsible for detecting and binding 
to DNA damage sites19. These are attached to the catalytic subdomains through the BRCA1 
C-terminus domain (BRCT) and the tryptophan-glycine-arginine (WGR) domain. The BRCT 
domain serves as the primary target for automodification (also called autoPARylation)20, which 
will be discussed in section 1.4 below. The WGR domain has the primary function of 
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Figure 1.3.1.  Two enzyme conformations. Upon binding to DNA, PARP adopts a compact 
conformation that greatly elevates catalytic activity. Modified and reprinted from Langelier & 
Pascal, Curr Opin Struct Biol, 2013. 
 
communicating between the zinc finger domains at the catalytic domain (CAT)21. The catalytic 
domain consists of two subdomains, the helical subdomain (HD) and the ADP-ribosyl 
transferase subdomain (ART). The HD subdomain is the primary recipient of communication 
from the zinc fingers, and is primarily responsible for regulating the catalytic activity, which is 
increased when a certain leucine residue is displaced by the WGR domain21. The ART domain 
is the site which binds the NAD+ and performs the catalysis22,23. This domain serves as the basis 
for the definition of the PARP family, and is therefore conserved across all 17 members. 
The PARP1 enzyme exists in one of two different conformational states based on whether or 
not it is bound to DNA (Figure 1.3.1)24. While there is some catalytic activity (=PARylation) in the 
unbound conformation, binding to DNA causes a shift to a more compact conformation which 
increases catalytic activity more than 500-fold. Since the NAD+ substrate can be present in 
either of these conformations, nicotinamide mimicking imaging agents cannot differentiate 
between the relatively inactive unbound enzyme and the highly active bound enzyme. This is 
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important because it means that nicotinamide based tracers can not predict PARylation activity, 
but can only predict PARP enzyme expression. In fact, these kinds of tracers have only shown 
correlation with PARylation when this also correlated with PARP expression levels25, but not 
when these two variables did not correlate26. 
1.4: The Enzymatic Cycle 
PARP enzymes form linear or branched polymer chains composed of up to 200 ADP-ribose 
units14. By catalyzing the hydrolyzation of the NAD+ substrate, the enzymes are responsible for 
the three steps of PAR anabolism (Figure 1.4.1) by attaching a single ADP-ribose unit to either 
an acceptor protein (step 1, mono-ADP-ribosylation) or to another ADP-ribose unit (steps 2 & 3, 
elongation and branching). Acceptor proteins are modified at charged amino acids within the 
protein (lysine, arginine, glutamate or aspartate), and can be the enzyme itself (usually at the
 
Figure 1.4.1.  Chemical function of PARP1. Anabolism shown in red, catabolism shown in 
green. Glycosidic cleavage sites indicated by green arrows. Modified and reprinted from 
Rouleau et al. J Cell Sci, 2004. 
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BRCT domain, termed automodification), histones (especially the linker histone H1 and the core 
histones H2A and H2B), or high-mobility group (HMG) proteins. Whether elongation or 
branching occurs is based on which of the two ribose units accepts the addition on the acceptor 
ADP-ribose unit (Figure 1.4.1). Nicotinamide is produced as a byproduct of the hydrolyzation 
reaction and – without ADP-ribose  – acts as a mild inhibitor of PARP enzymes (PARP1 Ki = 5.7 
µM27) which serves to help regulate the enzymatic process. Branching occurs after 20-50 ADP-
ribose units, but does not occur with all members of the PARP family. Catabolism is performed 
by the poly (ADP-ribose) glycohydrolase (PARG) enzyme, which generates both free ADP-
ribose units and free PAR polymers by hydrolyzing glycosidic bonds either at the end of the 
polymer chain (exoglycosidic activity) or in the middle (endoglycosidic activity). 
1.5: PARP inhibitors 
PARP mediated DNA repair is important for the survival of many cancerous cell types, and 
leads to resistance against DNA damaging chemotherapeutics28. Therefore, PARP inhibitors 
were developed with the initial goal of working in combination with DNA damaging therapies 
such as certain chemotherapeutics and ionizing radiation to increase the DNA damage load 
while simultaneously decreasing the ability to repair such damage, eventually leading to cell 
death. In addition to combination therapy, by blocking BER, PARP inhibition leads to the 
accumulation of unrepaired single-strand DNA breaks (SSBs), which develop into double strand 
breaks (DSBs) in replicating cells. These DSBs require HR repair for continued cell survival. 
This leads to the possibility that PARP inhibition might be used as a monotherapy in cases 
where the cancer cells are deficient in this DNA repair pathways.  (e.g. BRCA1/2 mutants29). 
This approach has been termed “synthetic lethality”. 
The first inhibitors were simple modified benzamides based on the nicotinamide byproduct of 
the PAR synthesis, which, as was pointed out before, is itself a mild inhibitor. Benzamides were 
preferred for specificity reasons as nicotinamide is involved in a number of other cellular 
processes not related to PARP30. It was found that the ring nitrogen was unnecessary for PARP 
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Figure 1.5.1.  PARP inhibitors. Shown here are the NAD+ natural substrate PARP1 and a 
selection of nicotinamide mimicking PARP inhibitors including all of those that have reached 
phase 3 clinical trial. Iniparib is included even though it was shown not to be a PARP1 inhibitor 
after the unsuccessful conclusion of a phase 3 trial. Also shown are AG14361 and AG14031, 
which have inspired some imaging agent analogues, and UPF1069, which is currently the most 
selective inhibitor for PARP2. The nicotinamide mimicking moiety in each molecule is 






inhibition, but that without it, the molecule could not be metabolized by NAD-biosynthetic 
enzymes. It was further found that the amide moiety was necessary for the inhibitory effect, and 
that substitutions were best tolerated at the position -3. It was found that, in particular, hydrogen 
bond acceptors or donors at this position improved potency (e.g. Figure 1.5.1: rucaparib, 
veliparib and talazoparib). Additional studies showed improved potency when the amide was 
fused into a bicyclic31 or pseudo-bicyclic32  (e.g. Figure 1.5.1: veliparib and niraparib) ring 
system so that the amide is locked into the best conformation for PARP inhibition. It was also 
shown that a heteroatom in position -5 improves potency32 (e.g. Figure 1.5.1: rucaparib and 
talazoparib). Cocrystallization studies confirmed all of these findings and revealed a large 
hydrophobic pocket adjacent to the nicotinamide binding site referred to as the 
 
Figure 1.5.2.  Molecular design considerations for PARP inhibitors. (a) Schematic drawing from 
cocrystallization studies showing hydrogen bonds (dashed lines) and hydrophobic contacts 
(parallel lines). Modified and reprinted from Ruf et al. Biochemistry. 1998. (b) Summary of 
inhibitor design principles. Modified and reprinted from Ferraris. J Med Chem, 2010. 
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adenine-ribose binding site (Figure 1.5.2a)23. Further development of inhibitors uses this pocket 
to add groups to improve potency, solubility, or other properties (Figure 1.5.2b)33. 
To date, six PARP inhibitors have reached stage three clinical trials. One of them, iniparib, was 
shown to not be a true PARP inhibitor only after it had entered stage three trials. Although 
iniparib showed positive results in phase two trials with triple negative breast cancer (TNBS)34, 
the drug failed in phase three35. In fact, the failure of iniparib might have been the end of clinical 
evaluation of PARP inhibitor therapy in general had it not been discovered that iniparib is in fact  
not actually a PARP inhibitor at all36. These studies show the importance of proper preclinical 
evaluation of potential therapeutics before they enter clinical trials37. Furthermore this validates 
the development of PARP imaging agents insofar as these imaging agents might serve as tools 
for evaluating therapeutics before they reach the clinic. 
Of the other five inhibitors (Table 1.5.1), three have made it to FDA approval. The first was 
olaparib, which was approved in December 2014 for treatment of BRCA mutated advanced 
stage ovarian cancer38. Since then, two others, rucaparib in December 201639 and niraparib in 
March 201740 have been approved for the same disease. In addition to these successes, there 
have been two phase three failures for veliparib, one in non small cell lung cancer (NSCLC) and 
the other in TNBS. Unlike iniparib’s failure, it is possible in these cases that failure does not
Table 1.5.1.  Properties of PARP inhibitors and summary of trial information. 
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mean that veliparib is completely ineffective. For instance, it could be that only a certain patient 
subgroup responds and therefore patient selection has to be improved. This is something that 
PARP imaging agents could be useful for. There is one other late stage PARP inhibitor, 
talazoparib, for which phase three results have not yet been reported, but looks promising in 
preclinical studies due to its superior trapping ability. 
1.6: Rucaparib and olaparib 
Most of the imaging agents presented in the following sections are based on either rucaparib or 
olaparib, both of which have been FDA approved for the treatment of advanced stage ovarian 
cancer. As such, it is helpful to provide an overview of the evolution of the chemical structures of 
each of these compounds in order to better understand the possibilities each provides for 
modification with respect to the introduction of an imaging moiety. 
1.6.1 Rucaparib 
The development of rucaparib (Figure 1.6.1) began with the identification of benzimidazole 
carboxamide as a particularly potent pharmacophore (Ki = 95 nM)41. It was then found that 
addition of a benzene ring to position -2 significantly increases potency (Ki = 15 nM with H 
instead of OH in Figure 1.6.1). These bicyclic compounds displayed potent in vitro activity but 
suffered from problems such as poor specificity, poor physical properties (low solubility, low 
melting points), and unfavorable pharmacokinetic profiles, or had in vivo side effects42. These 
problems were overcome by locking the benzamide in the s-trans conformation via a ring 
connection. The incorporation of ionizable substituents in the benzene ring was mainly to 
improve solubility, although an improvement in potency was also noticed. Further optimization 
resulted in the eventual clinical candidate43, but the important thing to note here is that the 
imaging agents based on rucaparib all sacrifice the ionizable benzene substituents in order to 
attach the imaging moiety, hence potentially sacrificing potency and solubility. 
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Figure 1.6.1.  Evolution of the chemical structure of rucaparib. Modified and reprinted from 
Ferraris. J Med Chem, 2010. 
 
1.6.2 Olaparib  
The development of olaparib began with the several bicyclic compounds, the most successful of 
which was phthalazinone44. As with rucaparib, the addition of a benzene ring improved potency. 
The fluoro substitution at the para position on this benzene ring was found to increase cellular 
potency more than two-fold45. Further studies showed that a wide variety of substituents were 
tolerated at the meta position on the benzene ring46, and this was exploited to introduce a 
piperazine, which greatly improved aqueous solubility. However, clinical demand necessitated 
further optimization to improve oral availability. It was reasoned that oral availability was 
impeded mainly by the high pKa of the secondary amine of the piperazine group, and so several 
acyl substitutions were studied, with cyclopropyl methanone chosen in the end because it 
showed improved cellular potency compared with methyl and ethyl acyl groups. It is important to 
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Figure 1.6.2.  Evolution of the chemical structure of olaparib. Modified and reprinted from 
Ferraris. J Med Chem, 2010. 
 
highlight that this cyclopropyl had only a modest effect on inhibitory potency, since this group is 
replaced in all of the imaging agents based on olaparib. 
After it was revealed that olaparib is a P-glycoprotein (P-gp) substrate47,48, which caused drug 
resistance by rapid removal of olaparib from the intracellular space, AZD2461 was developed as 
a close analogue to olaparib but with lower P-gp affinity49. AZD2461 replaced olaparib’s 
1-cyclopropylcarbonyl-piperazine with a 4-methoxy-piperidine. It is notable that, although 
PARP1 affinity is unaffected by this substitution, PARP3 affinity is greatly reduced in AZD2461 
compared to olaparib50. This is important because all of the imaging agents based on olaparib 
also replace the cyclopropyl group, not to decrease P-gp affinity but to add imaging functionality. 
The imaging agents that have been examined with regard to PARP3 affinity also show 
decreased PARP3 affinity compared to olaparib (see Figure 6.2.1 in chapter 6 below). 
1.7 Talazoparib and PARP trapping 
Talazoparib plays an important role in the small cell lung cancer (SCLC) studies presented in 
chapter 6. This molecule is of particular interest in SCLC due to its superior PARP trapping 
properties (Table 1.5.1), which have been found to be especially important for the treatment of 
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SCLC in particular51 and could prove to have wide ranging ramifications for PARP treatment in 
general. As such, it is useful to here give an overview of this mechanism of action, which is 
different from the normal inhibitory mechanism that was the aim of the original development of 
the first PARP inhibitors. 
PARP trapping is a process where prolonged binding of a PARP inhibitor prevents dissociation 
of the PARP enzyme from the damage site on DNA, which prevents DNA replication and 
transcription9. While catalytic inhibition blocks BER and leads to synthetic lethality in cells 
deficient in HR (see section 1.5), PARP trapping is thought to lead to many different kinds of 
damage requiring many different kinds of repair. Mutations affecting these other repair pathways 
cause sensitivity to trapping agents such as olaparib and rucaparib, but not to inhibitors showing 
poor trapping ability such as veliparib52, which leads to much greater potential for monotherapy 
options. The trapping mechanism was demonstrated by detecting PARP DNA complexes in 
cells treated with PARP inhibitors52. Trapped PARP–DNA complexes are more cytotoxic than 
unrepaired SSBs caused by PARP inactivation, and the mechanism also explains why PARP 
inhibitors exhibit significantly greater cytotoxicity than the absence of PARP1 altogether, and 
why the cytotoxicity of PARP inhibitors was eliminated by deletion of the PARP1 gene (Figure 
1.7.1)52,53. This has lead to the question of whether PARP inhibition could be used by itself as 
DNA damaging agent for use as a monotherapy in the treatment of cancer. 
 
Figure 1.7.1.  Enzymatic requirements of PARP inhibitor treatment. Modified and reprinted from 
Murai et al. Mol Cancer Ther, 2014. 
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One important note here is that although the PARP trapping mechanism is not independent of 
the catalytic inhibition mechanism of PARP inhibitors, the trapping ability of a PARP inhibitor 
does not track with its ability to inhibit PARylation (synthesis of PAR chains)52,54. The trapping 
ability has been shown to be dependent on the structure of the molecule, especially that part of 
the structure outside of the nicotinamide mimicking moiety. For instance, olaparib and 
talazoparib have the same phthalazinone core, but very different trapping properties53. 
Talazoparib’s trapping ability is said to be highly dependent on its stereochemistry outside the 
phthalazinone core53, although its enantiomer, LT674, is also several orders of magnitude lower 
in inhibitory potency (IC50 = 144 nM)55. 
The elucidation of the PARP trapping mechanism may revolutionize the development of PARP 
inhibitor therapy, although it is important to note that trapping ability also correlates with greater 
toxicity to normal tissue54. Dosing limitation due to this toxicity may prove to be proportionally 
disadvantageous to the benefit of greater trapping ability. This trapping mechanism is also an 
interesting area of exploration for PARP imaging agents as well, and it is even true that since 
PARP imaging agents are themselves inhibitors, the imaging agents themselves must also 
exhibit this trapping property. However, it remains to be seen whether this property has any 
effect on a PARP imaging agent’s utility. 
1.8: Conclusion  
The design and scope of PARP imaging research is grounded in the PARP research 
accumulated over the past fifty years, and what has been presented here is only a short 
summary. Although much progress has been made in this field of study, there are still many 
areas that need further exploration, and PARP imaging technologies could prove to be 
extremely powerful tools in this area. The ultimate goal, however, of the development of PARP 
imaging agents is their clinical translation. PARP inhibition therapy is rapidly being implemented 
in the clinic, and it is likely that this kind of therapy will find relevance in a variety of diseases. As 
PARP imaging agents begin to enter the clinic, these imaging techniques may begin to play a 
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central role in the implementation of PARP targeted therapies. With the recent push towards 
personalized medicine56, and the patient stratification and treatment monitoring techniques 
offered by highly specific imaging agents, PARP imaging agents have the potential to provide 
essential information to the clinicians who are providing PARP targeted therapies. It is with this 





CHAPTER 2: PARP IMAGING AGENTS 
This chapter is an adaptation of published work, and is reproduced in part, from Carney, B., 
Kossatz, S. & Reiner, T. Molecular Imaging of PARP. J Nucl Med (2017). Copyright 
 
2.1: Introduction 
Biomedical imaging has revolutionized medical science. Preclinically, it has helped to transform 
our understanding of biology, and clinically, it has greatly advanced our ability to diagnose and 
treat disease. Our goal has been to develop imaging agents based on PARP inhibitor 
technology so that we can take advantage of the preclinical and clinical benefits that biomedical 
imaging offers. PARP based optical imaging agents could be used for both diagnostic purposes 
and to improve surgical procedures through intraoperative imaging. Radiolabeled probes would 
allow direct measurement of PARP expression in patients, with the goal of improving patient 
stratification, quantification of target engagement of therapeutic inhibitors and non-invasive 
treatment monitoring. It is with these goals in mind that we describe the current state of the art 
of PARP imaging technology. 
2.2: Fluorescently Labeled PARP Imaging Agents 
The development of optical PARP agents is challenged by the intranuclear localization of 
PARP1/2. Hence, imaging requires targeting vectors that can freely cross both cell membranes 
and the nuclear envelope, and do not lose this ability after their conjugation with a fluorescent 
dye.  
2.2.1: BODIPY Labeled Compounds 
The most published optical PARP reporter, PARPi-FL1–12  (half maximal inhibitory concentration 
(IC50)=12.2 nM), is structurally similar to the Food and Drug Administration approved olaparib13 
(IC50=5.0 nM14). The fluorescence signal of PARPi-FL stems from the dye BODIPY-FL 
(excitation maximum/emission maximum, 503/512 nm), which was covalently linked to the 
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Figure 2.2.1.  Fluorescent PARP imaging agents. Nicotinamide mimicking benzamide moiety is 




Table 2.2.1.  Properties of fluorescent PARP imaging agents. 
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olaparib scaffold (Fig. 1)9. High-contrast imaging of PARP1-expressing nuclei in vitro and in vivo 
implies high cell permeability and rapid washout of unbound PARPi-FL3,5,7,9,12, indicating that the 
dye conjugation and resulting increase in molecular weight (PARPi-FL, 640 g/mol; olaparib, 435 
g/mol) do not strongly perturb the molecule’s binding affinity and cell permeability. Uptake 
specificity was shown by correlation of PARP1 protein expression and PARPi-FL retention, as 
well as by the ability to block PARPi-FL uptake by saturating PARP with olaparib9. One set of 
studies3,4 presented PARPi-FL as a tool to measure drug–target interaction in real time at 
subcellular resolution in vitro and in vivo using multiphoton fluorescence anisotropy microscopy. 
The anisotropy value of an excited fluorophore is linked to its mobility and hence provides 
insight into its binding state. The earlier study3 showed anisotropy measurements of PARPi-FL 
in vivo using a window chamber model. Later4, an indirect anisotropy approach was used to 
measure pharmacodynamic parameters of olaparib, allowing the identification of single cells that 
featured a low occupancy despite a high average target engagement. 
Another study1 presented an activatable version of PARPi-FL where an inactive, photo-caged 
BODIPY dye was conjugated to the olaparib scaffold (PARPi-BODIPYc; IC50=32nM). Ultraviolet 
light (350-410 nm) converted it to its fluorescent version, PARPi-BODIPYa (IC50=68nM) by 
photolytic cleavage of the 2,6-dinitrobenzyl caging group. Up to 3 hours of washing were 
required to receive a crisp nuclear signal of PARPi-BODIPYa, compared to 10 minutes for 
PARPi-FL, indicating decreased cell permeability and clearance (Figure 2.2.2a).  
PARPi-FL is the only optical PARP imaging agent that has been verified to accumulate in 
tumors in vivo. The first study5 to do so used PARPi-FL to image U87 and U251 orthotopic and 
subcutaneous glioblastoma xenografts ex vivo and found tumor/brain and tumor/muscle ratios 
>10 at 1 hour p.i. (i.v.), suggesting that PARPi-FL could be useful for intraoperative imaging of 
glioblastoma. PARPi-FL was also used for imaging of oral squamous cell carcinoma (OSCC). 
One study6 found increased PARPi-FL uptake 48 hours after irradiation which correlated with an 
increased PARP1 expression, suggesting that tumor response to radiation can be quantified. 
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Another study7 showed specific high contrast imaging (tumor to muscle/trachea/tongue ratios 
>3) in orthotopic OSCC models 90 min p.i. using clinical imaging instruments including a 
fluorescence endomicroscope and a surgical stereoscope (Figure 2.2.2b). This study also 
showed the feasibility of topical application of PARPi-FL, which accumulated in OSCC tumors 
after a 2 min application interval and reported penetration and nuclear accumulation of 
PARPi-FL >250 µm deep into tumor tissue (Figure 2.2.2c).  
 
Figure 2.2.2.  Fluorescent PARP imaging agents1,7,12,15. (a) In vitro staining with various 
fluorescent PARP inhibitors. (b) In vivo imaging of orthotopic oral squamous cell carcinoma with 
PARPi-FL using fluorescence stereoscope, confirmed by histology. (c) In vivo imaging of 
orthotopic oral squamous cell carcinoma xenografts after a 2-min topical application of 




2.2.2: Optical imaging of PARP1 in the NIR 
PARPi-FL is limited by low tissue penetration of the BODIPY-FL fluorescence (Exmax/Emmax: 
502nm/510nm). Imaging in the near infrared (NIR) spectrum (600-900nm) would allow for 
improved tissue penetration and therefore higher signal to background. AZD2281-TexasRed16 
(IC50=15.4nM; 596nm/615nm), was produced by bioorthogonal trans-cycloctene 
(TCO)/tetrazine(Tz) cycloaddition. In vitro imaging showed nuclear accumulation after first 
adding TexasRed-Tz, followed by AZD2281-TCO (Figure 2.2.2a), while a pre-reacted full-sized 
AZD2281-TexasRed (1536 g/mol) showed reduced cell permeation. A study17 that adapted this 
modular approach using AZD2281-TCO and Cy5-Tz also showed in vitro nuclear staining, but 
did not report IC50 values.  A labeling strategy similar to PARPi-FL produced 
Olaparib-BODIPY65012 (IC50=92nM; 646/660nm, 895 g/mol). The increase in size and 
hydrophilicity (cLogP of 6.0; PARPi-FL: 4.0) presumably affected permeability and off-target 
clearance, requiring in vitro washing intervals of 2 hours to visualize the nuclear staining (Figure 
2.2.2a). 
Charge was also reported as a significant factor in cellular distribution15. One study labeled 
olaparib with a new class of cell permeable silicon containing rhodamines (SiR, 653/670nm). 
These SiRs contained either a methyl group (SiR-Me) or a carboxyl group conjugated directly 
(SiR-COOH) or via a short aliphatic spacer (SiR-spacer-COOH). Olaparib-SiR-Me (IC50=99nM; 
MW=792 g/mol; cLogP=4.23) was cell permeable but only accumulated in mitochondria. The 
negatively charged Olaparib-SiR-COOH (IC50=100nM; MW=822 g/mol; cLogP=3.74) showed 
cytoplasmic staining, comparable to Olaparib-BODIPY 650. However, Olaparib-spacer-SiR-
COOH (IC50=112nM; MW=978 g/mol; cLogP=3.59) allowed imaging of nuclear PARP1, 
following a standard PARPi-FL staining protocol with a short wash (Figure 2.2.2a). This 
indicates that neutralization of the negative charge of SiR-COOH and increased hydrophobicity 
introduced by the spacer outweighed the handicap of the higher molecular weight. 
In conclusion, retention of fast cell permeation and rapid clearance of optical PARPi is most 
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essential for their performance. Although in vitro PARP1 staining has been shown for the NIR 
probes AZD2281-TexasRed and Olaparib-spacer-SiR-COOH, their in vivo performance remains 
unknown. Despite the general trend to move toward the NIR for optical imaging, in the specific 
case of PARP1 imaging, BODIPY-FL labeling currently remains the most promising approach. 
Its brightness, resulting from a high maximum absorption and high quantum yield, could even 
prove advantageous over most NIR fluorochromes when considering intraoperative imaging and 
detection of surface tumors where limited tissue penetration is not impeding the diagnostic 
value. 
2.3: Radiolabeled Compounds 
2.3.1: The First Radiolabeled PARP Inhibitors 
The first radiolabeled PARPi was developed for imaging the PARP1 hyperactivation in diabetes 
type I related necrosis. [11C]PJ3418 was based on PJ34 (IC50=170.2 nM19), which showed 
promise as a therapeutic agent for diabetes related endothelial dysfunction20. A rat model of 
type I diabetes showed higher uptake of [11C]PJ34 relative to untreated controls in the liver and 
the pancreas, indicating that [11C]PJ34 was capable of detecting disease related increased 
PARP1 activity. 
The first 18F labeled PARPi, [18F]FE-LS-75 (Ki=200nM)21, was designed to investigate the 
potential of LS-75 (Ki=18nM) to act as a neuroprotective agent by regulating PARP1 activity. 
[18F]FE-LS-75 was stable in plasma over 120 min, but no further biological studies have been 
published. 
2.3.2: Olaparib Based Tracers 
The first radiolabeled PARPi with structural similarity to olaparib used for PET imaging was 
18F-BO (IC50=17.9nM). Analogous to the fluorescent compounds, the cyclopropyl group of 
olaparib was replaced with an 18F labeled moiety. The probe was synthesized by TCO/Tz 
bioorthogonal click chemistry and purified either by conventional semipreparative HPLC22, or 




Figure 2.3.1.  Radiolabeled PARP imaging agents. Nicotinamide mimicking benzamide moiety 
is highlighted in blue, fluorescent moieties are highlighted in green, and radioactive nuclides are 




Table 2.3.1.  Properties of fluorescent PARP imaging agents. 
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cancer cells showed higher uptake of 18F-BO in MDA-MB-436 compared to MDA-MB-231 cells, 
which coincided with PARP1 expression. MDA-MB-436 xenografts showed an SUV of 0.9, and 
specificity was shown by blocking with 100mg/kg olaparib 12 hours prior to 18F-BO imaging, 
which reduced the SUV to 0.4. 18F-BO uptake also correlated to PARP1 expression in ovarian 
(SCOV3, A2780) and pancreatic (MIAPaCa-2, PANC-1) tumor models9. To evaluate the 
potential of 18F-BO to monitor treatment response, A2780 xenograft bearing mice were treated 
with therapeutic doses of olaparib and imaged with 18F-BO and FDG before and after treatment. 
18F-BO showed a drop in tumor/muscle ratio from 3.8 to 1.3 after treatment with olaparib, while 
no changes were observed for FDG. This shows PARP targeted specificity for 18F-BO but no 
specificity for FDG. 
The other olaparib based radiotracers, 18F-PARPi-FL and [18F]PARPi are the main subjects of 
this work in general and will be greatly elaborated upon in the following chapters. However, a 
brief summery will be given here. 
18F-PARPi-FL24,25 is a radiolabeled analog of PARPi-FL and currently the only dual modal 
PET/fluorescent PARP probe available. The radiosynthesis was achieved via Lewis acid 
assisted fluoride exchange with either triflic anhydride24 or tin tetrachloride25. With this kind of 
reaction, it was only possible to produce 18F-PARPi-FL with a maximum specific activity of just 
333 MBq/µmol. Irrespective of this, PET images showed tumor uptake, and quantification of 
18F-PARPi-FL in U87 glioblastoma xenografts at 2 hours p.i. showed a tumor standard uptake 
value (SUV) of 1.1. Blocking with 50 mg/kg olaparib reduced the SUV by 91% to 0.1, which was 
a strong improvement compared to 18F-BO, where blocking reduced the SUV by only 56%. Dual 
modal functionality was confirmed using epifluorescence imaging and autoradiography, where 
similar tumor/brain ratios between the radioactive (9:1) and fluorescent (7:1) signals were found. 
PET and biodistribution data, however, also revealed a relatively high signal in the bone (>10 
%ID/g), indicating that 18F-PARPi-FL suffered from defluorination in vivo.  
[18F]PARPi2,8 sacrificed BODIPY FL for a highly stable fluorobenzene ring without negatively 
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affecting uptake and specificity. [18F]PARPi uptake in orthotopic U251 glioblastoma xenografts2 
was increased to 2.2 %ID/g (18F-PARPi-FL: 0.8 %ID/g), with the similarly high specificity (87% 
blocking; 18F-PARPi-FL: 81%). Autoradiography revealed very high tumor/brain and 
tumor/muscle ratios (700:1 and 30:1). Biodistribution studies with subcutaneous xenografts 
confirmed the uptake and specificity findings. Bone uptake was much lower compared to 18F 
PARPi FL and could also be blocked by olaparib (83% reduction in uptake), indicating specific 
uptake rather than defluorination. [18F]PARPi was also evaluated for imaging of diffuse intrinsic 
pontine glioma in a genetically engineered mouse model8. This malignancy is difficult to monitor 
with established methods, and has seen very limited progress in terms of treatment options over 
the past decades26. Autoradiography and PET imaging showed localized, specific uptake. 
[18F]PARPi could also be used to monitor tumor progression non-invasively over several weeks, 
suggesting potential therapy monitoring applications. 
In addition to fluorinated PARPi, the iodinated compound 124/131I-PARPi10,27 (IC50=9nM) was 
developed. It is chemically identical to [18F]PARPi except that 131I  (single-photon emission 
computed tomography) or 124I (PET), takes the place of 18F in the halogenated benzene ring. 
Like [18F]PARPi, 124/131I-PARPi studies were first performed in orthotopic U251 tumors10. 
Autoradiography showed high tumor/brain (16:1) and tumor/muscle (6:1) ratios and high 
specificity (65% blocking). Single-photon emission computed tomography imaging with 
131I-PARPi was possible, and PET quantification with 124I-PARPi showed 0.43 %ID/g tumor 
uptake and a tumor/brain ratio of 40:1. A later study27 showed an alternative synthetic route to 
this radioiodinated PARPi with 123I and 125I. The study presented a single step iodination using a 
solid-state halogen exchange with a Br leaving group – producing higher overall yields and 
specific activities.   
2.3.3: Rucaparib Based Tracers 
Rucaparib (Ki=1.4nM28), the second Food and Drug Administration approved PARPi, has also 
inspired radiolabeled analogs, which are based on the former lead compound AG14361 
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(Ki=5.8nM). AG14361, which has been shown to be specific to PARP1 28, and its derived 
radiotracers feature a benzimidazole instead of rucaparib’s fluorinated indole. 
[18F]FluorThanatrace19,29–31 ([18F]FTT, IC50=6.3nM), which replaces dimethyl phenyl 
methanamine on AG14361 with 18F fluoroethoxy benzene, was first tested in MDA-MB-436 and 
MDA-MB-231 xenografts. PET imaging showed 3-5 %ID/g tumor uptake after 60 min, which 
was reduced to 2 %ID/g after olaparib blocking. [18F]FTT uptake was imaged in BRCA mutant 
(HCC1937) and compared to BRCA wild type (MDA-MB-231 and MCF7) tumor models. In vitro 
[18F]FTT uptake, reported as specific binding ratios in which nonspecific binding was subtracted, 
correlated with PARP1 and PAR levels, which were higher in BRCA mutant cells. PET imaging 
showed higher tumor/muscle ratios for HCC1937 (1.9:1) compared to MDA-MB-231 (1.5:1) and 
MCF7 (1.2:1). A different study29 compared in vitro [18F]FTT uptake in BRCA mutant (SNU-251) 
and wild type (SCOV-3) ovarian cancer cells. Again, it was shown that specific binding ratios 
correlated with PARP1 and PAR, which showed higher levels in SNU-251. It was further shown 
that BRCA mutant SNU-251 were more sensitive to PARP inhibition and radiation therapy than 
SCOV-3 cells. These findings suggest that [18F]FTT might be used to predict treatment efficacy 
using PARP inhibitor therapy, radiation or a combination of the two. 
In addition to [18F]FTT, there are two iodinated32,33 compounds based on the benzimidazole 
scaffold of AG14361. [125I]KX1 (Ki<8nM) is structurally identical to [18F]FTT except that 125I 
replaces the fluorethoxy moiety32,33. It was shown in vitro that [125I]KX1 correlated with PARP1 
expression in a panel of breast and ovarian  cancer cell lines, but not with PAR, as observed 
with [18F]FTT. Biodistribution showed that HCC1937 tumors had significantly higher uptake than 
MDA-MB-231, corresponding to PARP1 expression levels. Blocking with olaparib reduced 
[125I]KX1 uptake in HCC1937 tumors, but this was not statistically significant. No blocking was 
seen for MDA-MB-231. Autoradiographically, unblocked/blocked ratios of 2.7:1 for HCC1937 
and 0.92:1 for MDA-MB-231 tumors were found.  
Another study33 presented [125I]KX-02-019 (Ki=13.9 nM), a modified version of [125I]KX1, which 
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features a bicyclic instead of a tricyclic benzimidazole. [125I]KX-02-019 is a close analog of 
AG1403234 (Ki=6.7 nM), another rucaparib predecessor, with its chloride replaced by 125I. In vitro 
studies showed that [125I]KX-02-019 had higher specific binding ratios to PARP1 knockout 
mouse embryonic fibroblasts compared to either [18F]FTT or [125I]KX1. Biodistribution with 
EMT-6 murine mammary carcinoma bearing mice showed uptake close to 1 %ID/g at 2 hours 
with a tumor/muscle ratio of about 5. 
2.4: Clinical Translation of PARP Imaging Agents 
[18F]FTT is the first PARP targeted radiotracer that has been tested in humans 
(NCT02469129)31. [18F]FTT was tested in 8 healthy volunteers and in 8 patients with a variety of 
malignancies. It was found that, with a 370 MBq dose, the total effective dose was 5.1 mSv for 
males and 6.9 mSv for females, with the highest uptake in the spleen, pancreas and liver. PET
 
Figure 2.4.1.  First-in-human [18F]FTT study31. (a) Representative maximum-intensity projection 
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from healthy volunteer. (b) [18F]FTT uptake in liver metastasis (arrows) from patient with 
biphenotypic hepatocellular carcinoma and cholangiocarcinoma. 
 
images showed increased uptake in tumor regions for two patients, one with recurrent 
pancreatic ductal adenocarcinoma, and the other with biphenotypic hepatocellular 
carcinoma/cholangiocarcinoma (Figure 2.4.1). In addition to this, one phase I/II study recently 
opened to evaluate PARPi-FL for early detection of oral cancer after topical application 
(NCT03085147). The addition of molecularly targeted fluorescence contrast for visual tumor 
detection and navigation during surgery could represent an asset for physicians to discriminate 
healthy tissue and malignant growth. 
2.5: Conclusion 
PARP has been shown to be an interesting and valuable target for imaging. A wide variety of 
cancer types have been imaged with diverse clinical applications in mind. These include 
fluorescence assisted screening and diagnosis, intraoperative fluorescence guided surgery and 
PET guided patient stratification and treatment monitoring. Although the first PARP imaging 
agent was reported a mere 12 years ago, there are already two compounds in clinical trials. 
While, preclinically, PARP imaging agents are powerful tools for understanding the biology 
behind the DNA damage response system, the ultimate translational and clinical aims of these 
agents are to provide a real and tangible improvement in overall patient care. 
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CHAPTER 3: 18F-PARPI-FL  
This chapter is an adaptation of published work, and is reproduced in part, from Carlucci, G., 
Carney, B., Brand, C., Kossatz, S., Irwin, C. P., Carlin, S. D., Keliher, E. J., Weber, W. & Reiner, 




Among molecular imaging techniques, PET In particular has become one of the most prevalent 
in the clinical setting, emerging as one of the key diagnostic tools for whole-body imaging of 
cancer in the clinic. PET imaging is highly sensitive as well as quantitative and provides a 
resolution of tumors on a lesion-by-lesion basis. However, the technology does not outperform 
other imaging technologies in every aspect. PET is expensive, it exposes the patient to ionizing 
radiation, and it has poor temporal and spatial resolution1,2. 
Several features of intraoperative fluorescence imaging are orthogonal to PET: the fluorescently 
emitted light—typically in the visible and near-infrared (NIR) range—is heavily attenuated, which 
prevents deep-tissue imaging. However, intraoperative fluorescence imaging provides much 
higher (up to sub-cellular) resolution and has recently been used to add artificial optical contrast 
during surgical interventions3,4. This technique could become an important tool in the operating 
room and help to achieve more complete tumor resections, but it still lacks the deep tissue 
penetration to discover growths buried deep in the patient tissue as PET imaging is able to do. 
The creation of targeted bimodal probes, which fuse the benefits of different types of imaging 
agents, could lead to better and more accurate location of diseased tissue5,6. Bimodal 
intraoperative and deep tissue contrast could ultimately become particularly important for the 
surgical resection of glioblastoma, a highly infiltrative disease, where resection often remains 
incomplete7–9. Recently, it was demonstrated that enhanced fluorescent contrast agents 
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facilitate more complete resection of glioblastoma. The use of contrast-enhancing 
5-aminolevulinic acid during neurosurgical resections of glioblastoma resulted in a 6-month 
improved progression free survival4. 
Different reports have shown that the nuclear DNA repair enzyme PARP1 is overexpressed in a 
variety of diseases and that the expression levels of PARP1 have prognostic value10–13. This is 
evidenced in brain malignancies with elevated rates of PARP1 that contrast significantly with the 
low PARP1 protein content in healthy brain tissue14,15. Following these findings, we have shown 
that the elevated PARP1 expression can be exploited to image glioblastoma in mouse models 
of cancer with PARPi-FL, a fluorescently labeled PARP1-targeted imaging agent16–18. Similar to 
other fluorescent imaging agents, however, the tissue penetration depth of PARPi-FL is limited. 
Therefore, we hypothesized that a bimodal version of this small molecule would allow the 
detection of glioblastoma—both noninvasively using PET and at high resolution using 
fluorescence imaging. The goal of the current study was to use a 18F/19F exchange reaction19–22 
to transform the fluorescent PARPi-FL molecule into a structurally identical but PET-active 
imaging agent, 18F-PARPi-FL22. In the current study, we show that the PARPi-FL can be 
radiolabeled and used to augment the limitations of the “fluorescence only” intraoperative 
imaging molecule. 
3.2: Radiosynthesis of 18F-PARPi-FL  
The molecular structure of PARPi-FL is based on the PARP1 inhibitor olaparib18,23. Figure 
3.2.1a  (top) shows both the PARP1 targeting 2H-phthalazin-1-one scaffold of the small 
molecule (blue) as well as its fluorescent BODIPY-FL component (orange). In 18F/19F trans-
fluorination, one of the BODIPY-FL fluorine atoms is exchanged with 18F−, generating a bimodal, 
but otherwise structurally identical version of the fluorescent imaging agent (Figure 3.2.1a 
bottom). Based on previous reports19–22, we devised an automated strategy to generate the 
radiolabeled bimodal 18F-PARPi-FL (Figure 3.2.1b). The 18F/19F exchange was facilitated by the 
Lewis acid SnCl4 (Figure 3.2.2), yielding the targeted dual-modality imaging agent, as
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Figure 3.2.1. 18F-PARPi-FL synthesis. (a) Structure of PARPi-FL (top) and 18F-PARPi-FL 
(bottom). (b) Flow diagram for automated synthesis. 
 
 
Figure 3.2.2. 18F-PARPi-FL radiosynthesis scheme. The radiotracer was produced in a single 
step through a Lewis acid assisted isotope exchange.  
 
determined by reversed-phase HPLC and confirmed by mass spectrometry (MS) analysis 
[C34H32BF3N6O3: expected ESI-MS=640.2; observed ESIMS 639.2 (M-H+); Figures A.3.1 and 
A.3.2]. The manual execution of the 19F/18F trans-fluorination yielded specific activities of 2.9 ± 
0.7 mCi/µmol, with isolated radiochemical yields of 23 ± 8.2 % and radiochemical purities of 85 
± 9.8 %. The manual synthesis required 90 min, including HPLC purification, evaporation of 
solvents, and formulation of an injectable solution. For the optimization procedure, one condition 
at a time (time, temperature, concentration of starting material, starting activity, reaction volume, 
and concentration of SnCl4) was varied in order to find optimal reaction parameters (Figure 
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3.2.3a). Radiochemical yields correlated to the amount of 18F− starting activity (34.8 ± 1.1 % with 
45 mCi of 18F−). Yields were also seen to increase with decreasing amounts of SnCl4 [40.6 ± 3.3 
% with 10 eq. SnCl4 (µmol)/PARPi-FL (µmol)]. The specific activity was proportional to the 
activity of added 18F. With increasing temperature and SnCl4, the yields decreased, presumably 
due to larger fractions of PARPi-FL being subjected to degradation. Longer reaction times did 
not markedly increase the labeling yield. The automated 18F-PARPi-FL synthesis was beneficial 
compared to the manual process  (Figure 3.2.3b). Based on our screening, we were able to 
increase the specific activity by 266 % (from 3 to 9 mCi/µmol). The isolated radiochemical yields 
were increased by 187 % (from 23 to 43 %). Finally, the automated synthetic process was 
faster, allowing the 18F-PARPi-FL synthesis to be performed in only 70 min (90 min for manual).
 
Figure 3.2.3. Optimization of 18F-PARPi-FL radiosynthesis.  
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3.3: Immunohistochemistry and Autoradiography   
Using histological sections of healthy mouse brain and U87 MG glioblastoma xenografts, we 
showed that the PARP1 expression in the U87 MG tissues is increased by a factor of 11.4 (17.1 
± 1.6 and 1.5 ± 0.9% PARP1-positive area for U87 MG and healthy mouse brains, respectively, 
Figure 3.3.1). To probe the selective uptake of 18F-PARPi-FL, we performed autoradiographic 
staining on resected tissues (U87 MG tumor, brain, muscle) obtained from mice, which were 
  
Figure 3.3.1. H&E and PARP1 staining of U87 MG xenografts and brain tissues. PARP1 
expression in normal mouse brain (top) and U87 MG xenograft tissue (bottom). Morphological 
aspects are shown in H&E staining (left). PARP1 staining in adjacent sections is shown in low 
(middle panel) and high magnification (right). 
 
 
Figure 3.3.2. 18F-PARPi-FL autoradiography. H&E staining (left panels) and autoradiography 
(right panels) of (a) unblocked and (b) blocked U87 MG tumor slices; (c) tissue/muscle ratio 




injected with only the 18F-PARPi-FL (non-blocked) or 18F-PARPi-FL 30 min after injection of 
olaparib as blocking agent (blocked). Autoradiography showed a homogeneous distribution of 
radioactivity in the tumors of non-blocked mice (Figure 3.3.2a). The uptake in tumors of blocked 
mice was markedly lower, with an overall reduction of 80 ± 12 % (Figure 3.3.2b). Hematoxylin 
and eosin (H&E) staining demonstrated that the retention of radioactive material colocalized 
with viable tumor tissue. Blocking lowered the 18F-PARPi-FL tumor to muscle ratio by 
approximately 66% (7.5 ± 0.9 and 2.6 ± 1.6, PG0.001 for non-blocked and blocked mice, 
respectively). In contrast, the brain to muscle ratio did not undergo statistically significant 
changes (0.87 ± 0.48 and 1.02 ± 0.22 for non-blocked and blocked mice, P=0.646, respectively, 
Figure 3.3.2c). 
3.4: Surface Fluorescence Imaging  
 
Figure 3.4.1. Full organ fluorescence and autoradiography; (a) representative images of tumor 
and brain tissue obtained by IVIS optical imaging, including the corresponding (b) 
autoradiography and (c) white light images; (d) fluorescence intensity profiles across tumor and 
brain and (e) autoradiographic profile plot of the same organs. Radiant efficiency=emission light 
(photons/s/cm2/str)/excitation light (mW/cm2). White lines in panels (a) and (b) indicate the data 




The bimodal imaging capabilities of 18F-PARPi-FL were determined by combined 
optical/autoradiographic ex vivo analysis. The uptake of 18F-PARPi-FL in the tumor was higher 
than the observed accumulation in brain and muscle in both surface fluorescence imaging 
(tumor to brain ratio was sevenfold increased) and autoradiography (tumor to brain ratio was 
ninefold higher) (Figure 3.4.1a–c). The differences in imaging ratios (sevenfold versus ninefold) 
are likely due to the differences in penetration depths and readout techniques for the two 
imaging modalities. 
Olaparib-blocked organs showed greatly reduced uptake in the tumor (74 ± 12 and 66 ± 9% 
reduction for surface fluorescence imaging and autoradiography, respectively). Line profiles of 
tumors and brains were obtained with both imaging techniques. Autoradiographic staining and 
epifluorescence imaging provided corresponding organ uptake profiles (Figure 3.4.1d, e). These 
results indicate that 18F-PARPi-FL should be capable of generating high-contrast bimodal 
images of tumor tissue and that the tumor to brain ratio is sufficiently high to allow effective 
imaging of the tracer in the brain during intraoperative imaging procedures. 
3.5: Small Animal PET Imaging 
Small animal PET imaging studies were conducted to investigate 18F-PARPi-FL as a whole- 
body imaging agent. After administration of 100 – 200 µl (80 – 160 mCi/µmol) of the tracer, U87 
 
Figure 3.5.1. PET/CT images. (a) PET coronal and axial images (left) and corresponding CT 
images (right) of a mouse injected with 18F-PARPi-FL (b) PET coronal and axial images (left) 
and corresponding CT images (right) after pre-injection of blocking agent. 
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MG glioblastoma xenografts could be identified in the right shoulder of tumor-bearing mice in 
both coronal and axial PET/CT reconstructions (Figure 3.5.1a). The uptake of 18F-PARPi-FL in 
U87 MG tumors was 0.78 ± 0.1 %ID/g, which we were able to reduce to 0.15 ± 0.06 %ID/g by 
blocking with an excess of olaparib (500 mM, 3.7 µmol, in 100 µl 15% PEG300 85% 0.9% 
saline), similar to what has been done before17. The standardized uptake value (SUV) in U87 
MG tumors was 1.10 ± 0.53, which also could be reduced to 0.10 ± 0.06 by blocking pre-
injection of an excess of olaparib (50-fold). 
PET imaging revealed a high uptake in the liver and in the intestinal tract, which is consistent 
with hepatobiliary excretion and analogous to what we and others have seen for monomodal 
radiolabeled PARP1 imaging agents24,25 (Figure 3.5.1a, b). Activity was also observed in the 
bone and junctures, typically a result of defluorination of radiolabeled imaging agents during 
metabolic degradation. 
3.6: Blood Half-life and Biodistribution 
In order to explore the potential in vivo applications of 18F-PARPi-FL as a multimodality imaging 
probe, we evaluated its blood half-life (Figure A.3.6a). After tail vein injection of 18F-PARPi-FL 
(27 µCi, 100 µl), the observed weighted t1/2 was 15.6 min. The calculated tumor uptake in the 
positive control group, at 90 min p.i., was 0.78 ± 0.1% injected dose/gram (%ID/g). Tumor 
uptake dropped to 0.1 ± 0.02 %ID/g at 90 min p.i. for mice that received a pre-injection of 
olaparib. For each group, liver and kidney uptake of the radiotracer was lower in mice receiving 
a pre-injection of olaparib, indicating specific binding of the tracer to a certain extent additionally 
to the uptake due to excretion. (Liver 3.8±0.4 and 2.02±0.2 %ID/g, PG0.001 and kidneys 
0.7±0.1 and 0.4±0.1 %ID/g, PG0.05, for non-blocked and blocked, respectively) (Figure 3.5.1). 
The tumor to muscle ratio of 18F-PARPi-FL was 4 ± 0.6 at 90 min post injection. The tumor to 





Figure 3.5.1. Biodistribution study in selected tissues. After injection of 18F-PARPi-FL into tumor 
xenograft mice, mice were euthanized and the radioactivity in the organs was counted (n=4). (a) 
shows data scaled to the high bone uptake while (b) shows highlights the specificity of 








The primary objective of this study was to explore the synthesis and in vivo pharmacokinetics of 
18F-PARPi-FL as a potential bimodal PET/optical imaging agent for PARP1-targeted imaging of 
glioblastoma. We were able to develop a 70 minute automated protocol to produce the tracer 
with optimal yield and specific activity, which is inherently limited by the transfluorination 
reaction. This limitation, however, is mitigated by the need for such bimodal agents to adopt 
specific activities suitable to the fluorescent moiety as well as the PET26. We observed high 
tumor to noise ratios in both whole organ autoradiography and ex vivo fluorescent imaging. Both 
of these signals were highly specific, as demonstrated by the near complete blocking afforded 
by pre-injection of olaparib. This was confirmed in PET/CT images, which showed 0.78 %ID/g 
uptake with near complete blocking by pre-injection of olaparib. The PET/CT images also 
revealed hepatobiliary excretion, in accord with what has been reported before. The PET/CT 
images also showed high bone uptake, and all of these observations were corroborated by 
biodistribution studies. The high bone uptake was ascribed to metabolic defluorination, an 
explanation in agreement with known BODIPY chemistry27,28. Defluorination might limit the 
broad applicability of the imaging agent. However, the rate of defluorination and the resulting 
bone uptake might be reduced in vivo by addition of cytochrome P450 isozyme 2E1 (CYP2E1) 
inhibitors29,30. Nevertheless, we were able to show that 18F-PARPi-FL is a potentially valuable 
bimodal imaging agent that fuses optical and PET imaging, combining the advantages of whole-
body and high-resolution imaging. 
3.8: Experimental 
Materials. Commercially available compounds were used without further purification unless 
otherwise stated. Tetrabutylammonium bicarbonate (TBAB, 0.075 M in water) was purchased 
from ABX advanced biochemical compounds GmbH (Radeberg, Germany). Extra dry 
acetonitrile (MeCN) over molecular sieves was purchased from Acros Organics (Geel, Belgium). 
Water (>18.2 MΩcm-1 at 25 °C) was obtained from an Alpha-Q Ultrapure water system from 
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Millipore (Bedford, MA). Tin(IV) chloride (SnCl4, 1 M in methylene chloride) was purchased from 
Sigma Aldrich (St. Louis, MO). BODIPY-FL succinimidyl ester was purchased from Life 
Technologies (Carlsbad, CA). (AZD2281) was purchased from LC Laboratories (Woburn, MA). 
PARPi-FL was synthesized as described earlier18. No-carrier-added (n.c.a.) [18F]fluoride was 
obtained via the 18O(p,n)18F nuclear reaction of 11-MeV protons in an EBCO TR-19/9 cyclotron 
using enriched 18O-water. QMA light ion-exchange cartridges and C-18 light Sep-Pak® 
cartridges were obtained from Waters (Milford, MA). High performance liquid chromatography 
(HPLC) purification and analysis was performed on a Shimadzu UFLC HPLC system equipped 
with a DGU-20A degasser, a SPD- M20A UV detector, a RF-20Axs fluorescence detector, a LC-
20AB pump system, and a CBM-20A communication BUS module. A LabLogic Scan-RAM 
radio-TLC/HPLC-detector was used for purifications while a PosiRAM Model 4 was used for 
analysis. HPLC solvents (Buffer A: 0.1% TFA in water, Buffer B: 0.1% TFA in MeCN) were 
filtered before use. HPLC purification and analysis was performed on a reversed phase Atlantis 
T3 column (C18, 5 µm, 4.6 mm × 250 mm; flowrate: 0.8 ml/min; gradient: 0-17 min 30-90% B; 
17-24 min 90% B; 24-28.5 min 90%-30% B; 28.5-30 min 30% B). 
Electrospray ionization mass spectrometry (ESI-MS) spectra were recorded with a Shimadzu 
LC-2020 with electrospray ionization SQ detector. All PET imaging experiments were conducted 
on a microPET INVEON camera equipped with a CT scanner (Siemens, Knoxville, TN). Digital 
phosphor autoradiography of histological U87 MG tumors, muscle and brain were obtained 
using a Typhoon FLA 7000 laser scanner from GE Healthcare (Port Washington, NY). 
Cell culture. The human glioblastoma cell lines U87 MG were kindly provided by Dr. Ronald 
Blasberg (MSKCC, New York, NY). Cell lines were grown in Eagle’s Minimal Essential Medium 
(MEM), 10% (vol/vol) heat inactivated fetal bovine serum, 100 IU penicillin, and 100 µg/mL 
streptomycin, purchased from the culture media preparation facility at MSKCC (New York, NY). 
Mouse models. All animal experiments were done in accordance with protocols approved by 
the Institutional Animal Care and Use Committee of MSKCC and followed National Institutes of 
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Health guidelines for animal welfare. Female athymic nude CrTac:NCrFoxn1nu mice at age 6 - 
8 weeks were purchased from Taconic Laboratories (Hudson, NY). Non tumor-bearing mice 
used to determine the blood half-life of PARPi-FL (n = 4). Xenograft mouse models were used 
to determine the pharmacokinetics (n = 20). For subcutaneous injections, mice were 
anesthetized with 2% isoflurane (Baxter Healthcare) (2 l/min medical air). U87 MG cells were 
implanted subcutaneously (5 × 106 cells in 200 µl 1:1 PBS/matrigel® (BD Biosciences, San 
Jose, CA) in the right shoulder and allowed to grow for approximately two weeks until the 
tumors reached 5–10 mm in size. For all intravenous injections, mice were gently warmed with a 
heat lamp and placed on a restrainer. The tails were sterilized with alcohol pads, and injection 
took place via the lateral tail vein. 
Immunohistochemistry. Immunohistochemical staining of PARP1 was performed with 
formalin-fixed, paraffin-embedded U87 MG xenografts and mouse brain using the Discovery XT 
processor (Ventana Medical Systems, Tucson, AZ) at the Molecular Cytology Core Facility of 
MSKCC. Following deparaffinization with EZPrep buffer and antigen retrieval with CC1 buffer 
(both Ventana Medical Systems), sections were blocked for 30 min with Background Buster 
solution (Innovex, Lincoln, RI). Primary rabbit anti-PARP1 antibody (sc-7150, 0.4 µg/ml, Santa 
Cruz, Dallas, TX) was incubated for 5 h followed by a biotinylated goat anti-rabbit IgG for 1 h 
(PK6101, 1:200 Vector labs, Burlingame, CA). Signal detection was performed with a DAB 
detection kit (Ventana Medical Systems, Tucson, AZ) according to the manufacturers 
instructions. Sections were counterstained with hematoxylin and coverslipped with Permount 
(Fisher Scientific, Waltham, MA). Adjacent sections were stained with Hematoxylin and Eosin 
for morphological evaluation of the tissue. 
Radiosynthesis. In a typical experiment, the [18F]fluoride (~50mCi) in water was transferred 
into a sealed conical drying vessel containing TBAB (75 mM in water, 80 µl, 1.8 mg, 6.0 µmol). 
Water was removed from the [18F]F-/TBAB solution by azeotropic distillation with dry acetonitrile 
(3 × 1 ml) under a gentle stream of nitrogen at 110 °C. The dry residue was reconstituted with 
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100 µl of MeCN and cooled to room temperature. To this, PARPi-FL (50 µg, 0.78 µmol) in 
MeCN (50 µl) was added, followed by 10 equivalents of SnCl4 (100 mM in acetonitrile, 7.8 
µmol). The mixture was then heated at 35 °C for 30 min. After incubation, the reaction mixture 
was cooled to room temperature and diluted with ultrapure water to reach a final 20% MeCN 
concentration. The crude mixture was filtered with PES 0.22 µm 30 mm diameter (Shirley, MA) 
and automatically injected into the HPLC system (gradient A) for purification. The 18F-PARPi-FL 
peak was collected (rt: 17.5 min) and the solution passed through a C18 light-SepPak® 
cartridge (preconditioned with EtOH (5 ml) and water (5 ml). The cartridge was washed with 
water (3 ml) and 18F-PARPi-FL was eluted using EtOH (1 ml). The organic solvent was removed 
by rotary evaporation at 40 °C and the residual product formulated in 15% PEG300 in 0.9% 
saline for in vivo animal imaging and biodistribution. The labeling procedure was fully automated 
using a ScanSys radiochemistry module from ScanSys (Vaerloeser, Denmark). 
Small-animal PET imaging. Mice bearing subcutaneous U87 MG (n = 12) were divided in two 
groups (non blocked and blocked) and administered with 18F-PARPi-FL [200 µCi, 160 
mCi/µmol) in 200 µl 15% PEG300 in 0.9% sterile saline] via tail vein injection. Approximately 5 
min prior to PET acquisition, mice were anesthetized by inhalation of a mixture of isoflurane 
(Baxter Healthcare, Deerfield, IL, USA; 2% isoflurane, 2 l/min medical air) and positioned on the 
scanner bed. Anesthesia was maintained using a 1% isoflurane/O2 mixture. PET data for each 
mouse was recorded using static scans of 30 minutes and acquired at 1 h postinjection. The 
blocked cohort (n = 6) was pre-injected with the PARP1 inhibitor olaparib (500 mM, 3.7 µmol, in 
100 µl 15% PEG300 / 85% 0.9% saline). Images were analyzed using INVEON software 
(Siemens, Knoxville, TN). Quantification and %ID/g values were calculated by manually drawing 
regions of interests in four different frames and calculating the average values. Standard Uptake 
Values (SUV) were calculated for 3D regions of interest (ROI), using Inveon Research 
Workplace software (Siemens Medical Solutions, Knoxville, TX). Tumor ROIs drawn on the 
images, normalized to the injected dose and body weight and converted to SUV. 
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Ex vivo biodistribution. Biodistribution studies were performed in U87 MG xenografted 
athymic nude mice (n = 4). Mice were divided in two groups (positive controls and blocked) and 
administered with 18F-PARPi-FL [approximately 27 µCi, 160 mCi/µmol) in 200 µl, 15% PEG300 
in 0.9% sterile saline] via tail vein injection. The blocked group was pre-injected with an excess 
of olaparib (500 mM, 3.7 µmol, in 100 µl 15% PEG300 / 85% 0.9% saline). Mice were sacrificed 
by CO2 asphyxiation at 90 min p.i. and major organs were collected, weighed, and counted in a 
WIZARD2 automatic γ-counter (PerkinElmer, Boston, MA). The radiopharmaceutical uptake was 
expressed as a percentage of injected dose per gram (%ID/g) using the following formula: 
[(activity in the target organ/grams of tissue)/injected dose]×100%. 
Blood half-life. The blood half-life of 18F-PARPi-FL was calculated by measuring the activity of 
blood samples collected at different time points p.i. (5, 15, 30, 60, and 120 min). Female nude 
mice (n = 4) were injected via lateral tail vein with 18F-PARPi-FL (50 µCi in 200 µl 15% PEG300 
in 0.9% sterile saline) and blood samples were collected from the great saphenous vein of each 
animal at the predetermined time point. The collected blood was weighed and counted in a 
WIZARD2 automatic γ-counter (PerkinElmer, Boston, MA). The blood half-life was calculated 
using Prism 6.0c (GraphPad Software, La Jolla, CA) using a two-phase decay least squares 
fitting method and expressed as %ID/g. 
Autoradiography and Hematoxylin–Eosin staining. The collected organs were flash-frozen 
in liquid Nitrogen and fixed in Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, CA) and 
cut into 10 µm sections using a Vibratome UltraPro 5000 Cryostat (Vibratome, St. Louis, MO). A 
storage phosphor autoradiography plate (Fujifilm, BAS-MS2325, Fiji Photo Film, Japan) was 
exposed to the tissue slices overnight at -20 °C and read the following day. Relative count 
intensity of the sections in each image was quantified using ImageJ 1.47u processing software 
(source: http://rsbweb.nih.gov/ij/)31. Tumor/muscle and brain/muscle ratios were calculated 
using Prism 6.0c (GraphPad Software, La Jolla, CA). The same sections were subsequently 
subjected to H&E staining (hematoxylin–eosin) for white light microscopy. Surface fluorescence 
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imaging While the cellular pharmacokinetics16,18,32 and macroscopic/organ-specific distribution17 
of PARPi-FL have been reported in the past, the possibility of bimodal optical/PET imaging with 
18F-PARPi-FL has not been described. For this, U87 MG tumor bearing mice (n = 12) were 
injected with 18F-PARPi-FL [approximately 27 µCi, 160 mCi/µmol in 200 µL 15% PEG300 in 
0.9% sterile saline] via tail vein injection. After PET imaging, the mice were sacrificed and 
tumor, brain, and muscle harvested, placed on a petri dish and imaged with an IVIS Spectrum 
fluorescence imaging system (PerkinElmer, Boston, MA) and Living Image 4.4 software. As a 
negative control group, U87 MG tumor bearing mice (n = 4) were injected with vehicle only (200 
µl 15% PEG300 in 0.9% sterile saline). For blocking studies, U87 MG cells were implanted and 
grown in mice as stated above. The mice were injected with 18F-PARPi-FL as stated above, with 
the exception that they were injected with an excess Olaparib in 100 µl of 15% PEG300 in 0.9% 
sterile saline prior to injection of 18F-PARPi-FL. Image analysis for the 18F-PARPi-FL uptake and 
blocking study was performed by drawing regions of interest through each organ to calculate the 
cross-section fluorescence with ImageJ 1.47u image processing software. 
Statistical analysis. All data are expressed as mean ± SD. Differences between mouse 
cohorts were analyzed with the 2-sided unpaired Student test and were considered statistically 
significant when P < 0.05. 
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CHAPTER 4: [18F]PARPI-GLIOBLASTOMA MULTIFORME 
This chapter is an adaptation of published work, and is reproduced in part, from Carney, B., 
Carlucci, G., Salinas, B., Di Gialleonardo, V., Kossatz, S., Vansteene, A., Longo, V. A., 
Bolaender, A., Chiosis, G., Keshari, K. R., Weber, W. A. & Reiner, T. Non-invasive PET Imaging 
of PARP1 Expression in Glioblastoma Models. Mol Imaging Biol 18, 386-392 (2016). Copyright 
 
4.1: Introduction 
Although 18F-PARPi-FL1 represented a step forward in the design of PARP targeted PET 
agents, and the probe was especially valuable insofar as it offered a fluorescent moiety in 
addition to the PET, it’s clinical utility was limited by the high bone uptake attributed to metabolic 
defluorination. Our goal here was to design and synthesize a new molecule that exhibited 
similar tumor targeting properties as well as the high specificity of 18F-PARPi-FL, but also 
possessed greater in-vivo stability. To this end, we aimed to sacrifice the fluorescent BODIPY 
moiety that also served as a foundation for the boron-18F-fluorine bond that showed itself to be 
metabolically instable in order to install a more stable PET active moiety. With this motivation in 
mind, and inspired by our earlier designs1–7 and the work of others8, we synthesized [18F]PARPi, 
a single model 18F-labeled derivative of PARPi-FL. We determined the performance and basic 
binding parameters of [18F]PARPi in biochemical assays then showed that in optical imaging 
experiments, the radiolabeled tracer reaches its target on a cellular level, saturating PARP1 in 
the nuclei of glioblastoma cells. We determined the biodistribution of [18F]PARPi and showed in 
subcutaneous and orthotopic mouse models of glioblastoma that PARP1 expression can be 
visualized by PET with high signal/noise ratios. Even though the monomodel [18F]PARPi lacks 
the advantage of the dual model fluorescent signal of 18F-PARPi-FL, we believe that the two 
probes taken together, with the addition of olaparib and perhaps other PARP targeted 
therapeutics,  could represent a targeted, highly specific and actionable imaging toolbox with 
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many possible clinical applications. 
4.2: PARP1 Expression in Glioblastoma Models and Healthy Tissues 
 
Figure 4.2.1. PARP1 staining of an orthotopic mouse model. PARP1 immunohistochemical 
staining was conducted on formalin-fixed, paraffin-embedded mouse brains of nude mice using 
an anti-PARP antibody and IHC detection. Brown=PARP1 positive tissue. Blue=Hematoxylin 
counterstain. Red: Eosin stain. 
 
Even though our previous work with 18F-PARPi-FL utilized subcutaneous U87 MG xenografts, 
we wished to follow-up on the work done by Salinas et al.9 which made use of orthotopic U251 
MG xenografts. To that end, we wanted first to verify PARP expression in this model, which was 
only performed on subcutaneous U251 MG xenografts in the previous work. We found that 
PARP1 expression was strongly elevated in the area of the tumor growth with clear margins to 
surrounding normal brain tissue (Figure 4.2.1), corroborating the earlier findings. In addition to 
this, we measured PARP1 expression in several healthy tissues. A high PARP1 expression was 
also observed in the lymph node, concentrated to the follicle regions, and the spleen, 
particularly around the germinal centers (Figure 4.2.2). These areas correspond to areas of high 
B cell concentration. These B cell areas exhibit high PARP1 expression compared to areas like 
the paracortical area and the medullary chords in the lymph nodes, which respectively contain 
mostly T cells and macrophages, suggesting that B cells in particular among the lymphocytes 
exhibit high PARP1 expression. 
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Figure 4.2.2. PARP1 staining of healthy organs. Left to right, mouse lymph node (popliteal) 
spleen, liver, kidney, brain, and lung were immunostained to assess inherent PARP1 
expression. Tissue was formalin-fixed, paraffin-embedded and derived from B6 mice. 
Brown=PARP1 positive tissue. 
 
4.3: Chemistry and Radiochemistry 
The molecular structure of [18F]PARPi is based on the previously tested and validated 
2H-phthalazin-1-one scaffold of the small molecule therapeutic olaparib10. Our tracer was 
obtained by conjugating a 4-[18F]fluorobenzoic acid group to the PARP1 targeting small 
molecule. Its cold reference compound, 19F-PARPi, was synthesized in a single synthetic step 
from 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one10 and 4-fluorobenzoic 
acid, similar to coupling procedures applied earlier2 (Figure 4.3.1). 19F-PARPi was obtained with 
an isolated yield of 43%, and its identity confirmed by ESI-MS, ESI-HRMS, and NMR 
spectroscopy (Figure A.4.2-A.4.4). 
The radiolabeled version of the PARP1-targeted tracer, [18F]PARPi, was synthesized in three 
consecutive synthetic transformations. Similar to the cold material, it was produced from the 
PARP1-targeted 2H-phthalazin-1-one fragment. Its radiolabeled reaction partner 
4-[18F]fluorobenzoic acid was obtained from ethyl 4-nitrobenzoate, which was added to dry 
K[18F]-K222 and heated to 150 °C for 15 min to give ethyl 4-[18F]fluorobenzoate. The 
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Figure 4.3.1. [18F]PARPi radiosynthesis scheme. The radiotracer was produced in three steps 
starting from the labeling of ethyl nitro benzoate.  The ester is then hydrolysed and coupled to 
the precursor with standard HBTU chemistry. 
 
decay corrected radiochemical yield (dcRCY) for this transformation was determined by HPLC 
and found to be 70 %. Then, the ethyl protective group was removed in the presence of sodium 
hydroxide to yield 4-[18F]fluorobenzoic acid (dcRCY = 99%). Analogous to the non-radioactive 
material, the radiolabeled 4-[18F]fluorobenzoic acid was coupled to the phthalazinone precursor 
(dcRCY=35 %). The total synthesis time from the start of synthesis to obtaining an injectable 
formulation was 90 min, and the overall uncorrected radiochemical yield was 10%, with a 
specific activity of 48 mCi/µmol (1.8 GBq/umol, Figures 4.3.1 & Figure A.4.1). 
4.4: PARP1 Affinity, logP, and Plasma Protein Binding 
First, we determined the ability of our tracer to bind to PARP1 in a biochemical assay, 
analogous to methods we have previously described11. We found that the IC50 of 19F-PARPi was 
2.8±1.1 nM (Figure 4.4.1a), which is on par with the small molecule parent compound olaparib 
(5 nM10). We calculated the logPCHI of 19F-PARPi from its chemical hydrophobicity index (CHI), a 
measure of HPLC retention time12. The CHI for 19F-PARPi was 57.5, which translates to a 
logPCHI of 2.15±0.41. This is concordant with measuring the octanol/water partition 
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Figure 4.4.1. Biophysical properties. (a) The tracer exhibits binding properties similar to 
olapabarib and PARPi-FL. (b) The tracer also exhibits ideal biophysical properties for delivery to 
the nuclear target. 
 
coefficient of [18F]PARPi, where we determined the logPO/W to be 1.76 ±0.18 (Figure 4.4.1b). 
The logP of 19F-PARPi was higher than for olaparib (CHI=34.1, logPCHI=0.8), but both small 
molecules had comparable plasma protein binding (64 and 65 % for 19F-PARPi and olaparib, 
respectively). 
4.5: In Vitro Characterization  
We determined on a subcellular level whether [18F]PARPi binds to the same target as its parent 
compound olaparib. To show this, we performed in vitro assays with the nonradioactive 
19F-PARPi, olaparib, and the fluorescent imaging agent PARPi-FL, which we have shown to be 
 
Figure 4.5.1. PARPi-FL blocking. (a) In-vitro PARPi-FL blocking studies show target 
engagement from non fluorescent molecules. (b) Quantification shows that both 19F-PARPi and 
olaparib are capable of blocking the fluorescent signal from PARPi-FL, suggesting that all three 
molecules hit the same target. 
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highly selective for PARP1 and suitable as a surrogate marker to infer the subcellular 
distribution of olaparib6. Labeling cells with PARPi-FL leads to strong nuclear fluorescence due 
to retention of the imaging agent by PARP1. In the presence of olaparib, the binding sites for 
PARPi-FL were occupied, and the observed fluorescence is reduced by 69.6 ±22.3 % and 
71.2±20.0 % for U251 MG and U373 MG cells, respectively. Similarly, 19F-PARPi was able to 
compete for the same binding sites as PARPi-FL, resulting in a reduction of fluorescence 
intensity in the nucleus by 80.0±10.8 % and 78.8±10.4 % for U251 MG and U373 MG cells, 
respectively (Figure 4.5.1).  
4.6: Blood Stability and Blood Half life 
We estimated the in vivo stability of [18F]PARPi by incubating the radiotracer in whole blood for 
up to 4 h. Over the given time period, no radioactive metabolites were observed, indicating 
excellent stability and potentially low bone uptake of the tracer for in vivo applications (Figure 
4.6.1a). The blood half-life of [18F]PARPi was determined in athymic nude mice, which received 
the tracer via tail vein injection. Analogous to other small molecules of this type1,2,6, the agent 
was cleared rather quickly, with an alpha blood half-life of 1.27 min (85.51 %) and beta blood 
half-life of 31.14 min (14.49 %), resulting in a weighted blood half-life of t1/2(weighted)=5.6 min 
(Figure 4.6.1). 
 
Figure 4.6.1. Blood studies. (a) Stability studies show no radioactive metabolites for four hours. 
(b) The blood half life measurement shows a quick two phase decay with a relatively short 






Figure 4.7.1. Biodistribution studies. Biodistribution measurements show highly specific tumor 
uptake in the tumor as well as several other organs such as the spleen and lymph nodes. 
Hepatobiliary excretion is also exhibited. 
 
The tumor-to-muscle ratio was 5.1±0.9, and the tumor-to-brain ratio was 54.9±14.1 (Figure 
A.3.6.b). A high uptake was also observed in the hepatobiliary system with liver uptake values 
of 3.98±0.56 and 3.61±2.04 %ID/g, small intestine uptake of 2.94±0.91 and 2.35±0.70 %ID/g, 
and large intestine uptake of 2.24±0.59 and 1.73±0.80 %ID/g for unblocked and blocked 
cohorts, respectively. We also found that lymph node and spleen uptake were high, with 
2.80±0.51 and 4.04 ±1.23 %ID/g, respectively, and that their uptake was reduced after pre-
injection of olaparib by 95 and 94%, respectively (Figure 4.7.1). Highly selective uptake in these 
organs is based on their rather high PARP1 expression, shown in immunohistochemical 
stainings, which were obtained in non-tumor-bearing mice (Figure 4.2.2). Our biodistribution 
data was corroborated by PET/X-ray computed tomography (CT) imaging, with whole axial and 
coronal slices of subcutaneous tumor-bearing mice receiving only [18F]PARPi and both 
olaparib/[18F]PARPi (Figure 4.9.1). 
4.8: Autoradiography 
We used an orthotopic mouse model of U251 MG to determine the potential clinical impact of 
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Figure 4.8.1. Autoradiography in orthotopic U251 MG tumor-bearing mice. (a) Autoradiography 
and H&E staining of brain sections either unblocked (left) or blocked (right) with olaparib. Yellow 
arrows indicate location of tumor tissue. (b) Quantification of activity on autoradiographic 
sections in orthotopic U251 MG tumors and mouse brain and (c) muscle (n=6). Error bars are 
mean±SD. P values were calculated with Student’s t-tests, unpaired; *P<0.05; **P<0.01; 
***P<0.001; ****P<0.0001. 
 
[18F]PARPi as a non-invasive PARP1 imaging tracer. U251 MG cells expressed PARP1 at much 
higher levels than healthy brain, and orthotopic brain tumors had a high gradient in PARP1 
expression (Figure 4.2.1). In order to assess the alignment of [18F]PARPi retention and PARP1 
expression on a microscopic level in vivo, tumor-bearing mice were injected with [18F]PARPi and 
autoradiography was performed (Figure 4.8.1a). Using histology to localize the tumor regions of 
the brain, the autoradiographic analysis revealed significantly higher retention of [18F]PARPi 
inside orthotopic tumor tissue than in healthy surrounding brain (Figure 4.8.1a, 46.66±14.94 AU 
and 0.06±0.02 AU for orthotopic tumor and surrounding brain, respectively). Similarly—and 
consistent with in vitro imaging— we found that pre-injection of olaparib and hence saturation of 
PARP1 binding sites lead to almost quantitative reduction of [18F]PARPi (99 %, 0.44±0.41 AU 
and 0.03 ±0.01 AU for orthotopic tumor and surrounding brain, respectively). The uptake of 
[18F]PARPi in orthotopic tumor tissue was distinctly higher than in muscle (Figure 4.8.1b, c 
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1.36±0.21 AU and 1.50±0.31 AU for muscle tissue in tumor bearing and healthy mice, 
respectively). 
4.9: PET/CT and PET/MR Imaging 
We used both small-animal PET/CT and PET/magnetic resonance imaging (MRI) scanners to 
determine the accuracy and selectivity of non-invasive glioblastoma delineation with [18F]PARPi. 
Beginning with subcutaneous xenografts (Figure 4.9.1), PET images showed clear tumor 
delineation in addition to lymph node localization, an observation that has not been made before 
in PARP PET imaging. The images also showed the usual hepatobiliary excretion pattern 
 
Figure 4.9.1. PET images from subcutaneous U251 MG xenograft models. (a) Full body slices 
of unblocked mice centered at tumor site collected at 30 min (top) and 2 h (bottom) p.i. (b) Full 
body maximum intensity projections (MIPs) of unblocked mice collected at 30 min (left) and 2 h 
(right) p.i. (c) Full body slices of mice blocked by preinjection of olaparib, centered at tumor site. 
Images collected at 30 min (top) and 2 h (bottom) p.i. (d) Full body MIPs of mice blocked by 
preinjection of olaparib. Images collected at 30 min (left) and 2 h (right) p.i. 
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exhibited by PARP imaging agents, and all of these observations corroborate the 
measurements acquired in the biodistribution studies. As with the biodistribution studies, the 
PET images demonstrate the high specificity of the molecule at the tumor site as well as the 
stability of the compound with respect to defluorination, in sharp contrast to 18F-PARPi-FL. 
Imaging studies using othotopic xenografts showed similar results to the PET images of 
subcutaneous tumor bearing mice. Figure 4.9.2a shows axial brain slices, obtained 120 min 
after radiotracer injection, of tumor-bearing animals that received either only [18F]PARPi or 
olaparib/[18F]PARPi. For animals receiving only [18F]PARPi, the retained activity (2.15±0.79 
%ID/g) was eightfold higher than for animals that received both olaparib and [18F]PARPi
 
Figure 4.9.2. PET/CT imaging of [18F]PARPi in orthotopic brain tumor-bearing mice. (a) Fused 
PET/CT axial images of an orthotopic U251 MG tumor bearing mouse acquired at 2 h post-
injection of [18F]PARPi either unblocked (left) or blocked (right) with olaparib. (b) PET 
quantification of U251 MG tumors from images acquired at 30 min and 2 h post injection (n=10). 
(c) Representative 3D PET/CT images of an unblocked (left) or blocked (right) orthotopic U251 
MG tumor bearing mouse. Error bars are mean±SD. P values were calculated with Student’s 
t-tests, unpaired; *P<0.05. 
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(0.28±0.01 %ID/g, Figure 4.9.2b). Figure 4.9.2c shows representative 3D PET/CT 
reconstructions of orthotopic tumor-bearing mice that received [18F]PARPi or 
olaparib/[18F]PARPi.  
PET/MRI was used to confirm uptake of [18F]PARPi in the tumor tissue which is not well 
differentiated brain tissue with CT. MRI identified the tumor area based on on T1-weighted post-
contrast images, and the PET signal was confirmed to coalign with this MRI identified tumor 
area (Figure 4.9.3). 
 
Figure 4.9.3. PET/MRI images of [18F]PARPi in orthotopic brain tumor-bearing mice. Coronal 
view of [18F]PARPi PET images, contrast-enhanced MRI, and fused PET/MRI of orthotopic 
U251 MG tumor-bearing mice, either unblocked (top) or blocked (bottom) with excess olaparib. 
 
4.10: Conclusion 
The primary objective of this study develop a PARP1 targeted PET imaging agent with tumor 
targeting properties similar to that of 18F-PARPi-FL, but without the in-vivo defluorination 
presented by that molecule. Sacrificing the fluorescent moiety not only yielded a compound with 
high in vivo stability, but it also afforded higher specific activity than could be attained with the 
transfluorination reaction that yielded 18F-PARPi-FL. This could be one reason that [18F]PARPi 
showed higher uptake in tumor models than 18F-PARPi-FL, but it should also be pointed out that 
the two studies made use of two different tumor models, and that the U251 MG used in this 
study has slightly higher PARP1 expression than the U87 MG cell line used in the previous 
study as measured by the mRNA expression patterns reported by the cancer line encyclopedia 
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(CCLE)13. 
The novel PET imaging agent [18F]PARPi demonstrates an outstanding ability to non-invasively 
image PARP1 expression of gliomas and could have various applications in brain tumor 
research. Besides serving as a companion imaging agent for PARP1-targeting therapeutics, the 
agent could serve as a diagnostic for monitoring PARP1 expression before, during, and after 
treatment with cytotoxic agents. This could lead to new insights into the function of PARP1 
during cellular DNA damage response. Furthermore, the biodistribution data indicates that the 
imaging of PARP1 expression is not only feasible for brain tumors but potentially also for lung 
and soft tissue tumors. This is of high clinical relevance, because PARP1 inhibitors are under 
clinical investigation in lung cancer, breast cancer, and sarcomas. These properties make 
[18F]PARPi an excellent candidate for clinical translation. 
4.11: Experimental 
Materials. Commercially available compounds were used without further purification unless 
otherwise stated. 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (K222) was 
purchased from Sigma Aldrich (St. Louis, MO). Extra dry dimethyl sulfoxide (DMSO) over 
molecular sieves was purchased from Acros Organics (Geel, Belgium). Water (>18.2 MΩcm-1 
at 25 °C) was obtained from an Alpha-Q Ultrapure water system from Millipore (Bedford, MA). 
Olaparib (AZD2281) was purchased from LC Laboratories (Woburn, MA). PARPi-FL was 
synthesized as described earlier2. No-carrier-added (n.c.a.) [18F]fluoride was obtained via the 
18O(p,n)18F nuclear reaction of 16.5-MeV protons in an GE Healthcare PETTrace 800 using 
enriched 18O water. QMA light ion-exchange cartridges and C-18 light Sep-Pak® cartridges 
were obtained from Waters (Milford, MA). High performance liquid chromatography (HPLC) 
purification and analysis was performed on a Shimadzu UFLC HPLC system equipped with a 
DGU-20A degasser, a SPD-M20A UV detector, a LC-20AB pump system, and a CBM-20A 
communication BUS module. A LabLogic Scan-RAM radio-TLC/HPLC-detector was used for the 
radioactive signal. HPLC solvents (Buffer A: 0.1% TFA in water, Buffer B: 0.1% TFA in MeCN) 
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were filtered before use. HPLC analysis and purification was performed on a reversed phase 
Phenomenex Gemini column (C6-Phenyl, 5 µm, 4.6 mm, 250 mm). Analysis was performed with 
Method A (flowrate: 1.5 mL/min; gradient: 0-14 min 5-100% B; 14-17.5 min 100% B; 17.5-18 
min 100%-5% B); purification was performed with Method B (flowrate: 1.5 mL/min; isocratic: 
0-14 min 5-100% B; 14-17.5 min 100% B; 17.5-18 min 100%-5% B). Electrospray ionization 
mass spectrometry (ESI-MS) spectra were recorded with a Shimadzu LC-2020 with 
electrospray ionization SQ detector. All PET imaging experiments were conducted on a 
microPET INVEON camera equipped with a CT scanner (Siemens, Knoxville, TN). Digital 
phosphor autoradiography of orthotopic U251 MG tumors with surrounding brain tissue as well 
as muscle were obtained using a Typhoon FLA 7000 laser scanner from GE Healthcare (Port 
Washington, NY). 
Cell culture. The human glioblastoma cell lines U251 MG and U373 MG were kindly provided 
by the Laboratory of Dr. Ronald Blasberg (MSKCC, New York, NY). Cell lines were grown in 
Eagle’s Minimal Essential Medium (MEM), 10% (vol/vol) heat inactivated fetal bovine serum, 
100 IU penicillin, and 100 µg/mL streptomycin, purchased from the culture media preparation 
facility at MSKCC (New York, NY). 
Mouse models. All animal experiments were done in accordance with protocols approved by 
the Institutional Animal Care and Use Committee of MSKCC and followed National Institutes of 
Health guidelines for animal welfare. Female athymic nude CrTac:NCr-Foxn1nu mice at age 6-8 
weeks were purchased from Taconic Laboratories (Hudson, NY). Non tumor-bearing mice were 
used to determine the blood half-life of [18F]PARPi (n = 3). Xenograft mouse models were used 
to determine the pharmacokinetics (n = 12). For subcutaneous injections, mice were 
anesthetized with 2% isoflurane (Baxter Healthcare) (2 l/min medical air). U251 MG cells were 
implanted subcutaneously (5⨉106 cells in 150 µL 1:1 PBS/matrigel® (BD Biosciences, San 
Jose, CA) in the right shoulder and allowed to grow for approximately two weeks until the 
tumors reached 5–10 mm in diameter. For orthotopic injections, mice were anesthetized with 
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2% isoflurane (Baxter Healthcare) (2 L/min medical air). U251 MG cells (5⨉105 cells in 2 µL 
PBS) were injected 2 mm lateral and 1 mm anterior to the bregma using a Stoelting Digital New 
Standard Stereotaxic Device and a 5 µL Hamilton syringe. Cells were allowed to grow for 
approximately three weeks. For all intravenous injections, mice were gently warmed with a heat 
lamp and placed on a restrainer. The tails were sterilized with alcohol pads, and injection took 
place via the lateral tail vein. 
PARP1 Immunohistochemistry. Immunohistochemical staining of PARP1 was performed on 3 
µm section, obtained from with formalin-fixed, paraffin-embedded tumor-bearing and normal 
mouse brain using the Discovery XT processor (Ventana Medical Systems, Tucson, AZ) at the 
Molecular Cytology Core Facility of MSKCC. Following deparaffinization with EZPrep buffer and 
antigen retrieval with CC1 buffer (both Ventana Medical Systems), sections were blocked for 30 
minutes with Background Buster solution (Innovex, Lincoln, RI). Primary rabbit anti-PARP-1 
antibody (sc-7150, 0.4 µg/mL, Santa Cruz, Dallas, TX) was incubated for 5 hours followed by a 
biotinylated goat anti-rabbit IgG for 1 h (PK6101, 1:200 Vector labs, Burlingame, CA). Signal 
detection was performed with a DABdetection kit (Ventana Medical Systems, Tucson, AZ) 
according to the manufacturer’s instructions. Sections were counterstained with hematoxylin 
and coverslipped with Permount (Fisher Scientific, Waltham, MA). Adjacent sections were 
stained with Hematoxylin and Eosin for morphological evaluation of the tissue. 
Synthesis of 19F-PARPi. 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one was 
synthesized as previously described10. To 20 mg (54.5 µmol) of 4-(4-fluoro-3-(piperazine-1-
carbonyl)benzyl)phthalazin-1(2H)-one dissolved in 1 mL of MeCN, 9.2 mg (65.5 µmol) 4-
fluorobenzoic acid was added followed by 24.8 mg (65.5 µmol) of N,N,N’,N’-Tetramethyl-O-(1H-
benzotriazol-1-yl)uranium hexafluorophosphate (HBTU) and 18 µL (131 µmol) of Et3N. The 
reaction mixture was stirred for 5 minutes and purified by HPLC to yield the compound as an 
orange solid (11.5 mg, 23.5 µmol, 43%).1H-NMR (500 MHz, CDCl3) δ = 10.74 (s, 1H), 8.51-
8.49 (d, 1H), 7.83-7.76 (m, 2H), 7.82 (s, 1H), 7.45-7.44 (m, 2H), 7.38-7.36 (m, 2H), 7.14-7.08 
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(m, 3H), 4.33 (s, 2H), 3.75-3.39 (m, 8H). MS-ESI m/z [M + Na]+ = 511.2. HRMS-ESI m/z 
calculated for [C27 H22 N4 O3 F2 Na]+ 511.1558, found 511.1569 [M + Na]+. 
Radiosynthesis of [18F]PARPi. A QMA cartridge containing cyclotron-produced [18F] fluoride 
ion was eluted with a solution containing 9mg Kryptofix [2.2.2] (4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]hexacosane), 0.08 mL 0.15 M K2CO3 and 1.92 mL MeCN into a 5 mL 
reaction vial. Water was removed azeotropically at 120 °C. 500 µg of ethyl 4-nitrobenzoate 
dissolved in 100 µL of DMSO was then added to the reaction vial and heated to 150 °C for 15 
minutes. The reaction vial was then allowed to cool as 50 µL of 1M NaOH was added. The 
reaction mixture was stirred for 1 min and 50 µL of 1M HCl was added to quench. Then, 2 mg of 
4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one dissolved in 100 µL of DMSO 
was added followed by 10 mg of HBTU dissolved in 100 µL of DMSO and 20 µL of Et3N. The 
reaction mixture was stirred for 1 minute. 400 µL MeCN followed by 700 µL H2O was then 
added and the solution was injected onto a C6-Phenyl analytical HPLC column and eluted 
under isocratic conditions (Method B). [18F]PARPi eluted at (tR = 25.5 min), which was well 
resolved from the nitro analogue (4-(4-fluoro-3-(4-(4-nitrobenzoyl)piperazine-1-carbonyl)benzyl) 
phthalazin-1(2H)-one; tR = 30.1 min). For intravenous administration, the product-containing 
fraction was passed through a C18 light-SepPak® cartridge preconditioned with EtOH (10 mL) 
and water (10 mL). The cartridge was washed with water (3 mL) and [18F]PARPi was eluted 
using EtOH (400 µL). The solution was then diluted with 0.9% saline to 10% EtOH. The 
radiochemical purity of the final formulation was confirmed using analytical HPLC. Coelution 
with nonradioactive 19F reference compound confirmed the identity of the radiotracer. To 
measure radiochemical and chemical purity (>99%), [18F]PARPi was reinjected onto an 
analytical C6-Phenyl column (gradient A; tR = 11.4 min). 
IC50 Determination. A commercially available colorimetric assay (Trevigen, Gaithersburg, MD) 
was used to measure PARP-1 activity in vitro in the presence of varying concentrations of 
19F-PARPi. Three-fold dilutions of 19F-PARPi (final concentrations ranging from 1 µM to 33 pM) 
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were incubated with 0.5 U of PARP high specific activity (HSA) enzyme for 10 minutes in 
histone-coated 96-well plates. All experiments were carried out in triplicate. Positive control 
samples did not contain inhibitor, and background measurement samples did not contain 
PARP1. All reaction mixtures were adjusted to a final volume of 50 µL and a final concentration 
of 2% dimethyl sulfoxide (DMSO) in assay buffer. The remainder of the assay was performed 
according to the manufacturer’s instructions. PARP1 activity was measured by absorbance at 
450 nm in each well using a Molecular Devices SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale, CA). 
Chromatographic Hydrophobicity Index (logPCHI). The Chemical Hydrophobicity Indices 
(CHI) were measured using a previously developed procedure12. Briefly, reverse phase HPLC 
was used to measure the retention times of a set of standards with known CHI. A standard 
curve was then created to calculate the CHI of 19F-PARPi based on the HPLC retention time. 
Octanol−Water Partition Coefficient (logPO/W) The lipophilicity of the [18F]PARPi was acquired by 
adding 2.5 µCi to a mixture of 0.5 mL of 1-octanol and 0.5 mL of 25 mM phosphate buffered 
saline (pH 7.4) and mixed for 5 minutes. Then, the mixture was centrifuged at 15000 rpm for 5 
minutes. 100 µL samples were obtained from organic and aqueous layers, and the radioactivity 
of the samples were measured in a γ-counter WIZARD2 automatic γ-counter (PerkinElmer, 
Boston, MA). The experiment was performed in triplicate, and the resulting logPO/W was 
calculated as the mean ± SD. 
Plasma Protein Binding. The plasma protein fraction was determined using the Rapid 
Equilibrium Dialysis Device System (Life Technologies, Grand Island, NY) according to the 
manufacturer’s protocol. Membrane dialysis was performed with 500 µM 19F-PARPi in serum 
(500 µL) on one side of the membrane and PBS (700 µL) on the other side. The system was 
sealed with parafilm and incubated for 4 h at 37 °C on an orbital shaker set to 100 rpm. 
Thereafter, 50 µL of solution was taken from both sides, and samples were treated with 300 µL 
of precipitation buffer (90/10 acetonitrile/water with 0.1% formic acid) and vortexed to remove 
! 59!
protein before HPLC analysis. After injection, the [18F]PARPi peaks from each sample were 
integrated, and the protein bound fraction determined as %bound= [1 – (Concentration buffer 
chamber/Concentration plasma chamber)]⨉100. The final Albumin binding was calculated as 
the mean ± SD. 
PARPi-FL Blocking Studies. U251 MG or U373 MG (1 ⨉ 104 cells per well) cells were seeded 
into 12 wells each on a 96-well plate and cultured for 24 hours. The cells were then incubated 
either alone, with PARPi-FL (500 nM), or with PARPi-FL (500 nM) and Olaparib or 19F-PARPi in 
10-fold excess (5 µM) at 37 °C for 30 minutes. Experiments were performed in triplicate. 
Following incubation, cells were washed twice with media and twice with PBS and imaged with 
a Zeiss LSM 5Live confocal microscope. Images were then quantified using ImageJ 1.47u 
processing software. 
Blood Half-Life. The blood half-life of [18F]PARPi was calculated by measuring the activity of 
blood samples collected at different time points p.i. (5, 15, 30, 45, 60, 90 and 120 minutes). 
Female nude mice (n = 3) were injected via lateral tail vein with [18F]PARPi (50 µCi in 200 µL 
10% EtOH in 0.9% sterile saline) and blood samples were collected from the great saphenous 
vein of each animal at the predetermined time point. The collected blood was weighed and 
counted in a WIZARD2 automatic γ-counter (PerkinElmer, Boston, MA). The blood half-life was 
calculated using Prism 6.0c (GraphPad Software, La Jolla, CA) using a two-phase decay least 
squares fitting method and expressed as %ID/g. 
Blood Stability. [18F]PARPi (approximately 200 µCi, 45 mCi/µmol in 200 µL, 10% EtOH in 0.9% 
sterile saline) was added to 250 µL of whole human blood and incubated at 37 °C for increasing 
lengths of time (15, 30, 60, 120 and 240 minutes). [18F]PARPi was then extracted with 750 µL of 
MeCN, then centrifuged (5 minutes at 5000 rpm) to pellet blood cells and proteins. The 
supernatant was collected and prepared for HPLC injection by adding 750 µL mQ H2O and 
filtering. The blood stability was measured by HPLC analysis (Method A). 
Autoradiography and Hematoxylin–Eosin staining. One day after PET/CT imaging, the 
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same orthotopic U251 MG tumor bearing mice were administered with [18F]PARPi (80 µCi, 45 
mCi/µmol in 300 µL 10% EtOH in 0.9% sterile saline) via tail vein injection. Blocked mice from 
the previous day received another dose of Olaparib (37 mM, 3.7 µmol, about 80 mg/kg, in 100 
µL 15% PEG300 / 85% 0.9% saline). The mice were sacrificed after 2 hours and brain and 
muscle tissues harvested. The collected organs were fixed in Tissue-Tek O.C.T. compound 
(Sakura Finetek, Torrance, CA) and flash-frozen in liquid nitrogen and cut into 20 µm sections 
using a Vibratome UltraPro 5000 Cryostat (Vibratome, St. Louis, MO). A storage phosphor 
autoradiography plate (Fujifilm, BAS-MS2325, Fiji Photo Film, Japan) was exposed to the tissue 
slices overnight at -20 °C and read the following day. Relative count intensity of the sections in 
each image was quantified using ImageJ 1.47u processing software. Tumor/muscle and 
brain/muscle ratios were calculated using Prism 6.0c (GraphPad Software, La Jolla, CA). The 
same sections were subsequently subjected to H&E staining (hematoxylin–eosin) for 
morphological evaluation of tissue pathology and to compare the localization of the radiotracer 
with the location of tumor tissue. 
Ex vivo biodistribution. Biodistribution studies were performed in subcutaneous U251 MG 
xenograft bearing athymic nude mice (n = 12). Mice were divided in two groups (blocked and 
unblocked) and administered with [18F]PARPi (approximately 50 µCi, 45 mCi/µmol in 200 µL, 
10% EtOH in 0.9% sterile saline) via tail vein injection. The blocked group was pre-injected 30 
min prior with a 500-fold excess of olaparib (18 mM, 2 µmol, about 40 mg/kg, in 100 µL 15% 
PEG300 / 85% 0.9% saline). Mice were sacrificed by CO2 asphyxiation at 120 min p.i. and 
major organs were collected, weighed, and counted in a WIZARD2 automatic γ-counter 
(PerkinElmer, Boston, MA). The radiopharmaceutical uptake was expressed as a percentage of 
injected dose per gram (%ID/g) using the following formula: [(activity in the target organ/grams 
of tissue)/injected dose]⨉100%. 
PET/CT imaging. Mice bearing orthotopic U251 MG (n = 8) were divided in two groups 
(unblocked and blocked) and administered with [18F]PARPi (150 µCi, 45 mCi/µmol in 300 µL 
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10% EtOH in 0.9% sterile saline) via tail vein injection. The blocked cohort (n = 4) was pre-
injected with olaparib (37 mM, 3.7 µmol, about 80 mg/kg, in 100 µL 15% PEG300 / 85% 0.9% 
saline) 30 min prior to injection of [18F]PARPi. Approximately 5 min prior to PET acquisition, 
mice were anesthetized by inhalation of a mixture of isoflurane (Baxter Healthcare, Deerfield, IL, 
USA; 2% isoflurane, 2 L/min medical air) and positioned on the scanner bed. Anesthesia was 
maintained using a 1% isoflurane/O2 mixture. PET data for each mouse was recorded using 
static scans of 10 minutes and acquired at 30 and 120 minutes post injection. Quantification and 
%ID/g values were calculated by manually drawing regions of interests in three different frames 
and determining the average values using ASI Pro VM™ MicroPET Analysis software (Siemens 
Medical Solutions, Knoxville, TX). 
PET/MRI imaging. [18F]PARPi PET images were acquired on integrated in-line preclinical 
whole-body 1T PET/MRI system (Mediso, Budapest, Hungary). The animals were injected with 
200 µCi of [18F]PARPi and a 20 minutes static PET scan was acquired 2 hours post injection. 
200 µL of diluted gadopentate dimegumine in saline solution (1:5) (Magnevist®; Bayer Pharma, 
Wayne, NJ) was administered intravenously one minute prior to MRI acquisition. Tumor regions 
were identified on anatomic images acquired using a post-contrast T1-weigthed spin-echo (SE) 
acquisition (TE/TR = 12.4/671 ms, 0.3125 x 0.3125 mm in plane resolution and 1 mm slice 
thickness). 30 slices were acquired in order to cover the mouse. Data analysis and PET/MRI co-
registration was performed using VivoQuant™ software (inviCro LLC, Boston, USA). 
Statistical analysis. All data are expressed as mean ± SD. Differences between mouse 
cohorts were analyzed with the 2-sided unpaired Student test and were considered statistically 
significant when P < 0.05. 
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CHAPTER 5: [18F]PARPI-DIFFUSE INTRINSIC PONTINE GLIOMA 
This chapter is an adaptation of published work, and is reproduced in part, from Kossatz, S., 
Carney, B., Schweitzer, M. E., Carlucci, G., Miloushev, V., Maachani, U. B., Rajappa, P., 
Keshari, K., Pisapia, D. J., Weber, W. A., Souweidane, M. M. & Reiner, T. Biomarker based 




Brain and central nervous system (CNS) tumors are the most common solid tumor and the 
second leading cause of cancer related death in individuals 0 to 19 years of age in the United 
States and Canada1,2. Although the treatment and survival rates for more common forms of 
pediatric CNS tumors have improved3, survival significantly depends on the location and 
histologic subtype of the individual CNS lesions4,5. Certain types of brainstem tumors, 
particularly the diffuse intrinsic pontine glioma (DIPG), face a grim prognosis. Dozens of clinical 
trials have been conducted over several decades, evaluating a wide range of therapeutic 
strategies, but none of them could demonstrate a survival benefit beyond traditional external 
beam radiotherapy6–12. DIPG remains an incurable disease, with the mean survival being less 
than a year from diagnosis13. One unique feature of this tumor is the infiltrative and nonfocal 
growth pattern and the sparse uptake of MR contrast agents. Critically, although MRI can be 
used for initially diagnosing DIPG, this approach has proven imperfect for defining the true 
tumor burden and monitoring of treatment response14,15.  
As a result, established methods used for response monitoring in other CNS tumors are of 
limited value in DIPG16. Length of survival thus serves as the conventional measure of 
therapeutic efficacy. Intuitively, this falls short of being able to accurately monitor response to 
experimental therapeutics in early stages of clinical development, which therefore hinders the 
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effective and hypothesis-driven discovery of therapeutic strategies. Accordingly, CNS tumors 
that share an infiltrative and non-enhancing morphology would benefit enormously from new 
imaging technologies that can accurately diagnose and delineate tumor tissue. 
Particularly for brainstem diseases such as DIPG, where obtaining ex vivo materials for aiding 
diagnostic decision-making is not only challenging, but also not feasible on a longitudinal basis, 
we recognized that a noninvasive imaging biomarker has enormous value. We have used 
optically (PARPi-FL) and isotopically ([18F]PARPi) labeled versions of PARP1-targeted 
molecules previously for imaging of solid tumors and have shown their capability to image 
PARP1 expression in tumors with high specificity and sensitivity17–22. Using the 18F-labeled 
PARP1-targeted small molecule, [18F]PARPi, and its fluorescent sister agent PARPi-FL, we aim 
to explore three clinically relevant questions: (i)How does PARP1 expression in DIPG compared 
with healthy tissue, and do genetically engineered mouse models (GEMM) accurately reflect 
this? (ii) Do 18F-labeled PARP1 agents allow noninvasive delineation of DIPG in a pediatric 
DIPG mouse model? (iii) How accurately does [18F]PARPi reflect the tumor burden and tumor 
growth? 
We believe that a quickly and selectively distributing PARP1-targeted marker that can be 
injected intravenously can overcome many hurdles currently hampering the development of 
efficient DIPG therapeutics. Here, we test one such PET tracer, validate its high sensitivity and 
accuracy in pediatric GEMMs, and demonstrate its ability to delineate and monitor DIPG in vivo. 
5.2: PARP1 Expression in DIPG  
To probe the clinical relevance of PARP1 in DIPG, we obtained both biopsy tissue specimens 
as well as autopsy tissue from patients with histopathologically confirmed DIPG. In the 
examined infiltrative malignant brainstem glioma biopsies (n = 4), more than 90% of observed 
cell nuclei were positive for PARP1. PARP1 expression was present throughout the tumors, with 
the exception of necrotic tissue and areas with proliferative vasculature (Figure 5.2.1). Similarly,
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Figure 5.2.1. PARP1 expression in human biospecimens of DIPG. (a) Immunohistochemical 
staining of DIPG biopsy tissue for PARP1 (top) and H&E (bottom). From left to right: low 
magnification overview, viable tumor tissue, tumor area with microvascular proliferation (MVP), 
and necrosis (N). (b) PARP1 staining of a DIPG autopsy specimen showing infiltrative PARP1-
positive tumor cells in the dentate nucleus (top), but low PARP1 expression and cellular density 
in the frontal cortex of the same brain (bottom) (H&E in Supplementary Fig. S1A). (c) and (d), 
Quantification of PARP1 in biopsy (c) and autopsy (d). n = 4 histopathologically confirmed cases 
of DIPG; n = 1 DIPG autopsy brain. 
 
high PARP1 expression was observed in the autopsy specimen, where we were able to 
compare the tumor region with non-neoplastic neocortex in the same patient, which showed no 
tumor involvement. As opposed to the tumor, in the frontal cortex only, a subset of cells 
expressed PARP1, such as nuclei of oligodendritic cells and astrocytes, as well as nucleolei of a 
subset of neurons (Figure 5.2.1b and Figure A.5.1a). PARP1 abundance in DIPG was further 
amplified by the much higher cellularity of high-grade DIPG tissue compared with healthy tissue 
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(Figure 5.2.1b).  In grade IV biopsy and autopsy tissue, the total area covered by PARP1-
positive nuclei was high (28.5% ± 8.7% PARP1-positive area in biopsy and 17.5% ± 2.9% in 
autopsy tissue vs. 3.5% ± 0.9% in the frontal cortex of the same brain Figure 5.2.1c and Figure 
5.2.1d). The PARP1-positive area, together with the associated high target abundance, is 
fundamental for sufficient uptake of a molecularly targeted tracer, and to achieve a high tumor-
tobackground contrast. 
5.3: PARP1 Expression in Mouse Models  
Encouraged by the robustness of PARP1 expression in human DIPG, we turned to a mouse 
model with the aim of determining whether the high levels of PARP1 expression found in human 
tissue of DIPG is reflected in GEMMs of this malignancy. Specifically, we quantified and 
correlated PARP1 overexpression in a previously established DIPG mouse model of 
ntv-a/p53fl/fl, where tumors are formed after somatic gene transfer of oncogenes via retroviral 
delivery 23. For this study, we used two variants of the model, where cells are either injected into 
the pons of 2- to 4-day old mice (juvenile model) or into the right hemisphere of 4- to 6- week-
old mice (adult model). Upon occurrence of symptoms, which appear in both models within 4–6 
weeks after inoculation, brains were processed for histology and stained for PARP1 expression, 
proliferation index (Ki67), and morphological features (H&E). 
In the juvenile model, tumors were located primarily in the pons, but also showed spread to the 
third ventricle and parts of the hippocampus (Figure 5.3.1a). All tumor areas showed a strong 
proliferative activity, particularly toward the infiltrative edges, whereas the central regions of 
tumors contained a mix of Ki67-positive and Ki67-negative cells. All other regions of the brain 
showed almost no Ki67 expression at all (Figure 5.3.1a). Analogous to what was found for Ki67, 
PARP1 expression was also significantly higher within areas of infiltration as compared with 
healthy, nontumorous tissues (Figure 5.3.1a). Interestingly, PARP1 expression was rather 
homogeneous throughout the tumor, with the exception of necrotic areas. Regarding 
nontumorous brain areas, we detected slightly higher PARP1 expression in the cortex and the 
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Figure 5.3.1. PARP1 expression in mouse model. (a) Immunohistochemical staining of 
tumor-bearing brains following tumor generation in ntv-a/p53fl/fl mice. Anti-PARP1, anti-Ki67 
(proliferation), and H&E staining for morphological evaluation were carried out on adjacent 
sections. (b) Quantification of PARP1 staining in juvenile and adult tumor-bearing mice. ROIs 
were placed on tumor (Tu) regions and anatomically defined brain regions (Co, cortex; Po, 
pons; Ce, cerebellum; Th, thalamus; n ≥ 3 animals/4–7 ROIs per region). (c) 






cerebellum compared with pons and thalamus. While lower than what we found for tumor 
tissues, physiological PARP1 expression was observed in the Purkinje cell layer in the 
cerebellum and the dentate gyrus (Figure A.5.1b). When we quantified the PARP1-positive area 
of the regions of interest (ROI) in tumor and nontumor affected brain areas of healthy animals in 
the juvenile model, we found a PARP1-positive area of 35.9% ± 7.1% in the tumor, compared 
with 7.4% ± 1.2% in the cortex, 3.8% ± 1.1% in the pons, 3.1% ± 0.9% in the thalamus, and 
5.9% ± 1.5% in the cerebellum (P < 0.01, t test, vs. cortex, pons, thalamus, cerebellum; Figure 
5.3.1b). When tumors were induced in the cerebral hemisphere of adult mice, very similar 
PARP1 staining (Figure A.5.1c) and expression values were found (33.6% ± 4.8% PARP1-
positive area). Expression in different brain areas was significantly lower (2.1% ± 0.15% in the 
cortex, 1.0% ± 0.1% in the pons, 0.8% ± 0.3% in the thalamus, and 2.1% ± 0.6% in the 
cerebellum (P < 0.01, t test, vs. cortex, pons, thalamus, cerebellum; Figure 5.3.1b). Ratios of 
PARP1 expression in tumor tissue compared with healthy brain areas were generally high. In 
the juvenile model, they ranged from 5.0 ± 0.6 to 13.8 ± 2.4 (tumor/ cortex and tumor/thalamus, 
respectively) and in the adult model from 16.1 ± 2.2 to 35.8 ± 10.4 (tumor/cortex and tumor/ 
thalamus, respectively; Figure 5.3.1c). Overall, PARP1 expression levels in tumors were found 
to be statistically indistinguishable between the juvenile and adult model applying a random 
effects model and using a Likelihood Ratio Test (X2 = 1.57, P = 0.21). Our GEMM PARP1 
expression data corresponds to PARP1 expression in human DIPG biospecimens that showed 
grade IV histopathology (Figure 5.2.1). 
5.4: DIPG Localization with [18F]PARPi  
As a next step, and analogous to what we have seen for the fluorescent PARP1 tracer 
PARPi-FL, we tested whether the fluorescent agent's PET active counterpart [18F]PARPi could 
be used for noninvasive DIPG imaging. We injected the radiolabeled imaging agent 
intravenously in tumor-bearing juvenile ntva/p53fl/fl mice. Correlation of autoradiography images 




Figure 5.4.1. PARPi-FL microscopy and [18F]PARPi autoradiography. Mice were injected with 
PARPi-FL or [18F]PARPi upon occurrence of symptoms of tumor growth (gait instability, weight 
loss, crouching, head swelling). Mice were sacrificed and brains were processed for 
cryoconservation 2 hours p.i. of PARPi-FL. Adjacent sections were stained for PARP1 
expression and H&E. (a) PARPi-FL microscopy. Cryosections were costained with Hoechst 
DNA stain. n = 5. (b) High magnification images. (c) [18F]PARPi autoradiography. (d) 
Quantification of autoradiography where ROIs were placed on activity hotspots, tumor-adjacent 
brain, and corresponding sections in healthy brains (n = 3–8 ROIs per specimen). (e) 
Quantification of autoradiography where ROIs were placed on entire sections. (f) Signal ratios 




areas infiltrated by tumor cells (Figure 5.4.1c), identifying tumor activity hotspots, and even 
tumors of less than 1.5 mm diameter showed uptake of [18F]PARPi with clear contrast to 
background. In mice that did not receive an injection of virus carrying DF1 cells, no activity 
hotspots or histological signs of malignant growths were found, indicating that the uptake is 
connected to PARP1 expression and, consequently, tumor specific (Figure 5.4.1c). 
Quantification of the signal intensity showed clearly higher signal in DIPG than in normal brain 
of tumor bearing and control animals (Figure 5.4.1d). When size and number of hotspots was 
not considered and average signal intensity of tumor-bearing brains was compared with normal 
brains, there was also a clear, statistically significant cutoff value between the groups with no 
overlap (Figure 5.4.1e; P < 0.0001, Student unpaired t test). To evaluate the strength of contrast 
ratios between the different groups, we calculated mean values for each group. The average 
signal in entire sections containing tumor hotspots was 7 times higher than healthy brain 
sections. The average signal in ROIs focusing on tumor hotspots was 15-fold higher than in 
tumor-adjacent areas of the same sections and 47-fold higher than randomly assigned areas of 
the same size in healthy brains (Figure 5.4.1f). 
Encouraged by the robustness of our PET imaging tracer, we decided to use the juvenile DIPG 
mouse model to noninvasively probe the specificity of [18F]PARPi accumulation in vivo, using 
both animals that showed symptoms of tumor presence and agematched healthy controls. For 
tumor-bearing mice, PET/CT images 2 hours p.i. revealed an accumulation of [18F]PARPi in the 
pons of animals that could be correlated to the presence of tumor on H&E and PARP1 
histological slides (Figure 5.4.2a). Probing the selectivity of [18F]PARPi, we injected 1 mg 
olaparib before injection of the tracer. This was done in an attempt to saturate available binding 
sites, and consequently block the uptake of the tracer. For this cohort of mice, no accumulation 
of the probe could be observed, irrespective of tumor tissue being present in the pons, as 
confirmed by H&E- and PARP1-stained slides (Figure 5.4.2a). [18F]PARPi PET/CT imaging of 
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Figure 5.4.2. PET/CT images. (a) Representative PET/CT images of the brainstem region 
compared with H&E and PARP1 staining of the same animals. White arrow = tumor location. (b) 
Quantification of %ID/g of the entire brain was derived from the PET/CT data set using the CT 
as reference for creating VOIs. (c) Similarly, the %ID/g was analyzed for the brainstem region 
using the CT as reference for creating VOIs. 
 
healthy mice looked similarly negative. For quantification, volumes of interest (VOIs) were 
created to encompass either the entire brain or the pons of each animal using the CT images for 
anatomical reference. Calculation of the percentage of injected dose per gram (%ID/g) revealed 
that the average %ID/g was significantly increased to 0.45 ± 0.07 %ID/g in tumor-bearing brains 
injected with [18F]PARPi, compared with healthy animals and animals receiving a preinjection of 
olaparib (0.25 ± 0.03 %ID/g and 0.23 ± 0.02 %ID/g, respectively; P < 0.05; Figure 5.4.2b). The 
differences were even more pronounced when only the pons was considered (0.63 ± 0.19 
%ID/g vs. 0.25 ± 0.01 and 0.22 ± 0.03 %ID/g, respectively; P < 0.05; Figure 5.4.1c). Hence, 
binding specificity could be confirmed by statistically significant reduction of [18F]PARPi uptake 
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by preinjection of excess PARP1 inhibitor olaparib. No statistically significant differences were 
found between healthy animals and animals receiving olaparib (P = 0.3 when considering the 
whole brain and P = 0.1 when considering the pons; Student unpaired t test). 
5.5: Comparison with MRI, CT and Histology 
Next, we compared the ability of different in vivo imaging modalities to spatially resolve the 
growth pattern of DIPG, using histology as a gold standard. We could confirm that the location 
and extent of the tumor as determined using [18F]PARPi PET accurately represents the tumor 
volume and the area of increased PARP1 expression (white arrow, Figure 5.5.1). In the adult 
model of DIPG, we were also able to delineate tumors in T2-weighted MRI. Increased interstitial 
edema caused a strong MRI signal change, which was not seen in [18F]PARPi-PET images 
(orange arrow, Figure 5.5.1). Using CT alone, tumors did not show contrast due to absence of 
soft tissue contrast in small animal CT. Outside of the brain, [18F]PARPi generated a strong  
 
Figure 5.5.1. Comparison with MRI. Top (left to right): CT, PET, and PET/CT 1 hour p.i. of 
[18F]PARPi. Bottom (left to right): T2-weighted 1.05T MRI image, PARP1 IHC (brown staining), 
and H&E. All images are from the same animal. PET/CT and MRI were conducted on the same 
day and the animal was sacrificed immediately after MRI to preserve the brain for histology. 
White arrow, tumor location. Orange arrow, an accumulation of cerebrospinal fluid, which 
causes a strong MRI signal, but is not seen in [18F]PARPi imaging. 
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signal in the gut, due to its hepatobiliary excretion (Figure A.5.3). Beyond the gut, it specifically 
localizes only to PARP1-expressing tissues, which can be seen by comparing PARP1 IHC of a 
range of tissues and organs (Figure A.5.4) to biodistribution data of [18F]PARPi with and without 
blocking using olaparib (Figure A.5.5), revealing the spleen, lymph nodes, salivary gland, and 
pancreas as tissues with PARP1 expression. 
5.6: Comparison with Other PET Brain Tracers 
To determine whether PARP1 expression and [18F]PARPi uptake in the brain coincides with the 
elevated metabolism and DNA synthesis rate typically seen for aggressively growing malignant 
cells, we subjected tumor-bearing animals to [11C]Choline and [18F]FLT PET/CT in addition to 
[18F]PARPi PET/CT. All animals (n = 5) also received noncontrast-enhanced MRI scans (Figure 
5.6.1a). Unequivocal tumor detection with [11C]Choline imaging (10 minutes p.i. of 378 ± 343 
µCi) led to a visible tumor to background contrast in 3/5 animals. The mean %ID/g in tumor was 
2.74 ± 0.71 and in nontumor tissue 1.96 ± 0.34 %ID/g). [18F]PARPi and [18F]FLT were both 
conducted at 2 hours p.i. of comparable amounts of activity (162 ± 22 mCi and 147 ± 19 mCi for 
[18F]PARPi and [18F]FLT, respectively). The mean uptake in tumor was 0.3 ± 0.12 %ID/g for 
[18F]PARPi and 1.27 ± 1.19 %ID/g for [18F]FLT, showing higher overall uptake, but also higher 
variability in probe uptake, yielding less consistent uptake values (Figure 5.6.1b). The 
background uptake in nontumor brain tissue was lower for [18F]PARPi than [18F]FLT (0.08 ± 0.04 
%ID/g vs. 0.18 ± 0.15 %ID/g, respectively. Although both [18F]PARPi and [11C]Choline showed 
statistically significant differences in mean %ID/g comparing tumor and nontumor areas (P = 
0.02 and P = 0.04, respectively, paired two-tailed t test), [18F]FLT did not (P = 0.1). However, we 
observed a high variability of the signal and the number of animal studies was rather small. 
Tumors were also visible in T2-weighted MRI images acquired on a 1.05T MRI; however, strong 
variations of the T2 signal within animals was observed. Histological evaluation of all tumors 
confirmed presence of PARP1 overexpression within tumor tissue (Figure 5.6.1a). We 
confirmed that [18F]PARPi is able to delineate brain tumors with a clear contrast with normal 
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brain tissue, and uptake location is in agreement with metabolic PET tracers. Although these, 
together with MRI, are also able to delineate tumors, they cannot provide information on PARP1 
expression, target engagement, and treatment eligibility monitoring, which is a unique feature of 
[18F]PARPi. 
 
Figure 5.6.1. Comparison with other PET imaging agents. (a) Representative PET/CT images 
of the same tumor-bearing animal (adult model, right hemisphere) using [18F]PARPi (2 hours 
p.i.), [11C]Choline (5 minutes p.i.), [18F]FLT (2 h p.i.), and MRI (T2 weighted) compared with 
PARP1 IHC and H&E histology. [18F]FLT and MRI were conducted 48 hours after the 
[18F]PARPi and [11C]Choline imaging. Calibration bar represents %ID/g. (b) Quantification of the 






5.7: Monitoring Tumor Progression 
We further evaluated the capability of [18F]PARPi to monitor tumor growth by performing weekly 
imaging using ntv-a/p53fl/fl mice injected with DF1 cells in the right hemisphere at 4–6 weeks of 
age. We were able to detect focal accumulation of [18F]PARPi in week 5 p.i., showing hotspots 
of activity of 1.5–2.0 mm in size. These hotspots showed considerably increased mean and max 
%ID/g within one week (Figure 5.7.1a and Figure A.5.6a). The hotspots in the PET/CT imaging 
could be confirmed to correlate with tumor tissue using histology. The [18F]PARPi retention was 
quantified using a retrospective approach, where the confirmed tumor location in week 6 was  
 
Figure 5.7.1. Tumor growth monitoring. (a) Tumor development was followed over the course of 
6 weeks. H&E and PARP1 histology were conducted after the last imaging time point. (b) VOIs 
were created in the tumor region and control region using the PET/CT and histologically 
confirmed tumor location. These were then applied to earlier imaging time points. (c) Mean and 
(d) max %ID/g for 3 to 6 weeks post-tumor inoculation. 
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used to draw a VOI in the same region of all scans recorded in previous weeks (Figure 5.7.1b). 
Quantification of mean and maximum %ID/g in the tumor area showed that an increase in 
uptake was observed in week 5, which strongly increased in week 6, whereas the uptake in 
nontumorous tissue and the entire brain remained unchanged over the course of the experiment 
(Figure 5.7.1c and Figure 5.7.1d). Tumor-bearing animals began showing symptoms such as 
weight loss, crouching, gait-instability and scruffy fur in week 6 of the experiment and had to be 
sacrificed by week 7. One animal showed no uptake of [18F]PARPi over 7 weeks and was 
histologically confirmed to have no tumor growth (Figure A.5.6b). 
5.8: Conclusion 
In summary, our radiolabeled small-molecule [18F]PARPi efficiently targets PARP1, in vitro and 
in vivo, a biomarker that is highly expressed in DIPG. To date, no biomarkers are used as the 
standard of care in diagnosis or treatment of DIPG. Our results indicate that not only does 
[18F]PARPi allow serial imaging, but histological slides also show that PARP1 expression might 
correlate to different types of CNS neoplasms (including benign lesions), inflammation, and 
radiation induced necrosis. Notably, quantification of [18F]PARPi in the brain indicates that it 
might be possible to determine the presence of tumor by looking at the average total brain 
uptake. Because PET imaging only requires miniscule amounts of radiolabeled tracer, the 
imaging technology we present here would not interfere with therapeutic treatment protocols 
and might provide robust treatment criteria for patients—even before the progression/regression 
of tumor tissue is observed. In conclusion, our preclinical results indicate a strong rationale for 
further investigating [18F]PARPi, and clinical translation of our small molecule is within reach. 
5.9: Experimental 
Human biospecimens. Formalin-fixed paraffin-embedded tissue (FFPE; n = 4 surgical biopsies 
and n = 1 autopsy specimen of diffuse midline glioma) were obtained from the tissue archives at 
Weill Cornell Medicine. The use of archival tissues was approved by the Institutional Review 
Board (IRB) at Weill Cornell Medical College and consent was waived as by the IRB approval. 
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In vivo tumor generation. DIPG development was modeled using a glioma model based on 
the RCAS/tv-a system where tumors are initiated by somatic gene transfer of oncogenes into 
genetically engineered mice carrying oncogenic driver mutations23. Specifically, we used p53 
deficient nestin/tv-a mice (ntv-a/p53fl/fl mice), which express the retroviral receptor for the RCAS 
vector in neuroglial progenitor cells. In vivo tumor development was initiated by the delivery of 
two oncogene-expressing RCAS vectors (RCAS-PDGFB and RCAS-Cre), which were 
transfected into immortalized chicken fibroblasts using the Fugene 6 transfection kit (no. 
11814443001; Roche) according to the manufacturer’s recommendations (DF-1 cells)24. DF1 
cells were obtained from ATCC (ATCC® CRL12203™) in 2014. Cells were expanded 
immediately and all experiments were conducted on the same batch of cells frozen as Passage 
2. Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L glucose, 
L-glutamine, and sodium pyruvate with 10% FBS and 2% normocin at 39°C, 5% (vol/vol) CO2, 
and passaged every 3-4 days under sterile conditions. 
To generate tumors, RCAS-PDGFB and RCAS-Cre DF1 were mixed in a 1:1 ratio and diluted to 
a concentration of 100,000 cells/µl before injection of 1 µl of cell suspension. To generate a 
pediatric tumor model, newborn pups aged 2-4 days were injected. Pups were held with a light 
grip on the ears to ensure the skull sutures were visible. Using a beveled needle on a 10 µl 
Hamilton syringe, the needle was lowered 2 mm deep into the brain from an approximate 
location of 2 mm posterior to lambda to target the pons. After 1 µl of cells was pushed free hand 
into the brain, the needle was held in the brain for a few seconds. A similar strategy was used in 
adult mice (4-6 weeks at time of injection). Injections were made using a stereotactic frame 
(David Kopf Instruments Model 900) and a micro4 injection pump and controller (World 
Precision Instruments). Mice were anesthetized using 2% isoflurane. The skull was exposed 
and the injection site at coordinates 2 mm right and 0.5 mm anterior from Bregma, and 3.5 mm 
deep from the skull surface, was identified. A small hole was drilled into the skull surface, and 
the syringe (World Precision Instruments Nanofil Syringe) was lowered into the brain. One µl of 
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cell suspension was infused at a rate of 100 nl per minute. The syringe was left in the skull to 
settle for 5 minutes before and after the infusion. Animals were continuously monitored for 
common symptoms including weight loss, gait instability, hunched bodies, and scruffed fur. In 
juvenile and adult mice, symptoms started showing around 4-5 weeks post-inoculation. All 
animal experiments were performed in accordance with institutional guidelines and approved by 
the IACUC of MSK, and followed NIH guidelines for animal welfare. 
Immunohistochemical staining. Staining was carried out using primary antibodies against 
PARP1 (sc-7150, Santa Cruz Biotechnology), Ki67 (proliferation; AB16667, Abcam), and CD31 
(endothelial cells; DIA-310, Dianova) using formalin-fixed, paraffin-embedded sections (FFPE). 
If we aimed to detect i.v. injected PARPi-FL fluorescence in adjacent sections, frozen samples 
were used. 
PARP1 immunohistochemistry of human and mouse FFPE sections was carried out using the 
automated Discovery XT processor (Ventana Medical Systems). Three-µm sections were 
deparaffinized with EZPrep buffer, antigen retrieval was performed with CC1 buffer (both 
Ventana Medical Systems), and sections were blocked for 30 minutes with Background Buster 
solution (Innovex). Anti-PARP1 antibody (0.2 µg/ml) was incubated for 5 h, followed by 1 h of 
incubation with biotinylated goat anti-rabbit IgG (PK6106, Vector Labs) at a 1:200 dilution. For 
IHC detection, a DAB detection kit (Ventana Medical Systems) was used according to the 
manufacturer’s instructions. Sections were counterstained with hematoxylin and cover-slipped 
with Permount (Fisher Scientific). 
CD31 and Ki67 staining of FFPE or frozen sections were carried out using the Leica Bond RX 
(Leica Biosystems). FFPE sections were deparaffinized and frozen sections were baked for 1 h 
at 50°C. Then sections were pretreated with Leica Bond ER2 Buffer (Leica Biosystems) for 20 
min at 100°C before each staining. For Ki67, sections were incubated with 1 µg/ml Ki67 rabbit 
polyclonal for 1 h followed by either 10 min 1:200 Tyramide AlexaFluor 488, for IF, or protocol F 
(default from manufacturer), for IHC. For CD31 staining, sections were incubated with 1 µg/ml 
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CD31 rat monoclonal for 1 h and a linker antibody—1.5 µg/ml biotinylated rabbit anti-rat 
Vectastain ABC kit (Vector Laboratories) for 8 min, followed by 10 min 1:200 Tyramide 
AlexaFluor 488 (for IF) or protocol F (default from manufacturer), for IHC. Adjacent sections 
were stained for H&E for morphological evaluation. 
Multicolor immunofluorescence staining. To evaluate co-localization of PARPi-FL, PARP1, 
CD31, and Ki-67, multicolor immunofluorescence (IF) staining on cryosection was conducted 
following a manual staining protocol using the same antibodies as mentioned above. IF 
detection was performed with Streptavidin-HRP D (from DABMap Kit, Ventana Medical 
Systems), followed by incubation with Tyramide Alexa Fluor 488 (T20932, Invitrogen), Alexa 
Fluor 568 (T20935, Invitrogen), or Alexa Fluor 594 (T20935, Invitrogen) prepared according to 
the manufacturer’s instructions, to allow for simultaneous detections of all markers. Sections 
were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) for 10 minutes and cover-slipped 
with Mowiol® mounting medium (Sigma-Aldrich). Incubating with a nonspecific IgG from the 
same species as the primary antibody instead of the primary antibody controlled for non-specific 
binding of the secondary antibody. For morphological evaluation of tissue characteristics, H&E 
staining was performed on adjacent sections. Fluorescence images were captured using a 
Leica (Buffalo Grove, IL) SP5-upright confocal microscope equipped with suitable lasers and 
emission filters.  
Synthesis of PARPi-FL. Synthesis of the optical imaging agent PARPi-FL was carried out as 
previously described18. Briefly, the NHS-ester of the green fluorescent dye BODIPY-FL 
(Invitrogen, Carlsbad, CA) was conjugated to 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl) 
phthalazin-1(2H)-one for 4 h at room temperature. The product PARPi-FL was purified by 
preparative HPLC (Waters’ XTerra C-18 5 µm column, 7 ml/min, 5% to 95% of acetonitrile in 
15 min) with a yield of 70-79% as a red solid and its identity was confirmed using ESI-MS 
(MS(+) m/z = 663.4 [M+Na]+). Analytical HPLC analysis (Waters’ Atlantis® T3 C18 5 µm 
4.6 × 250 mm column) showed high purity (>97%) of the imaging agent. For storage at -80 °C, 
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PARPi-FL was formulated in polyethylene glycol (PEG300, Sigma-Aldrich) at a concentration of 
1 µg (1.5 nmol)/µl. Before in vivo injection, PBS was added until a final concentration of 30% 
PEG300 in PBS was reached. Intravenous injection in juvenile mice was limited to a final 
volume of 50 µl (15 µg/22.4 nmol PARPi-FL).  
Synthesis of [18F]PARPi. Similar to PARPi-FL, [18F]PARPi is based on the structure of olaparib 
and was synthesized similar to a protocol reported before21. Specifically, a QMA cartridge 
containing cyclotron-produced [18F] fluoride ion (50 mCi, 1.85 GBq) was eluted with a solution 
containing 9 mg Kryptofix [2.2.2] (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8] 
hexacosane), 0.08 ml 0.15 M K2CO3, and 1.92 ml MeCN into a 5 ml reaction vial. Solvents 
were removed azeotropically at 120 °C under N2. Afterward, 500 µg of ethyl 4-nitrobenzoate in 
100 µl of dry DMSO were added and the mixture was heated to 150 °C for 15 min. Next, 50 µl of 
NaOH was added, followed by 50 µl of HCl. Then, 2 mg of 4-(4-fluoro-3-(piperazine-1-
carbonyl)benzyl)phthalazin-1(2H)-one in 100 µl of dry DMSO were added, followed by 10 mg of 
HBTU dissolved in 100 µl of DMSO and 20 µl of Et3N. Finally, 400 µl of MeCN and 1 ml H2O 
were added to the mixture and the product was purified by HPLC yielding 38.4 ± 2.5%. 
Synthesis of [11C]-Choline. [11C]Choline was produced in the Radiochemistry & Molecular 
Imaging Probes Core Facility at MSKCC by the on-site PETtrace800 cyclotron and GMP 
production facility using an established workflow25,26. In brief, [11C]Choline was synthesized by 
11C-methylation of dimethylethanolamine (DMEA, 40 µl) in acetone and the reaction mixture was 
incubated at room temperature in a GE FXM synthesizer (GE, Fairfield, CT). Next, the product 
was isolated and extracted using a cation-exchange cartridge (CM light, Milford, MA) previously 
rinsed with ethanol. The final product was eluted with sterile saline (dcY > 30% in a 15-minute 
total synthesis time) through a sterilization filter for further imaging studies. 
Synthesis of 3’-deoxy-3’[18F]-fluorothymidine ([18F]FLT). Synthesis of [18F]FLT was carried 
out as described before27,28. Briefly, a QMA cartridge containing cyclotron-produced [18F] fluoride 
ion (50 mCi, 1.85 GBq) was eluted with a solution containing 9 mg Kryptofix [2.2.2] 
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(4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane), 0.08 ml 0.15 M K2CO3, and 
1.92 ml MeCN into a 5 ml reaction vial. Solvents were removed azeotropically at 120 °C under a 
slight flow of nitrogen. Thereafter, 5 mg of precursor 3-N-Boc-5’-O-dimethoxytrityl-3’-O-nosyl-
thymidine (6.02 µmol) in 500 µl dry acetonitrile were added, then the reaction mixture was 
heated to 150 °C for 10 min. After cooling to room temperature, 1 N hydrochloric acid (400 µl) 
was added and the reaction mixture was heated to 90 °C for 10 min. The reaction mixture was 
neutralized by the addition of 2 M sodium acetate solution (1.3 ml) and purified by HPLC 
yielding 16.7% (21.7% decay-corrected) of pure [18F]FLT.  
Autoradiography. To determine the localization of [18F]PARPi in the brain after i.v. injection, we 
conducted autoradiography on tumor-bearing (n=4) and healthy (n=2) animals (juvenile 
ntv-a;p53fl/fl mice, injected with DF1 cells at postnatal day 2-4). Animals were injected with 150-
170 µCi [18F]PARPi via retroorbital injection and sacrificed at 2 h p.i. The brains were extracted 
without perfusion, embedded in OCT compound (Sakura Finetek), and immediately frozen on 
dry ice. 20 µm serial cryosections were sliced from frontal to caudal using a cryostat (Vibratome 
Ultra Pro 5000). Nine coronal sections, selected in an equidistant fashion to cover all brain 
areas, were selected for autoradiography and adjacent sections were H&E stained for 
morphological correlation of tissue pathology and radiotracer localization. A storage phosphor 
autoradiography plate (Fujifilm, BAS-MS2325, Fiji Photo Film) was exposed to the tissue slices 
overnight at -20 °C and read the following day. Relative count intensities were determined using 
ImageJ 1.47u processing software (source: http://rsbweb.nih.gov/ij/). Regions of Interest (ROIs) 
included entire brain sections and activity hotspots, which were identified as tumor on H&E. To 
calculate count ratios between groups (tumor hotspot/normal adjacent brain, tumor-bearing 
brain/normal brain), the mean value of each group was used. 
PET/CT imaging—general. PET/CT images were acquired on an Inveon PET/CT (Siemens) 
and reconstructed scans were analyzed using the Inveon Research Workplace Software. To 
acquire PET/CT images, animals were anesthetized with 2% isoflurane and positioned on the 
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scanner bed. For [18F]PARPi imaging, animals were intravenously injected with 120–180 mCi of 
the tracer 2 hours before PET/CT imaging, if not indicated otherwise. Typically, PET data were 
collected for 5–10 minutes, followed by CT. Correction for partial volume effects was not carried 
out, due to the lack of availability of a reference standard for tumor volume. 
Specificity of [18F]PARPi accumulation in vivo. To determine specificity of in vivo 
accumulation of [18F]PARPi, juvenile ntv-a;p53fl/fl mice with tumors located in the brainstem (n . 
6) or control mice without tumors (n = 3) were divided into three groups. Tumor-bearing and 
healthy (=control) animals were injected with [18F]PARPi (n = 3/group) or tumor-bearing animals 
were injected with 1 mg olaparib 30 minutes before injection of [18F]PARPi (n = 3) to occupy 
specific binding sites ("Block"). We calculated the percentage of injected dose/gram (%ID/g) for 
the entire brain or the pons region of all three groups. Therefore, we created three-dimensional 
volumes of interest (VOI) using the CT data acquired together with the PET images. 
Subsequently, animals were submitted to intracardiac perfusion and preservation of brains for 
histology as described above. H&E staining and PARP1 IHC (methodology described above) 
were used to compare localization of [18F]PARPi to the presence of tumors. 
Comparison of [18F]PARPi, [18F]FLT, and [11C]Choline in PET/CT using adult mice. The 
PET contrast agents [18F]FLT and [11C]Choline, which are clinically used for imaging 
malignancies of the brain, as well as MRI, were compared with [18F]PARPi imaging. Here, we 
used ntva;p53fl/fl mice injected with DF1 cells in the right hemisphere at 4- to 6-weeks-old (n = 
5). Each animal underwent all four imaging procedures. Five weeks after tumor inoculation, we 
first imaged [11C]-Choline and [18F]PARPi on the same day, followed by [18F]FLT and MR 
imaging 48 hours later. For [11C]Choline imaging, we injected 100–900 mCi per animal. Imaging 
was started 10 minutes after intravenous injection of [11C]Choline for 10 minutes, followed by 
CT. Five hours later, 100–200 mCi [18F]PARPi was injected into the same animals and imaged 2 
hours p.i. using a 5-minutes scan protocol followed by CT. Two days later, we imaged the same 
animals using [18F]FLT after injection of 120–180 mCi. Images were acquired at 2 hours p.i. 
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using a 10-minutes scan followed by CT. Later on the same day, we acquired MR images of the 
same animals. 
PET/CT imaging in adult mice using [18F]PARPi to follow tumor Growth. To monitor tumor 
growth rate and determine minimum required tumor volumes for imaging, we conducted an 
imaging study over the course of 6 weeks using ntv-a;p53fl/fl mice injected with DF1 cells in the 
right hemisphere at 4- to 6-weeks-old (n = 4). At 3 weeks after tumor inoculation, we started a 
weekly imaging schedule. Every 7 days, we injected 100–200 mCi [18F]PARPi and conducted 
PET/CT imaging 2 hours p.i. using a 5-min PET scan, followed by CT. At the end of the study, 
we conducted an MRI. Intracardiac perfusion was carried out as described above and brains 
were submitted for H&E and PARP1 histology. Quantification of the %ID/g was carried out 
retrospectively. VOIs were created after tumor development was confirmed using the PET/CT 
and MRI images from week 6 and placed in the same brain areas in the PET/CT images of the 
previous weeks. Furthermore, the %ID/g of the entire brain, independent of tumor presence or 
size, was analyzed. 
Magnetic resonance imaging. MRI was performed on a 1.05 T small animal imaging system 
(NanoScan, Mediso Inc.). The imaging protocol included localizer gradient-echo images used to 
plan sequential high-resolution T2-weighted, pre-contrast T1-weighted image, and post-contrast 
T1-weighted images. The axial slice FOV was 32 ⨉ 32 mm, 2 mm slice thickness (no slice gap), 
with 8 slices sufficient for full brain coverage. The matrix size was 128 ⨉ 128. A NEX of 4 
provided sufficient SNR. For the T2-weighted images, TR was 4377 ms, effective TE was 90 
ms, and ETL was 32. 
Statistical analysis. For histological analysis, we evaluated at least 3 different stained samples 
with more than 5 analyzed fields-of-view before statistical analysis was carried out. In vivo, a 
minimal animal number per group of 3 mice was required for statistical analysis and was 
extended to 5 where possible. Unless otherwise stated, data points represent mean values and 
error bars represent standard deviations of biological replicates. Statistical analysis was carried 
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out using Prism 6.0c (GraphPad Software) and R. To evaluate differences between groups we 
used the unpaired Student t test, assuming populations with an equal SD, unless otherwise 
stated. If more than two groups were compared, we corrected for multiple comparisons using 
the Holm-Sidak method. Cutoffs for statistically significant differences between groups were 





CHAPTER 6: [18F]PARPI-SMALL CELL LUNG CANCER 
This chapter is an adaptation of another work, and is reproduced in part, from Carney, B., 
Kossatze S., Lok B.H., Schneeberger, V., Gangangari K.K., Pillarsetty, N.V.K., Weber W.A., 
Charles C.M., Poirier J.T., Reiner T.. Target Engagement Imaging of PARP Inhibitors in Small 
Cell Lung Cancer. (under revision) 
 
6.1: Introduction 
While the diagnosis and treatment of many malignancies have seen significant improvements 
over recent decades1, the 5-year survival rates of small cell lung cancer (SCLC), a subset of the 
general lung cancer population (13%, 29,000 of 221,000 patients in US annually) remain around 
5% and are below 1% for the over 60% of patients that are diagnosed with extensive stage 
disease. The standard of care for advanced SCLC has essentially remained stagnant for more 
than 30 years.  
The lack of progress, in part, can be attributed to the aggressive nature of this disease, which is 
exceptionally proliferative and rapidly develops resistance to chemotherapy. Therefore, novel 
treatment approaches are needed. Therapeutics that are targeted against a tumor specific 
biomarker have gained large interest because they can specifically act against tumor cells 
without the systemic toxicity and side effects of chemo- or radiotherapy. In the clinical reality, 
however, only a subset of patients responds well to targeted therapies. A better understanding 
of the spatial distribution and quantification of the target as well as the intratumoral drug-target 
interaction could strongly improve targeted therapy approaches by identifying particularly 
sensitive or resistant patient sub-populations, and by allowing ongoing monitoring of emerging 
resistance, enabling rapid change in chemotherapy regimens. 
A radiolabelled, non-invasive imaging tracer would be an ideal candidate for such a diagnostic 
tool, because it would allow unlimited “sampling” of all metastases in an individual patient and 
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provide contemporaneous uptake values, allowing quantitative measurements before, during 
and after treatment cycles.  
One class of therapeutics that are being investigated as new treatment options for SCLC, are 
poly ADP-ribose polymerase (PARP) inhibitors. PARP inhibition, and the associated 
perturbation of the single-stranded DNA repair pathway, has been shown to be a promising 
therapeutic approach in both preclinical and clinical research settings2. The combination of 
PARP inhibitors and DNA damaging agents, such as temozolomide, has seen recent success 
and sufficient delivery of both drug classes potentiates their therapeutic effects2,3. One reason 
for this is that DNA damage repair plays an important role in the sensitivity of SCLC to 
chemotherapeutic agents, and consequently, current standard of care therapies for SCLC 
contain at least one DNA damaging agent. This sensitivity can be attributed in part to the 
genetics of this disease: nearly all patients have loss of the tumor suppressor genes TP53 and 
RB1, which are critical to the normal function of multiple DNA damage response pathways and 
G1/S checkpoint maintenance, respectively4,5. Critically, there is not only consistent protein 
overexpression of PARP1 in SCLC, but also increased sensitivity to PARP1/2 inhibitors, despite 
of intact BRCA6. Based on these observations and the underlying genetics of the disease, 
PARP inhibition is gaining considerable attention as a novel systemic treatment for SCLC (i.e., 
NCT02289690, NCT02734004, NCT01286987).  
 “One-size-fits-all” flat dosing regimens, or weight-based dosing regimens, have generally been 
used for members of this drug class, several of which have advanced to phase III trials. While 
this may be sufficient for some clinical applications, many patients – and in particular SCLC 
patients – may benefit from an immediate readout for determining the degree of on-target 
intratumoral PARP inhibition and, consequently, an imaging probe that can monitor and quantify 
PARP1/2 inhibition success. 
In light of the expanding clinical relevance of PARP therapeutics, and the diversity of novel 
agents in this area, we became interested in exploring in vivo pharmacodynamic monitoring of 
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PARP inhibitor target engagement in SCLC. A number of PARP therapeutics have entered late 
phase clinical research (niraparib, talazoparib, veliparib) or are already FDA approved 
(rucaparib, olaparib). While all of these small molecules possess unique pharmacokinetic 
profiles and therapeutic indices, they share one common binding motif: the NAD+ active site 
pocket of PARP. Therefore, while the development of an imaging tracer for each individual 
therapeutic would require considerable preclinical and clinical resources, we hypothesized that 
a single imaging tracer may be used to quantify target engagement for a broad group of PARP 
inhibitors, unlike other classes of drugs.  
To test this hypothesis, we designed a series of experiments central to clinical translation of 
PARP target engagement imaging, which that addresses 3 fundamental questions: 1) What is 
the range of PARP expression in SCLC and will this range support quantitative assessment of 
PARP imaging? 2) Are the putative imaging reagents, [18F]PARPi and PARPi-FL, selective 
binders of PARP and do they have the same binding profile as their therapeutic counterparts? 
3) Can target inhibition of PARP be quantified for PARP therapeutics generally and can our 
PARP imaging agents non-invasively predict target engagement in vivo?  
We believe that finding and validating [18F]PARPi as a widely applicable, easy-to-use general 
PARP target engagement imaging agent is of high value for optimizing SCLC treatment. Such 
an agent would not only serve as a “companion imaging agent” for one individual molecularly 
targeted drug, but rather a whole class of therapeutics, dramatically expanding and amplifying 
its potential utility in clinical practice. Here, using patient-derived xenograft models of SCLC, we 
present a highly sensitive and accurate technology for quantifying PARP inhibitors and target 
engagement in vivo in support of the clinical relevance of [18F]PARPi for treatment monitoring 
and prediction. 
6.2: PARP Family Cross Reactivity 
PARP enzymes are a family of 17 proteins that share the same catalytic PARP domain7. PARP 
inhibitors have been shown to exhibit a wide range of pharmacologic specificity within this 
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Figure 6.2.1. Cross family reactivity. Heat map visualizing enzymatic activity screening of 10 
small molecules against 12 PARP enzymes at 100 nM concentration (for additional 
concentrations, see Figure A.6.1). 
 
family7. For SCLC in particular, upregulation and overexpression of PARP1 has been 
demonstrated, and is proposed as a therapeutic target6. In developing PARP targeted imaging 
agents, we first wanted to ensure that the modifications made for imaging did not substantially 
alter target engagement with the key PARP enzymes. To determine the specificity of our 
imaging agents within this family of enzymes, and to compare their inhibition profile to clinically 
relevant PARP therapeutics, we conducted an enzyme activity inhibition screening across all 
available enzymes. Included in the study were 5 inhibitors in phase III clinical trials or FDA 
approved: olaparib, veliparib, talazoparib, niraparib, and rucaparib, together with our imaging 
agents [18F]PARPi and PARPi-FL. We also included AG14361, (Ki(PARP1) < 5 nM)8, UPF1069 
(IC50(PARP2) = 0.3 ± 0.1 µM)9, and iniparib as negative control. We assessed the inhibitory 
activities of the PARP therapeutic agents and our imaging agents across 12 PARP enzymes 
including tankyrases TNKS1 and TNKS2 (Figure 6.2.1 and Figure A.6.1). The imaging agents 
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generally exhibited comparable or higher specificity for PARP1/2 compared to the therapeutic 
molecules. At 100nM, all therapeutic molecules, except niraparib, inhibited activity in PARP3 as 
well as PARP1/2 (>35% for PARP3, >90% for PARP1 and PARP2). Talazoparib also exhibited 
inhibition for both tankyrase enzymes, TNKS1 and TNKS2. 19F-PARPi (the non-radioactive 
analogue to [18F]PARPi) and PARPi-FL showed very low inhibition of TNKS1 and TNKS2 (≤5%) 
and PARP3 (≤30%). Inhibition of PARP1 and PARP2 was strong (both >90%), overlapping with 
the therapeutic clinical candidates – and providing a rational basis for using our imaging agents 
as general sensors for PARP1/2 target engagement. Further comparison of all inhibitors used in 
this study showed similar binding affinities for all inhibitors including the imaging agents, with 
low nanomolar IC50 values reported for both PARP1 and PARP2 (see Chapter 1: Table 1.5.1). 
One notable difference is in the trapping ability reported for each inhibitor, a mode of efficacy 
whereby the inhibitor traps the PARP enzyme at the site of DNA damage, leading to further 
DNA damage and ultimately cell death10,11. It has been reported that talazoparib is the most 
effective PARP trapping agent12, as well as the most potent PARP inhibitor in SCLC clinical 
testing13. 
6.3: PARP1 Expression in SCLC PDX Models 
In order to better understand the possible benefit of PARP targeted therapy and imaging for 
SCLC, we investigated PARP1 expression in 8 different PDX lines and tissues from 6 different 
mouse organs (Figure 6.3.1). Using PARP1 specific antibody staining on tissue microarrays, we 
found that all SCLC PDX exhibited elevated PARP1 expression compared to lung, kidney, 
muscle, liver and brain. All 7 PDX SCLC lines exhibited greater than 60% PARP1 positive area 
(between 64 ± 6% PARP1 positive area for JHU-LX92 and 86 ± 3% PARP1 positive area for 
JHU-LX102), while all organs, except for spleen, exhibited lower than 5% PARP1 positive area 
(Figure A.6.2), emphasizing the quantitative difference in PARP1 density for binding of PARP1 
targeted agents. Spleen showed higher PARP1 expression than the other organs, with a 26 ± 
1% PARP1 positive area. The lowest PARP1 expression was seen in lung squamous cell PDX 
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Figure 6.3.1. PARP expression in PDX cell lines. PARP1 expression was assessed via 
immunohistochemistry staining on tissue microarrays (TMAs) in 8 PDX lines and 5 normal 
control tissues. Scale bar represents 200 µm (whole core) and 20 µm (inset). All PDX cell lines 
are SCLC, except JHU-LX88, which is squamous cell lung cancer. (See Figure A.6.2 for 
quantification). 
 
line, JHU-LX88, with 18 ± 6% PARP1 positive area. JHU-LX22 and JHU-LX48 (subsequently 
used for in vitro and in vivo studies), expression was 85 ± 4% and 78 ± 6% PARP1 positive 
area, respectively. 
6.4: Pharmacokinetics 
In order to map the pharmacokinetics of [18F]PARPi in the JHU-LX48 PDX model, and to identify 
the time point that provides ideal tumor/background ratios, we injected tumor bearing mice with 
[18F]PARPi and imaged the mice at 30, 60 and 120 min post injection (Figure 6.4.1a). At 30 min, 
the tumor was visible above the background signal of muscle (1.34 ± 0.28 %ID/g and 0.90 ± 
0.06 %ID/g, respectively), but the differences were not statistically significant (n = 3, P = 0.1016; 
Figure 6.4.1b). However, at the 60 min time point, the muscle uptake had begun to clear and 
activity had fallen sharply to 0.44 ± 0.03 %ID/g, while the tumor signal was retained (0.94 ± 0.04 
%ID/g), yielding P = 0.0002 (Figure 6.4.1b). This trend continued to the 120 min time point, with 
uptake at 0.12 ± 0.02 %ID/g for the muscle, while tumor uptake remained constant at 0.87 ± 
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Figure 6.4.1. In vivo kinetics of [18F]PARPi. Tumor bearing mice (n=3) were injected with 
[18F]PARPi and imaged at 30, 60 and 120 min p.i. (a) Representative MIPs. (b) Quantification 
for tumor and muscle grouped by time point (left) and grouped by organ (right). (c) Two phase 
decay curve showing wash out of the tracer from the muscle while the tumor site remains 
relatively constant after 60 min (left). Also shown are tumor to muscle ratios (right). 
 
0.21 %ID/g (Figure 6.4.1b). The PARP1/2 imaging agent [18F]PARPi is therefore well suited to 
image in PARP1-expressing tumors, quickly clearing from non-target tissue while binding 
strongly to tumor over the course of 2 h resulting in a tumor/muscle ratio of 7.6 ± 2.7 in JHU-
LX48 bearing animals (P = 0.0072; Figure 6.4.1c). 
6.5: Tumor Size Studies 
In order to obtain quantitative data on how tumor size correlates with tracer uptake, we 
performed repeated [18F]PARPi imaging studies in a cohort of JHU-LX48 PDX mice over the 
course of eight weeks (n = 6; Figure 6.5.1a). We evaluated the quantitative performance of the 
imaging probe over tumor volumes ranging from <25 mm3 to >1000 mm3. Once tumors reached 
a size greater than 50 mm3, tumor size had no statistically significant effect on the mean 
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Figure 6.5.1. Tumor size to [18F]PARPi uptake correlation. Tumor bearing mice (n=6) were 
injected [18F]PARPi and imaged once a week over 8 consecutive weeks starting one week after 
xenografting. (a) Representative MIPs from the same mouse over 8 weeks. (b) Quantification 
(n=6) of mean uptake (top) and max uptake (bottom) tumors grouped by tumor size. The figure 
includes the standard deviation as indicated by the shaded area. 
 
 [18F]PARPi signal. Mean signal remained steady at 0.86 ± 0.22 %ID/g for sizes ranging 50 mm3 
to 1300 mm3 with the highest single value at 1.24 %ID/g and the lowest single value at 0.47 
%ID/g (Figure 6.5.1b). Separating the data into groups organized by tumor size, we observed 
that at very low tumor volumes (<50 mm3) uptake values appear lower, presumably because of 
the partial volume effect14 and the associated detection limit of the small animal PET/CT used 
for these experiments. The highest mean uptake values (0.97 ± 0.18 %ID/g) were observed for 
tumor sizes between 100 and 200 mm3. With larger tumor sizes, mean signal decreased slightly 
until reaching a minimum of 0.71 ± 0.22 %ID/g for tumor sizes between 400 and 800mm3, 
presumably due to an increasing fraction of necrotic tissue in larger tumors. Necrotic tissue 
does not retain [18F]PARPi, and therefore reduces the mean uptake. This was confirmed by the 
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maximum uptake values (Figure 6.5.1b). Organized into groups, the maximum uptake showed a 
continuous increase as tumor size increased in this range, from 2.62 ± 0.27 %ID/g for 50-100 
mm3 to 3.06 ± 0.61 %ID/g for 800-1300 mm3 (Figure 6.5.1b). Maximum uptake across tumors 
sizes 50-1300mm3 was 2.85 ± 0.49 %ID/g.  
6.6: Biodistribution 
We also conducted a biodistribution study and found differences in organ uptake compared to 
other immunocompromised mouse models from previous studies15 (Figure 6.6.1). Uptake in the 
tumor was 0.74 ± 0.24 %ID/g, similar to the quantification of PET images. SCID mice showed a 
greatly reduced signal in the lymph nodes (0.74 ± 0.24 %ID/g) and spleen (0.74 ± 0.24 %ID/g) 
compared to nude mice (Figure 6.6.1). Additional studies were performed in healthy mice in 
order to verify that this difference was not due to the differing disease models (Figure A.6.3). 
SCID mice lack mature T cells, B cells, and NK cells compared to the athymic nude mice which 
only lack T cells. It has previously been shown that [18F]PARPi uptake in these organs 
correlates with areas of high PARP1 expression as measured by immunohistochemistry16 (see 
 
Figure 6.6.1. Biodistribution study in selected tissues. Tumor bearing mice (n=5/group) were 
injected either with [18F]PARPi alone, or with a previous injection of olaparib (50 mg/kg) 30 min 
prior to [18F]PARPi. 
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Chapter 4: Figure 4.7.1). These areas also correlate with internal anatomical structures with 
high B cell concentration such as the follicles of the lymph nodes. In addition to this, we found in 
this study that a high concentration of the bone uptake seen in the previous study is actually 
attributable to bone marrow (12.64 ± 2.04 %ID/g) instead of the bone proper (Figure A.6.3). This 
marrow uptake was also substantially reduced in the SCID mice (1.24 ± 0.13 %ID/g), although 
the uptake remained high compared to other organs. The marrow uptake in SCID mice, 
however, was still specific insofar as is was nearly completely eliminated by preinjection of 
olaparib (0.58 ± 0.19 %ID/g). 
6.7: Autoradiography 
In the preclinical setting, olaparib is administered at dosing levels of 50 mg/kg, whereas 
talazoparib is used at much lower doses (e.g. 0.3 mg/kg)17. These trends are also reflected in 
the clinical setting (protocols: NCT02032823, NCT02184195, NCT01945775). Target 
engagement studies using olaparib and talazoparib showed that both molecules were capable 
of reducing [18F]PARPi signal in tumor and muscle tissue when administered 30 min prior to the 
tracer (Figure 6.7.1a-c). Using PARP1 IHC staining, we could show comparably high PARP1 
expression in tumors of all groups, while expression in muscle was very low, confirming validity 
of the autoradiography findings (Figure 6.7.1d). Target engagement was not equivalent for 
olaparib and talazoparib at their respective therapeutically active doses. Autoradiography 
demonstrated that doses of olaparib were capable of completely blocking tumor uptake (96% of 
[18F]PARPi uptake blocked), while talazoparib was only capable of blocking tumor uptake by 
45% (Figure 6.7.1e). A significant reduction of [18F]PARPi was also observed in muscle tissue 




Figure 6.7.1. Autoradiography. Tumor bearing mice (n=3/group) were injected either with 
[18F]PARPi alone, or with a previous injection of talazoparib (0.3 mg/kg) or olaparib (50 mg/kg) 
30 min prior to [18F]PARPi. (a) [18F]PARPi alone: tumor (top) and muscle (bottom) were 
collected sliced and either exposed overnight (left), stained with H&E (middle) or stained for 
PARP1 (right). (b) [18F]PARPi  with a prior injection of talazoparib. (c) [18F]PARPi  with a prior 
injection of olaparib (d) Sections scaled to show nuclear targeted stain. (e) Quantification of 
autoradiography and PARP1 stain. 
 
6.8: In Vivo Therapeutic Dosing Characterization 
Since we saw that talazoparib, at the therapeutic doses used preclinically17, does not exhibit 
complete target engagement we next aimed to study different doses of olaparib and talazoparib 
and to correlate these doses to the level of target engagement as shown by [18F]PARPi blocking 
(Figure 6.8.1). A positive control cohort (receiving vehicle control instead of PARP inhibitor) 
showed a mean [18F]PARPi uptake of 0.87 ± 0.21 %ID/g.  
The results for olaparib showed that the therapeutic dose level is much higher than required to 
achieve near-quantitative target engagement. Doses of 50 mg/kg showed 78% blocking with a 
mean uptake of 0.19 ± 0.03 %ID/g, and 15 mg/kg resulted in similar 75% blocking with a mean 
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Figure 6.8.1. Variable dose blocking study. JHU-LX48 SCLC PDX bearing mice (n=3/group) 
were injected first with olaparib (0-50 mg/kg) or talazoparib (0-15 mg/kg). Mice were then 
injected with [18F]PARPi 30 min later, and imaged 120 minutes later. (a) Representative MIPs 
from 4 different doses each, for olaparib (left) and talazoparib (right). (b) Quantification of PET 
images for tumor uptake at each of 4 different doses of olaparib (left) and talazoparib (right), as 
well as value for mice not dosed. (c) Curve fitting analysis for olaparib (left) and talazoparib 
(right) showing calculated 50% blocking doses. (d) Comparison of olaparib and talazoparib at 
equal doses (left) and at the relative therapeutic doses (right). 
 
uptake of 0.22 ± 0.01 %ID/g (P > 0.25) (Figure 6.8.1b). When we reduced the dose to 5 mg/kg 
we saw a significant reduction to 59% target engagement (0.36 ± 0.03 %ID/g, P < 0.005), 
compared to the control cohort. At 1.5 mg/kg target engagement was further reduced to 34% 
(0.57 ± 0.06 %ID/g, P < 0.001). This value is not statistically different from the control values (P 
> 0.1). We fit a single phase decay curve (R2 = 0.8629) to this data (Figure 6.8.1c, left) to 
calculate the 50% blocking dose to be 3.17 mg/kg. 
For talazoparib, the therapeutic dose was found to be insufficient to achieve complete target 
engagement. Doses of 0.3 mg/kg resulted in 50% target engagement (0.44 ± 0.06 %ID/g 
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[18F]PARPi in tumor tissue). An increase of the administered dose to 0.9 mg/kg further 
increased the target engagement to 64% (0.32 ± 0.05 %ID/g, P < 0.05). Increase in dose to 5 
mg/kg resulted in 89% target engagement (0.10 ± 0.02 %ID/g, P < 0.05), while 15 mg/kg 
showed no further increase in target engagement (84%, 0.14 ± 0.01 %ID/g, P > 0.05) (Figure 
6.8.1b). A single phase decay curve (R2 = 0.8462) (Figure 6.8.1c, right) was used to calculate 
the 50% blocking dose to be 0.36 mg/kg. 
Interestingly, while target engagement was more complete for olaparib when using doses used 
in preclinical therapeutic studies (78% and 50% for olaparib and talazoparib, respectively; 
Figure 6.8.1d), talazoparib achieved a more quantitative target engagement at similar doses 
(59% and 89% for olaparib and talazoparib at 5 mg/kg, respectively, 75% and 84% for olaparib 
and talazoparib at 15 mg/kg, respectively; Figure 6.8.1d).  
6.9: In Vivo Therapeutic Kinetics Characterization 
The dosing studies showed a significant difference between olaparib and talazoparib in their 
ability to block [18F]PARPi signal in the tumor at a single defined time point. An important factor 
in measuring the deposited effective doses, however, is how long the inhibitor occupies the 
binding site. Therefore we sought to determine the residence time of olaparib and talazoparib in 
vivo. We conducted experiments to measure the on-target residence time using [18F]PARPi by 
varying the amount of time (1 to 48 h) between administration of the drug and administration of 
the tracer (Figure 6.9.1).  
For olaparib, we found that, at 50 mg/kg, an initial scan showed 74% target engagement (0.24 ± 
0.00 %ID/g) at 60 min between injection of olaparib and [18F]PARPi. Mice with longer time 
intervals between injection of drug and tracer showed gradual increase in [18F]PARPi signal 
(Figure 6.9.1a, top) until, at 48 h, we measured tumor uptake to be 0.88 ± 0.15 %ID/g, which 
was not statistically different from the control cohort of mice which did not receive olaparib. We 
fit a two phase decay curve (R2 = 0.8548) to the target engagement data and used this to 
calculate a weighted half-life of 9.4 h (Figure 6.9.1b, top). This number represents the amount of  
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Figure 6.9.1. In vivo kinetics of different PARP inhibitors. Tumor bearing mice (n=3/group) were 
injected first with olaparib (50 mg/kg) or talazoparib (0.3 mg/kg). Mice then were injected 
[18F]PARPi 1 to 48 h later, and imaged via PET/CT 120 min after that. (a) Representative MIPs 
from 4 different time points after olaparib (top) and talazoparib (bottom) administration. (b) 
Quantification of PET images for tumor uptake at each of 6 different time points represented as 
a percentage of blocked signal. (c) Overlay of quantification curves. (d) Summary of in vivo 





time it took for half of the [18F]PARPi signal in the tumor to return after a (therapeutic) dose of 50 
mg/kg olaparib. We also used this curve to calculate an area under the curve, which was 1078 
%h for olaparib. This number is a measure for the target engagement of a single dose of 
olaparib (50 mg/kg) over 48 h. Complete 100% target engagement over 48 hours would result in 
an integral of 4800 %h.  
We repeated this procedure for talazoparib and found that, at 0.3 mg/kg, the 60 min time point 
showed 0.40 ± 0.02 %ID/g with 56% target engagement. Again, we found a gradual increase in 
[18F]PARPi signal as we increased the interval between drug and tracer (Figure 6.9.1a, bottom). 
At 48 h, we measured 0.82 ± 0.18 %ID/g, which was not statistically different from the control 
cohort of mice which did not receive talazoparib. We fit a two phase decay curve (R2 = 0.6328) 
to the target engagement data and used this to calculate a weighted half-life of 9.8 h (Figure 
6.9.1b, bottom). This number represents the amount of time it took for half of the [18F]PARPi 
signal in the tumor to return after a dose of 0.3 mg/kg talazoparib. We also used this curve to 
calculate an area under the curve, which was 1021 %h. This number represents the total 
amount of [18F]PARPi signal blocking a single dose of 0.3 mg/kg talazoparib provides over the 
course of 48 h. 
Hence, we found comparable tumor residence times for olaparib and talazoparib, despite 
differences in the applied dose, differences in the initial target engagement and reported 
differences in affinity and trapping potential (Figure 6.9.1d). 
6.10: Conclusion 
In this study, we demonstrated the feasibility of quantitative in vivo target engagement of a 
family of PARP inhibitors in SCLC PDX models using a molecularly targeted PET imaging 
agent. An imaging agent like this could have important implications for PARP inhibitor treatment 
planning and monitoring in the clinic. The molecular imaging oriented approach to drug 
characterization and target engagement measurement presented here provides a robust and 
adaptable method for answering important questions regarding the interaction of a targeted drug 
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with its intended binding site in a quantifiable manner in vitro and in vivo. Imaging techniques 
like this have the potential not only to revolutionize the way that drugs are prepared but also 
used in the clinic, and could pave the way for more robust and successful patient selection and 
treatment monitoring. More specifically, our PET imaging agent [18F]PARPi might be used to 
quantify target engagement of phase III and FDA approved PARP1 inhibitors in vivo without the 
need of creating individual companion imaging agents for each drug. This non-invasive, whole 
body approach could potentially preclude the need for multiple temporally and spatially 
separated biopsies, and would allow quantification of target engagement for each lesion in an 
individual. [18F]PARPi PET may provide a robust tool for treatment and patient selection with 
profound clinical-translational implications. 
6.11: Experimental 
SCLC PDX Models. PDX were propagated as previously described18,19. In brief, LX lines were 
derived at Johns Hopkins University from patients with treatment-naive late stage SCLC. After 
PDX model establishment, serial passaging into 6- to 8-week-old female NSG mice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ; The Jackson Laboratory) was performed for these experiments. 5 × 
10^6 viable cells/mouse were injected with a 1:1 mix of Hank’s balanced salt solution and 
Matrigel basement membrane (Corning, Corning, NY, USA) as a final volume of 100 µL 
subcutaneously into the right shoulder. PDX identity was confirmed by Short Tandem Repeat 
analysis using the PowerPlex 18 panel (Promega, Madison, WI, USA; DDC Medical is Fairfield, 
OH, USA). Because of the lines’ inherent varying preferences to grow in vitro/propagate in vivo, 
we chose LX22 for all in vitro experiments, whereas LX48 was chosen for in vivo experiments.  
General PET/CT Imaging. All PET/CT images (90 mice, total) were acquired on an Inveon 
PET/CT (Siemens) and reconstructed scans were analyzed using the Inveon Research 
Workplace Software. To acquire PET/CT images, animals were anesthetized with 2% isoflurane 
and positioned on the scanner bed. Animals were intravenously injected with 200-300 µCi of 
[18F]PARPi in 100-200 µL 10% EtOH in 0.9% sterile saline. The tracer was allowed to clear for 2 
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h prior to PET/CT imaging. PET data were collected for 5-10 min, followed by CT. All images 
were analyzed using Inveon Workspace (Siemens Healthcare Global, Erlangen, Germany). 
PET/CT Imaging Agent Kinetics. JHU-LX48 SCLC PDX tumor bearing mice (n=3/group, 3 
groups, 9 mice total) were administered 200-300 µCi of [18F]PARPi and imaged at 30, 60, or 120 
min post injection. Different mice were used for each group to eliminate, as much as possible, 
the influence of anesthesia on tracer distribution. Activity concentration was quantified by 
averaging the mean values taken from VOIs drawn on the chosen organs as they appeared in 
the CT and portrayed as a mean %ID/g ± SD. 
Biodistribution. Healthy nude (n=6/group, 2 groups, 12 total), healthy NOD/SCID (n=6/group, 2 
groups, 12 total), or tumor bearing NOD/SCID (n=6/group, 2 groups, 12 total) mice were 
injected either with or olaparib as a blocking agent (50 mg/kg) 30 min prior to injections 200-300 
µCi of [18F]PARPi in 100-200 uL 10% EtOH in 0.9% sterile saline. [18F]PARPi injection. Animals 
were sacrificed at 2 hours post injection of the radioactive probe, and major organs were 
collected, weighed, and counted in a Wizard2 automatic γ-counter (PerkinElmer, Boston, MA). 
The radiopharmaceutical uptake was expressed as a percentage of injected dose per gram 
(%ID/g) using the following formula: [(activity in the target organ/grams of tissue)/injected 
dose]⨉100%. 
PET/CT Tumor Size Study. JHU-LX48 SCLC PDX cells where implanted into NOD/SCID mice 
(n=6 mice) 7 days prior to the first imaging. At this time point, and once every 7 days thereafter, 
imaging was carried out as described above. This was continued for 8 consecutive weeks until 
mice were sacrificed to avoid surpassing a tumor size limit of 1500 mm3. Activity concentration 
was quantified by averaging the mean or max values taken from VOIs drawn over the entire 
tumor as it appeared in the CT and portrayed as a mean or max %ID/g ± SD. 
PET/CT Dosing Study. JHU-LX48 SCLC PDX tumor bearing mice (n=3/group, 9 groups, 27 
mice total) were administered varying doses of a therapeutic inhibitor via tail vein injection to 
serve as blocking agents prior to imaging. The doses administered for olaparib were 50 mg/kg, 
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15 mg/kg, 5 mg/kg and 1.5 mg/kg. The doses administered for talazoparib were 15 mg/kg, 5 
mg/kg, 0.5 mg/kg and 0.3 mg/kg. Imaging was performed as described above, beginning 30 min 
after administration of the blocking dose. Activity concentration was quantified by averaging the 
mean values taken from VOIs drawn over the entire tumor as it appeared in the CT and 
portrayed as a mean %ID/g ± SD. 
In Vivo Kinetics. JHU-LX48 SCLC PDX tumor bearing mice (n=3/group, 15 groups, 45 mice 
total) were administered therapeutic doses of olaparib (50 mg/kg) or talazoparib (0.3 mg/kg) via 
tail vein injection to serve as blocking agents prior to imaging. The amount of time in between 
administration of the blocking agent and tracer was varied from 1 to 48 h. Specifically, the time 
points used were 1, 2, 4, 8, 24, and 48 h. After allowing this clearance time for the blocking 
agent, the imaging was performed as described above. Activity concentration was quantified by 
averaging the mean values taken from VOIs drawn over the entire tumor as it appeared in the 
CT and portrayed as a mean %ID/g ± SD. 
Statistical Analysis. Data are expressed as mean ± SD. Statistical analyses were performed 
with GraphPad Prism, Version 7.0a (La Jolla, CA). Non-parametric, two-tailed student’s t-tests 
with assumption of unequal standard deviations were used to calculate statistics. P values < 
0.05 were considered significant. 
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CHAPTER 7: [18F]PARPI-DIFFUSE LARGE B-CELL LYMPHOMA 
This chapter is an adaptation of published work, and is reproduced in part, from Tang, J., 
Salloum, D., Carney, B., Brand, C., Kossatz, S., Sadique, A., Lewis, J., Weber, W. A., Hans-
Guido, W. & Reiner, T. A Targeted PET Imaging Strategy to Differentiate Malignant from 
Inflamed Lymph Nodes in Diffuse Large B-Cell Lymphoma. PNAS (2017). 
 
7.1: Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoma, accounting for 
37% of all non-Hodgkin lymphoma (NHL) cases in the United States1. The current standard-of-
care treatment, known as R-CHOP, consists of one targeted antibody against CD20 (rituximab) 
and four chemotherapies (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and 
prednisone). Although R-CHOP can cure approximately 50% of patients with DLBCL, the 
refractory or relapsed cases have very poor prognosis and require timely medical interventions2. 
Therefore, accurate and sensitive diagnostic methods play a pivotal role in improving the clinical 
outcome of DLBCL3.  
At early stages, DLBCL infiltrates lymphatic tissues such as lymph nodes, spleens, and bone 
marrow across the body; at advanced stages, DLBCL tend to metastasize to non-lymphatic 
tissues such as brain and spinal cords, as well as many other tissues4. To address the systemic 
nature of DLBCL, whole-body imaging techniques, such as positron emission tomography 
(PET), computed tomography (CT), and magnetic resonance imaging (MRI), were adopted to 
improve the diagnosis and disease staging of DLBCL5. PET imaging is an important imaging 
modality for DLBCL diagnosis, due to its high sensitivity, short acquisition time, and the 
availability of several imaging probes6,7. Particularly for DLBCL, [18F]FDG-PET imaging is the 
current standard-of-care diagnosis, because the fast-proliferating lymphoma cells consume a 
high level of glucose and incorporate large amounts of [18F]FDG8. The tracer has been proven 
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to be a reliable diagnostic for DLBCL detection6,9, identification of bone marrow metastasis10,11, 
and therapy monitoring12. 
However, the reliability of [18F]FDG-PET can be affected by the imaging agent uptake of non-
malignant tissues that also consume high levels of glucose. For example, inflamed lymph nodes 
are rich in immune cells with high [18F]FDG uptake, which can then produce high [18F]FDG-PET 
signals and result in false positive diagnoses in DLBCL patients13,14. In addition, 
immunotherapies, particularly checkpoint inhibitors15 and chimeric antigen receptor T cells16, 
have shown great efficacy in refractory/relapsed DLBCL and are likely to receive clinical 
approval in the near future. These immunotherapies can induce inflammation-driven 
“pseudoprogression”, which cannot be easily distinguished from true tumor progression with 
[18F]FDG-PET17. There is therefore an unmet clinical need for an imaging approach that can 
distinguish malignant from inflammatory tissues, and such a method would reduce the 
frequency of biopsies and provide accurate therapy monitoring, as well as increase the 
precision of surgical interventions. 
We created a PET-imaging strategy based on a potential new DLBCL biomarker. We found 
DLBCL expresses much higher levels of PARP1 than all other major cancer types, as well as 
healthy tissues in humans. In a mouse DLBCL model, we used a PARP1-targeted PET imaging 
probe to accurately differentiate malignant from normal or inflamed lymph nodes – using both 
non-invasive PET/CT imaging and ex vivo γ-counting. The clinically established [18F]FDG-PET 
failed to distinguish malignancy from inflammation in the same settings. Our PARP1-targeted 
PET imaging approach presents an attractive addition to PET imaging for DLBCL, particularly 
when inflammation presents high risks of misdiagnosis of the disease. 
7.2: PARP1 Expression in DLBCL 
In The Cancer Genome Atlas (TCGA) database18, we found that human DLBCL expresses the 
highest levels of poly [ADP-ribose] polymerase 1 (PARP1) among all major cancer types (Figure 






Figure 7.2.1. PARP1 expression in DLBCL. (a) PARP1 expression levels in biopsied tissue 
measured by mRNA levels. Data from the TCGA. (b) PARP1 expression levels in immortalized 
cancer cell lines measured by mRNA levels. Data from the CCLE. (c) Immunoblot assay 





PARP1 expression of 18 DLBCL-derived human cell lines was higher than the average 
expressions of cell lines from other major human cancers (Figure 7.2.1b). Finally, 7 selected 
DLBCL cell lines were found to express higher levels of PARP1 protein than normal human B 
cells (Figure 7.2.1c). These data suggest that PARP1 is a potential target to help differentiate 
DLBCL from normal tissues in humans. 
7.3: The DLBCL Mouse Model 
To evaluate PARP1 as a potential diagnostic marker for DLBCL, we created an animal model 
that closely simulates the human disease. Previous studies have found that MYC and BCL2 are 
two essential oncogenes to drive the pathogenesis of DLBCL20–22. In the current model, we used 
retroviral infection to introduce murine Myc oncogene into hematopoietic precursor cells (HPCs) 
with oncogene Bcl2 driven by the Vav promoter23. HPCs expressing Myc and Bcl2 proteins were 
transplanted into sub-lethally irradiated immunocompetent C57BL/6 (B6) mice so that a disease 
with an identical genetic makeup to its human counterpart could be established in the animals. 
Expression of the red fluorescent protein (RFP) is linked to that of Myc to track the progeny cells 
derived from the transplanted HPCs. 20 days after the HPC transplantation, the animals 
exhibited about 10% loss of body weight, splenomegaly, lymphadenopathy, low blood
 
Figure 7.3.1. PARP1 expression in mouse model of DLBCL. (a) Immunohistochemistry shows 
the lymph nodes of DLBCL mice (n = 5) are larger than those of B6 mice (n = 5) and most cells 
express RFP. (b) Immunohistochemistry measurements on the adjacent slices reveal higher 




hemoglobin levels, elevated white blood cell counts, and decreased blood platelets, all of which 
are symptoms similar to human DLBCL24 (Figure A.7.1a). Like human DLBCL (Figure 7.2.1), 
lymphoma cells from DLBCL mouse spleens expressed much higher levels of PARP1 than 
those from healthy B6 mice (Figure A.7.1b). In addition, over 90% of immune cells in the 
lymphatic tissues of DLBCL mice expressed RFP, confirming their origin from the transplanted 
HPCs (Figure A.7.1c). In DLBCL lymph nodes, over 90% area of tissue sections was stained 
positive with RFP (Figure 7.2.1a) and the integrity of germinal centers was lost (Figure A.7.1d), 
demonstrating massive lymphoma penetration. Finally, the area stained positive with PARP1 
was significantly higher in DLBCL lymph nodes than the healthy controls (Figure 7.2.1b; P < 
0.05). These data demonstrate that our animal model accurately recapitulates the 
physiopathology and genetic makeup of human DLBCL, particularly the high PARP1 levels of 
the disease. 
7.4: PET/CT Imaging 
 
Figure 7.4.1. PET/CT images of DLBCL model. (a) Representative MIPs (left) and slices of 
DLBCL mice (top, n = 7), B6 mice (middle, n = 4), or DLBCL mice pre-injected with olaparib 
(bpttpm, n = 4). (b) Quantification of PET signal in lymph nodes. 
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PET/CT imaging is the current standard-of-care approach to diagnose and monitor DLBCL25. To 
test if [18F]PARPi is a feasible PET imaging probe for DLBCL, we first measured its specificity in 
our DLBCL mouse model. We performed [18F]PARPi PET/CT imaging (Figure 7.4.1) on DLBCL 
mice (n = 7), B6 mice (n = 4), and DLBCL mice pre-injected with olaparib (500 µg, 1.15 µmol, n 
= 4). Compared to B6 mice, DLBCL mice showed a 5.6-fold increase of PET signal in their 
lymph nodes (p = 0.002). Pre-injection of olaparib diminished the accumulation by 87% (p = 
0.0012), demonstrating that [18F]PARPi accumulation was specific to PARP1 (Figure 7.4.1). 
This PARP1-specific accumulation was found in B6 mouse lymph nodes, which express 
relatively high levels of PARP1 as well (Figure A.7.3b-c). Furthermore, the ex vivo radioactivity 
measurement with γ-counting linearly agreed with the in vivo PET/CT reading, demonstrating 
the highly quantitative rigor of this approach (Figure A.7.2a). Finally, the total amount of 
[18F]PARPi per DLBCL lymph node was 10-fold higher than that of B6 ones (p = 0.0028, Figure 
A.7.2b). These data demonstrate that PARP1-targeted PET imaging can accurately differentiate 
malignant DLBCL lymph nodes from the normal ones. 
7.5: Biodistribution 
We then performed comparative biodistribution of [18F]PARPi in DLBCL mice, B6 mice, and 
DLBCL mice pre-injected with olaparib (500 µg, 1.15 µmol). Most tissues of DLBCL mice 
showed much higher [18F]PARPi retention than those from B6 mice (Figure 7.5.1). Importantly, 
the high accumulation in DLBCL tissues could be blocked by pre-injection of olaparib, 
demonstrating that the retention was PARP1-specific and suggesting that infiltration of B 
lymphoma cells may be the cause for the higher [18F]PARPi retention (Figure 7.5.1). To confirm 
this, we focused on lymph nodes, spleens, salivary glands, livers, and pancreas. In B6 mice, 
only lymph nodes, spleens, and salivary glands but not livers and pancreas showed PARP1-
specific accumulation of [18F]PARPi (Figure A.7.3a and Figure A.7.3b). In DLBCL mice, on the 
contrary, all 5 tissues displayed higher [18F]PARPi accumulation (Figure 7.5.1 and Figure 
A.7.3b). In all 5 DLBCL tissues, the cells rich in PARP1 also expressed RFP, the genetic tag of 
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Figure 7.5.1. Biodistribution studies. DLBCL mice injected with [18F]PARPi (n = 12), B6 mice 
injected with [18F]PARPi (n = 4), and DLBCL mice injected with [18F]PARPi and blocked with 
olaparib (n = 7). 
 
B lymphoma cells, demonstrating that the high PARP1-specific accumulation of [18F]PARPi was 
a direct result of B lymphoma cell infiltration (Figure A.7.3c). These data suggest that 
[18F]PARPi, in addition to being an appealing PET imaging probe, can also be used to monitor 
the metastatic progression of DLBCL in multiple tissues. 
7.6: Comparison to FDG in an Inflammation Model 
Because of the high uptake of glucose exhibited by inflammatory immune cells in the tissues, 
[18F]FDG-PET faces difficulty in distinguishing inflammation from true malignancy in lymph 
nodes. Although B cells express rather high levels of PARP1 among the major immune cell 
types themselves (Immunological Genome Project)26, DLBCL cells express higher levels of 
PARP1 than normal B cells (Figure 7.2.1 and Figure 7.3.1). Therefore, we hypothesized that a 
PARP1-targeted PET imaging could exploit this biological difference and differentiate malignant 
from inflamed lymph nodes in vivo.  
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Figure 7.6.1. Inflammation model immunohistochemistry. PARP1 immunostaining images of 
lymph nodes from DLBCL (left), B6 with local inflammation (middle), and normal B6 mice (right). 
 
We induced inflammation in superficial cervical lymph nodes by systemically injecting Flt3L, a 
peptide that induces dendritic cell production27, and locally injecting Poly-IC around these lymph 
nodes of B6 mice to induce regional inflammation. Lymph nodes derived from this mouse model 
displayed bigger volumes (Figure 7.6.1) but intact structure compared to the normal ones, 
demonstrating the established inflammation.  
Immunostaining of lymph nodes from the DLBCL mice, the inflamed model mice, and normal B6 
mice showed that DLBCL lymph nodes displayed consistently high PARP1 expression across 
the whole tissue, whereas inflamed and normal lymph nodes showed much less PARP1 
expression, which was confined to germinal centers (Figure 7.6.1). 
We first performed [18F]FDG PET/CT imaging on DLBCL mice, B6 mice with inflamed lymph 
nodes, and normal B6 mice. We found that [18F]FDG uptake in non-lymphatic tissues around the 
head and neck area was higher than in lymph nodes (Figure 7.6.2a). Autoradiography 
confirmed the PET imaging results by showing a high uptake of [18F]FDG in the salivary gland 
and brain in mice with inflamed lymph nodes (Figure A.7.4a), consistent with ex vivo γ-counting 
(Figure A.7.4c). Importantly, inflamed lymph nodes showed identical [18F]FDG uptake levels 
compared to DLBCL lymph nodes, demonstrating the inability of [18F]FDG-PET to differentiate 
inflammation from malignancy in DLBCL lymph nodes (Figure 7.6.2b).  
We then performed [18F]PARPi-PET/CT imaging on mice with the same 3 conditions. The 
PARP1-targeted imaging clearly differentiated the malignant lymph nodes from either inflamed 




Figure 7.6.2. Comparison of [18F]PARPi to FDG in an inflammation model. (a) Representative 
FDG MIPs (left) and slices of DLBCL mice (top, n = 3), B6 mice (middle, n = 3), or DLBCL mice 
pre-injected with olaparib (bottom, n = 3). (b) Quantification of FDG PET signal in lymph nodes. 
(c) Representative [18F]PARPi MIPs (left) and slices of inflammation model mice (top, n = 5), B6 
mice (middle, n = 5), or DLBCL mice pre-injected with olaparib (bottom, n = 5). (d) Quantification 




the head and neck area, the low uptake of [18F]PARPi in other non-lymphatic tissues highlighted 
malignant lymph nodes (Figure 7.6.2c). Quantification of PET imaging revealed 76% higher 
signal in malignant lymph nodes than inflamed ones (Figure 7.6.2d, P < 0.001) and 152% higher 
than the normal ones (Figure 7.6.2d, P < 0.0001). Compared to normal lymph nodes, inflamed 
ones only showed modest PET signal increase (Figure A.7.4b P < 0.01), and this elevation was 
not significant in ex vivo γ-counting (Figure 7.6.2d, P = 0.078). Quantitative biodistribution 
confirmed that lymph nodes and spleens from DLBCL mice had much higher [18F]PARPi 
accumulation than those from the other two groups (Figure A.7.4d). 
Altogether, these results demonstrate that PARP1-targeted PET imaging can accurately 
differentiate malignant from inflamed or normal lymph nodes in DLBCL, due to the differential 
expression of PARP1 in these conditions. 
7.7: Conclusion 
In conclusion, we identified PARP1 as a potential diagnostic marker for DLBCL from patient 
samples. We developed a PARP1-targeted PET imaging approach that displays greater 
sensitivity than the current standard-of-care [18F]FDG-PET imaging in differentiating malignant 
from inflamed or normal lymph nodes PARP1-targeted PET imaging could even prove useful in 
assessing cancer immunotherapies for DLBCL. Cancer immunotherapies often induce massive 
immune cell infiltration and consequently cause pronounced inflammation in tumors, increasing 
local metabolism level28. This inflammatory phenomenon presents tremendous challenges to 
the traditional therapeutic response evaluation methods, which often use high metabolic rates 
as an indicator for cancer progression29,30. For DLBCL, immunotherapies such as checkpoint 
inhibitors15 and CAR-T cell therapy16,31 are rapidly advancing in the clinical development. A 
novel imaging method that can differentiate inflammation from malignancy is instrumental to 
evaluate the clinical efficacy of these new therapies. In this case, our PARP1-targeted PET 
imaging approach seems to be an appealing solution to this urgent need. This novel targeted 
PET imaging approach has the potential to shift the paradigm of PET imaging in DLBCL.  
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7.8: Experimental 
PARP1 expression data in human tissues and cell line. For PAPR1 expression in human 
cancer samples, data were downloaded from cBioportal (http://www.cbioportal.org/)32, which 
imported the raw sequencing data from The Cancer Genome Atlas (TCGA, 
https://cancergenome.nih.gov/)18. PARP1 mRNA expression levels were analyzed in 9129 
patient samples. All available PARP1 mRNA data as of June 2016 were downloaded and 
transformed to a plot with Prism 6 (GraphPad). For PARP1 expression in human cancer cell 
lines, data were downloaded from Cancer Cell Line Encyclopedia 
(https://portals.broadinstitute.org/ccle/home). Similarly, all available PARP1 mRNA expression 
data from 1036 cancer cell lines were downloaded in June 2016.  
Synthesis of PARPi-FL. The synthesis was carried out as previously described33. In summary, 
BODIPY-FL NHS ester (5.0 mg, 12.8 mmol, Invitrogen, Carlsbad, CA, USA) was conjugated to 
4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one (9.4 mg, 25.6 mmol) in the 
presence of triethylamine (4.6 µl). Purification by preparative HPLC (Waters’ XTerra C-18 5 µm 
column, 7 ml/min, 5% to 95% of acetonitrile in 15 min) afforded PARPi-FL in 70-79% yield as a 
red solid. Analytical HPLC analysis (Waters’ Atlantis® T3 C18 5 µm 4.6 × 250 mm column) 
showed high purity (>97%) of the imaging agent. The identity of PARPi-FL was confirmed by 
using ESI-MS (MS(+) m/z = 663.4 [M+Na]+). For imaging studies, PBS (115 µl) was slowly 
added to an aliquot of PARPi-FL (50 µg, 78 nmol) in 50 µl of poly(ethylene glycol) (PEG300, 
Sigma-Aldrich, St. Louis, MO, USA) to obtain a final injection volume of 165 µl. 
Synthesis of [18F]PARPi. [18F]PARPi was synthesized by using a labeling procedure similar to 
what has been reported before34. Briefly, a QMA cartridge containing cyclotron-produced [18F] 
fluoride (50 mCi, 1.85 GBq) was eluted with a solution containing 9 mg Kryptofix [2.2.2] 
(4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8] hexacosane), 0.08 ml 0.15 M K2CO3 and 
1.92 ml MeCN into a 5 ml reaction vial. Solvents were removed azeotropically at 120 °C under 
nitrogen gas. Afterwards, 500 µg of ethyl 4-nitrobenzoate (Sigma) in 100 µl of dry DMSO was 
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added and the mixture was heated to 150 °C for 15 minutes. 50 µl of 1M NaOH was then added 
followed by 50 µl of 1M HCl. Then, 2 mg of 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl) 
phthalazin-1(2H)-one in 100 µl of dry DMSO was added followed by 10 mg of HBTU dissolved 
in 100 µl of DMSO and 20 µl of Et3N. 400 µl of MeCN and 1 ml H2O were then added to the 
mixture and the product was purified by HPLC with a yield (non-decay corrected) of 38.4 ± 2.5% 
and a specific activity of 0.97 ± 0.41 Ci/µmol.  
Generation of the DLBCL animal model. All animal experiments were approved by the 
Institutional Animal Care and Use Committee (IACUC) of Memorial Sloan Kettering Cancer 
Center. 8-to16-week old female C57BL/6 (B6) mice were purchased from Jackson Laboratories. 
We isolated vavP-Bcl2 transgenic fetal liver cells from vavP-Bcl2 heterozygous animals at 
embryonic day 14.5 (E14.5). The HPCs were grown in vitro for 4 days in a specially adapted 
growth medium as described previously35 and were retrovirally transduced with MSCV vectors 
directing the expression of Myc-IRES-Rfp. The HPCs were transplanted into sub-lethally 
irradiated wild type recipients and the onset of the disease was monitored twice per week by 
palpation.  
Spectrofluorimetry. DLBCL mice were intravenously injected with 50 µg of PARPi-FL, with or 
without 500 µg of olaparib injected 30 min prior to PARPi-FL. Animals were sacrificed 2.5 hours 
after the injection and perfused with 20 ml PBS. Lymph nodes and spleens were collected, 
weighed, and stored in 500 µl of RIPA lysis buffer (Boston Bioproducts, Ashland, MA, USA) in 
bead-filled homogenizing vials (Lysing Matrix D, MP Biomedicals, Cat# 6913-050). Tissues 
were homogenized in a MP homogenizer (MP Biomedicals, Ashland, MA, USA). Later, 200 µl of 
homogenate was transferred to a new 1.5 ml tube and 750 µl of acetonitrile, 200 µl of water, 
and 50 µl of 10% Triton X-100 (volume/volume) were added to the vials. The vials were 
vortexed for 60 seconds and then incubated in 4 °C for 16 hours. Afterwards, the vials were 
centrifuged at 15,000 g for 20 min and 200 µl supernatant was collected for analysis. In a plate 
reader (SpectraMax, Molecular Devices, CA, USA), the solution was excited at 507 nm and 
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fluorescent signal was measured at 530 nm. The concentration of PARPi-FL in the solution was 
calculated by comparing the readings to standards with various concentrations of PARPi-FL. 
The total PARPi-FL in the original tissues was calculated and the accumulation was presented 
as the percentage of injected dose of PARPi-FL per gram of tissues (%ID/g). 
Histology. Lymph nodes of DLBCL or B6 mice were collected and fixed in 4% 
paraformaldehyde for 2 days. The tissues were then washed with 70% ethanol and embedded 
with paraffin by following a standard histology protocol. Histology slides were stained with 
standard hematoxylin and eosin staining, immunostaining with antibodies specific to PARP1 
(Santa Cruz, SC-7150) or specific to B220 (Abcam, clone RA3-6B2). The stained slides were 
digitalized with a slide scanner (Panoramic MIDI, PerkinElmer, MA, USA) and images were 
analyzed and quantified by Panoramic Viewer (PerkinElmer, MA, USA). For each animal, on 
average 5 lymph node images were analyzed per DLBCL mouse (n = 5 in total) or B6 mouse (n 
= 5 in total). 
Biodistribution and autoradiography. Mice were injected with 300 µCi of [18F]PARPi or 
[18F]FDG. Blocking with olaparib was performed by administering 500 µg 30 min before 
[18F]PARPi injection. Animals were sacrificed at 2.5 hours post injection of the radioactive probe 
and perfused with 20 ml PBS. Radiotracer accumulation in lymph nodes, spleens, salivary 
glands, livers, pancreas, kidneys, blood, hearts, lungs, stomach, small intestines, large 
intestines, muscle, bone, and brain was determined by first weighing the tissues and then 
measuring their radioactivity in a gamma counter (PerkinElmer, Waltham, MA, USA). The 
relative activity per tissue is presented as a percentage of injected dose per gram of tissue 
(%ID/g). For autoradiography, radiotracer accumulation in spleens, lymph nodes, salivary 
glands, livers, and pancreas was determined by placing the tissues in a film cassette against a 
phosphor imaging plate (BASMSM-2325, Fujifilm, Valhalla, NY, USA) for approximately 30 min. 
Phosphor imaging plates were read in a Typhoon 7000IP plate reader (GE Healthcare, 
Pittsburg, PA, USA).  
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Inflammation of lymph nodes. C57BL/6 mice with 8-to-16 weeks of age received daily 
intraperitoneal injections of Flt3L (Celldex) at the dose of 30 µg for 5 days. On day 4, 100 µg of 
PolyI:C (InvivoGen, cat# tlrl-pic) dissolved in 50 µl PBS was injected subcutaneously around the 
superficial cervical lymph nodes. On day 5, after the injection of Flt3L, the mice were injected 
with [18F]FDG or [18F]PARPi and imaged with a PET/CT scanner (Inveon, Siemens Healthcare 
Global, Erlangen, Germany). After the imaging, lymph nodes, spleens, salivary glands, brains, 
and tibia bones were collected, weighed, and counted with a gamma counter. Accumulation of 
radioactive tracers in the tissues was presented as the percentage of injected dose per gram of 
tissues (%ID/g). 
Western blot. DLBCL cell lines (KARPAS422, SU_DHL_4, Su_DHL_6, DB, SU_DHL_10, 
WSU_DLCL2, and DoHH2) and human primary B cells were purchased from ATCC and were 
cultured in the conditions recommended by the vendor. Western blots were performed by using 
the whole cell lysates or supernatant as previously described35. In brief, 30 µg protein per 
sample was resolved on SDS-PAGE gels and transferred to Immobilon-P membranes 
(Millipore). Antibodies specific to PARP1 (Cell Signaling Technologies #9542) and actin (Cell 
Signaling Technologies #3700) were used. Enhanced chemiluminescence was used for 
detection (ECL; GE Healthcare).  
Confocal microscopy. PARPi-FL accumulation was correlated with PARP1 expression in 
lymph nodes by immunofluorescence staining on histological sections as described before 36. 
Lymph nodes of DLBCL mice were snap-frozen 2 hours after intravenous injection of 50 µg 
PARPi-FL, with or without injection of 500 µg of olaparib 30 min prior to the PARPi-FL injection. 
10 µm cryosections of DLBCL lymph nodes were fixed in 4% paraformaldehyde for 8 minutes, 
followed by blocking with 3% (volume / volume) goat serum (Sigma-Aldrich, St. Louis, MO). 
Antibodies were diluted in 1% (weight / volume) BSA and 0.3% (volume / volume) Triton X-100 
in PBS. Anti-PARP1 primary antibody (sc-7150, Santa Cruz Biotechnology, Santa Cruz, CA) 
was incubated overnight at 4 °C (1 µg/ml), followed by incubation with secondary AlexaFluor® 
! 116!
680 goat anti-rabbit antibody (A21076, Molecular Probes, Eugene, OR) for 1 hour at 4 °C (2 
µg/ml). Sections were mounted with Mowiol® (Sigma-Aldrich, St. Louis, MO) containing Hoechst 
33342 DNA Stain (Sigma-Aldrich, St. Louis, MO). Fluorescence images were captured using a 
Leica (Buffalo Grove, IL) SP5-upright confocal microscope, equipped with a 405 nm laser for 
detection of cell nuclei, a 488 nm laser for detection of in vivo applied PARPi-FL, and a 633 nm 
laser for detection of PARP1 antibody stain, each paired with suitable emission filters. 
Flow cytometry. Previous protocols were adapted to analyze the tissues in the current study37. 
Briefly, at 2.5 hours after intravenous injection of PARPi-FL, blood was collected in EDTA-
treated tubes, and the animals were perfused with 20 ml PBS. For PARP1 blocking 
experiments, 500 µg olaparib was intravenously injected into the mice 30 min before the 
injection of PARPi-FL. Afterwards, lymph nodes, bone marrow, and spleens were collected and 
gently diced. A single-cell suspension was created by removing tissue aggregates, extracellular 
matrix, and cell debris from the solution. Red blood cells were removed from the blood sample 
using a red blood cell lysis buffer (Biolegend, Cat# 420301). PARPi-FL was detected on the 
FITC channel. To identify B cells, T cells, neutrophils, and other myeloid cells, antibodies 
specific to CD45 (clone 30-F11), CD11b (clone M1/70), CD11c (clone N418), B220 (cone RA3-
6B2), and CD3 (cone 145-2C11) were used. Antibodies were purchased from eBioscience and 
Biolegend. The FITC channel of the flow cytometer was calibrated by using FITC calibration 
beads (Spherotech, Cat# ECFP-F1-3), and FITC channel variation was corrected by 
normalizing to the beads’ signal. All samples were measured on a Fortessa flow cytometry 
analyzer (BD Biosciences, San Jose, CA, USA). Results were analyzed with FlowJo (Ashland, 
OR, USA) and statistics were calculated with Prism (GraphPad, La Jolla, CA USA). 
Micro PET/CT imaging. Mice were injected with [18F]PARPi or [18F]FDG at doses of 
approximately 300 µCi/mouse, and the mice were imaged on an Inveon small-animal micro 
PET/CT scanner (Siemens Healthcare Global, Erlangen, Germany) under isoflurane-induced 
(Baxter Healthcare, Deerfield, IL, USA) anesthesia 2 hours after the radioactive tracer injection. 
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For PARP1 blocking experiments, 500 µg olaparib was intravenously injected into the mice 30 
min before the injection of [18F]PARPi. Whole body static PET scans were recorded for 15 min 
with about 50 million coincidence events. The imaging data were normalized to correct for non-
uniform PET response, dead-time count losses, positron branching ratio, and physical decay to 
the time of injection, but no attenuation, scatter, or partial-volume averaging correction was 
applied. The counting rates in the reconstructed images were converted to activity 
concentrations (percentage injected dose [%ID] per gram of tissue [%ID/g]) via a system 
calibration factor derived from imaging a mouse-sized water-equivalent phantom containing 18F. 
Images were analyzed using Inveon Workspace (Siemens Healthcare Global, Erlangen, 
Germany). Activity concentration was quantified by averaging the maximal values of at least 5 
ROIs drawn on consecutive slices of the chosen organs. 
Radioactive cell sorting. DLBCL mice were injected with [18F]PARPi at the dose of 
approximately 300 µCi per animal. For PARP1 blocking experiments, 500 µg olaparib was 
intravenously injected 30 min before the injection of [18F]PARPi. 2.5 hours after the [18F]PARPi 
injection, mice were sacrificed and 500 µl blood was collected and stored in tubes pre-filled with 
EDTA. Red blood cells were removed as described above in the flow cytometry section. The 
enriched white blood cells were purified by following standard magnetic-activated cell sorting 
(MACS) procedures provided by the vendor (Miltenyi Biotec, Cologne, Germany). Briefly, the 
white blood cells were incubated with anti-B220 (Miltenyi Biotec, cat# 130-049-501) or anti-
Ly6G (Miltenyi Biotec, cat# 130-092-332) antibodies conjugated with paramagnetic beads for 30 
min. After wash with flow cytometry buffer, the solution was passed through a magnetic column, 
followed by buffer washing. Finally, cells with bound antibodies were eluted from the columns. 
The cells were then immediately stained with a cocktail of antibodies that recognize CD45, 
CD11b, Ly6G, and B220. After the staining, cells were fixed (eBioscience, 00-8222-49), their 
radioactivity was counted in a gamma counter (PerkinElmer, Waltham, MA, USA) and decay-
corrected. After the counting, the stained cells were left in 4 °C for 24 hours (more than 10 
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decay half-life times of 18F fluorine) for the decay of 18F. After radioactivity decay, counting 
beads were added to the cell suspension, so that the purity and the numbers of cells in each 
sample could be analyzed by a Fortessa flow cytometer (BD). Finally, the percentage of injected 
dose per billion cells (%ID/109 cells) was calculated using the following formula: the average 
percentage of injected dose of [18F]PARPi per purified billion cells in a tube (%ID/109 cells) = 
percentage of decay-corrected injected dose (%ID) / the number of cells in that tube. 
Statistics. PARP1 mRNA expression data of patient samples and human cancer-derived cell 
lines were presented as median plus or minus the interquartile range. Other data were 
presented as the mean with the standard errors of the mean (SEM) or standard deviation (SD) 
as error bars. Non-parametric, two-tailed student’s t-tests with assumption of unequal standard 




CHAPTER 8: CONCLUSION AND FUTURE DIRECTIONS  
8.1: Development of [18F]PARPi 
This work has really been about the development of a single molecule, [18F]PARPi. This 
development stretched back to when Dr. Reiner first began modifying the PARP targeting 
scaffolding offered by the best clinical PARP therapeutic available, olaparib1–3. One of these 
molecules, the fluorescent PARPi-FL, was highly successful, and generated most, if not all, of 
the fluorescent imaging research presented in Chapter 2, Section 2.2. Indeed, it is the only 
foreseeable fluorescent clinical candidate, and is one of only two imaging agents to reach the 
clinic (see Chapter 2, Section 2.2). However, the 18F labeled PET tracer developed at this time, 
18F-BO, was not so successful. In retrospect, it probably suffered from the poor in vivo kinetics 
caused by its relatively large size4. Naturally, the success of PARPi-FL led to the notion that if 
PARPi-FL could be radiolabelled, this new PET tracer would not only benefit from the success 
of the fluorescent agent, but would itself be fluorescent and so would offer a dual modality 
PET/fluorescent PARP targeted imaging agent. A synthetic route was therefore devised5 and 
the work presented here picks up. We were able to successfully optimize the 18F labeling of the 
dual model tracer, 18F-PARPi-FL, but the tracer proved instable in vivo (Chapter 3)6, and so an 
alternative had to be devised. We therefore designed a new, single model tracer, [18F]PARPi, 
with the goal of efficient and specific in vivo PARP targeting, and high in vivo stability. This is the 
main subject of this work and has proven to be as successful a PET agent as PARPi-FL is a 
fluorescent agent. 
8.2: Preclinical studies with [18F]PARPi 
Our first preclinical validation followed in the footsteps of PARPi-FL7 and 18F-PARPi-FL6, we 
utilized an orthotopic glioblastoma multiforme (GBM) mouse model. [18F]PARPi showed itself to 
meet the criteria we had set out for it (Chapter 4), but while this model was of extreme interest 
for PARPi-FL insofar as fluorescent guided surgery could prove to be of extreme value to the 
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clinical treatment of GBM, we thought that it would be interesting test [18F]PARPi in a central 
nervous system (CNS) disease that was not so easily delineated by magnetic resonance 
imaging MRI (see Chapter 4, Figure 4.9.3). This produced a collaboration with Dr. Mark 
Souweidane’s lab, which specializes in diffuse intrinsic pontine glioma. DIPG. In these 
genetically engineered mouse models (GEMMs), we found that [18F]PARPi indeed provided a 
more targeted contrast than MRI (or at least the 1T MRI we had available, see Chapter 5, 
Figure 5.5.1)8. So, in some cases, like DIPG, [18F]PARPi might prove to be a better diagnostic 
tool than MRI, or at least an important addition. In addition to this collaboration, we collaborated 
with the labs Dr. Charles Rudin and Dr. John Poirier, who were looking at PARP targeted 
therapies for treatment of small cell lung cancer (SCLC)9. They identified talazoparib as the 
most effective PARP inhibitor for treatment of SCLC, and so we were interested to see if 
[18F]PARPi could be used to detect any differences between talazoparib and other inhibitors in 
vivo. This was the first time that either PARPi-FL or [18F]PARPi was used to detect PARP target 
engagement of therapeutics other than its parent compound, olaparib. We found that [18F]PARPi 
could indeed detect a difference between talazoparib olaparib (see especially the dosing study, 
Chapter 6, Figure 6.8.1), and that this supported the conjecture that the two were operating by 
two different therapeutic mechanisms. Finally, inspired by our consistently high, and extremely 
specific [18F]PARPi signal from organs with high concentrations of B-cells, and also by the fact 
that B-cell lymphomas present the highest PARP1 expression in both The Cancer Genome 
Atlas and the Cancer Cell Line Encyclopedia, we decided to look at [18F]PARPi in diffuse large 
B-cell lymphoma (DLBCL). We found that [18F]PARPi could show infiltration of lymphoma cells 
in a wide variety of organs (see Chapter 7, Figure 7.5.1) and that PET quantification of the 
lymph nodes in particular could even differentiate between lymphoma infiltrated lymph nodes 
and inflamed lymph nodes, a distinction that the standard PET tool for DLBCL, 
[18F]fludeoxyglucose (FDG) could not make.  
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8.3: Clinical studies with [18F]PARPi (Future Directions) 
Although clinical studies are underway for PARPi-FL in oral squamous cell carcinoma (OSCC, 
NCT03085147), clinical studies for [18F]PARPi are still in the approval process. We have 
successfully transitioned the synthesis into the radiopharmacy, and the clinical trial will probably 
start sometime towards the end of 2017 or the beginning of 2018, so we will have to wait until 
then to discover whether [18F]PARPi will be as useful in the clinical setting as it has been in the 
preclinical setting. 
8.4: Conclusion 
The development of PARP imaging agents is quite an interesting subject of study, and PARP 
imaging has already shown itself to be highly valuable in the preclinical setting. The ultimate 
goal, however, is to create an agent that is of some utility in the clinic. It is only our sincere belief 
that one day, one of our PARP imaging agents could help extend the life or improve the quality 




CHAPTER 9: OTHER PROJECTS  
Section 9.3 is an adaptation of published work, and is reproduced in part, from Büchel, G. E., 
Carney, B., Shaffer, T. M., Tang, J., Austin, C., Arora, M., Zeglis, B. M., Grimm, J., Eppinger, J. 
& Reiner, T. Near-Infrared Intraoperative Chemiluminescence Imaging. ChemMedChem (2016). 
 
9.1: Introduction 
In addition to the work that has been presented on PARP PET imaging agents, several other 
projects warrant mention. These projects are at various stages of completion, and are on 
diverse topics that did not quite fit into the [18F]PARPi narrative. However, the work is interesting 
and is presented here for the sake of completeness and to highlight the highly collaborative 
nature of the work being done between the laboratories at Hunter College and Memorial Sloan 
Kettering. 
9.2: Rucaparib Fluorescence 
 




During the course of the work on small cell lung cancer presented in Chapter 6, it was 
discovered that one of the FDA approved PARP inhibitors, rucaparib, was indeed fluorescent 
without any modifications to the structure necessary (Figure 9.2.1). Rucaparib has just been 
approved by the FDA in 2017 for treatment of ovarian cancer1. PARPi-FL, which our lab has 
used successfully as a PARP targeted fluorescent imaging agent for several years2–5, is based 
on the FDA approved drug, olaparib, but is not yet itself FDA approved. The modification which 
gives the molecule its fluorescent properties also slightly alters the PARP targeting properties of 
the molecule (olaparib IC50 = 5 nM6, PARPi-FL IC50=12.2 nM3, see also the PARP family binding 
assay, Chapter 6 section 2 and Figure 6.2.1). Rucaparib, by virtue of the fluorescence being an 
inherent property of the original FDA approved therapeutic molecule, does not have these 
potential drawbacks. In addition, PARPi-FL is nearly twice the size of rucaparib in terms of 
molecular weight, and rucaparib is usually administered as either a phosphate or 
camphoresulfonate (CSA) salt7. These factors are likely to give rucaparib vastly different 
biophysical properties compared to either olaparib or PARPi-FL. These considerations amount 
to strong motivation for the development of rucaparib as not only a therapeutic inhibitor, but as a 
fluorescent imaging agent as well. The one obvious drawback to rucaparib’s fluorescence is 
that, while for in vivo imaging near infrared (NIR, 700-1000 nm) wavelengths are ideal for 
avoiding absorption by naturally occurring biological light absorbers (especially hemoglobin)8, 
rucaparib’s highest wavelength absorption/excitation peak is well below this range at 360 nm 
(although PARPi-FL also has a shorter than ideal absorption/excitation peak at around 500 nm, 
which generally limits it to surface imaging in vivo, see Chapter 2, Section 2). This short 
excitation wavelength potentially limits the clinical utility of rucaparib, but there is still much 
possible usefulness for rucaparib in the preclinical setting with in vitro and ex vivo microscopy 
studies, and we therefore set out, in collaboration with Michael Drain’s group at Hunter College, 
to probe the fluorescent properties of the compound. 
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Figure 9.2.2. Fluorescence properties of rucaparib compared to NATA. (a) Structures and 
absorbance and emission spectra for both compounds at various concentrations. (b) 
Comparison of absorbance and excitation spectra for both compounds. 
 
Rucaparib’s fluorescence properties are probably due to the indole moiety inherent to the 
original structure. Rucaparib has structural elements in common with the amino acid tryptophan, 
which is also fluorescent owing to a similar indole moiety. We therefore set out to measure the 
photophysical properties of rucaparib using the tryptophan analogue 
N-acetyl-L-tryptophanamide (NATA). In summary, we found that, in phosphate buffered saline 
(PBS, pH=7.4) rucaparib has excitation maxima at 245, 270 and 360 nm with a single emission 
peak with a maximum at 465 nm (Figure 9.2.2a and b). The quantum yield was 30%, and 
therefore was higher than NATA’s reported value of 13%9,10. This is probably due to the 
additional benzene ring that is conjugated with the indole moiety in rucaparib but not in NATA. 
The excitation and emission maxima for rucaparib are also significantly red shifted compared to 
NATA, which is probably also due to the additional benzene ring. The fluorescence lifetime for 
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Figure 9.2.3. Dependence of rucaparib fluorescence on solvent properties. 
rucaparib is quite similar to that of NATA, with a value of 6.8 ns.  
Another widely explored property of tryptophan fluorescence is the variation of the quantum 
yield based on what solvent is being used10. We sought to explore this property in rucaparib as 
well and found varying fluorescence spectra depending on what solvent conditions were being 
used. Specifically, we found that quantum yield, as a function of the emission peak height (no 
quantum yields were actually calculated), dropped significantly as the solvent was made more 
acidic (Figure 9.2.3). 
In conclusion, this molecule presents an opportunity to utilize fluorescence microscopy 
techniques for the exploration of PARP biology in vitro, and does so without any modifications 
whatsoever on the structure of a compound that has already received FDA approval. This not 
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only represents an extraordinary opportunity for preclinical science, but also presents clinical 
applications in the areas of treatment monitoring on patient samples following PARP treatment.  
9.3: Eu-HOPO Lanthanide Luminescence  
89Zr based PET imaging has been in development for several years and was originally born out 
of a desire to find a suitable PET active radioisotope for antibody based imaging11. The most 
prominent chelator used for 89Zr-antibody PET imaging is desferrioxamine (DFO), a chelator 
originally used for iron. An important aspect of this is that DFO is six coordinate while Zr 
chemistry seems to demand eight coordinate chelation11.  
Indeed, DFT calculations suggest two additional water molecules to complete the coordination 
sphere12, although no crystal structure has yet been reported. Some demetallation of 89Zr-DFO 
complexes does occur, and this is noticeable in PET imaging by the increase of bone signal 
over time due to the natural accumulation of free Zr4+ ions in the bone. This has lead to efforts in 
 
Figure 9.3.1. Harnessing lanthanide luminescence for 89Zr-HOPO based immuno-PET. (a) 
Comparison of the 89Zr complex and the Eu complex. (b) Luminescence spectra. Modified and 
reprinted from Abergel et al. J Med Chem, 2010. 
 
! 127!
the labs of Lynn Francesconi to develop a new chelator more suitable for Zr chemistry, and one 
chelator was originally designed for actinide sequestration15, but the octadentate chelator was 
shown in small animal biodistribution studies to have superior in vivo stability when compared to 
the hexadentate DFO14.  Another well known characteristic of the HOPO ligand is its use as an 
“antenna” for lanthanide luminescence16. An antenna is a chromophore that acts to collect the 
energy from an excitation source and then transfers this energy to the metal which then 
performs the light emission17. We sought, in collaboration with Lynn Francesconi’s group at 
Hunter College, to use this antenna effect to quantify the number of HOPO chelators per 
antibody for the 89Zr-HOPO based immuno-PET imaging (Figure 9.3.1). 
 
Figure 9.3.2. Eu-HOPO Mass Spec. 
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First, we performed the coordination chemistry with the chelator alone according to the 
literature16, in methanol at 50 °C. However, we soon found that the synthesis worked well even 
when performed in PBS at room temperature, and these conditions are better for the eventual 
work with antibodies and were used for the luminescence experiments with the plate reader. 
Luminescence readings from a SpectraMax® M5 Multi-Mode Microplate Reader confirmed that 
the luminescence from the complex was bright enough to be measured by the plate reader and 
that the signal increased, although not entirely linearly, with concentration of material. We also 
saw that the Eu by itself only had negligible background signal, and that it was feasible to 
synthesize the complex without purification for the purposes of the chelator measurements. With 
this in mind, free EuCl3 was used for all the background measurements with the plate reader. 
 
Figure 9.3.3. Eu-HOPO lanthanide luminescence as measured on a SpectraMax® M5 Multi-
Mode Microplate Reader. Eu-HOPO luminescence is clearly higher than background EuCl3 
luminescence. This is visible on both a linear scale (top) and a log scale (bottom). The signal 
increases with concentration (left), though not in a linear fashion at the concentrations studied. 
Also visible is the increase in signal/background afforded by the long lifetime. 
Signal/background can be increased by including a delay time (middle) or extending the 
































































































We were also able to detect the reported long (805 µs16) lifetime of the luminescent signal using 
the “delay time” setting on the plate reader, which delays the detection of the emission for some 
period after the excitation. This eliminates the signal from fluorescent agents, which typically 
have much shorter emission lifetimes. We found that at a delay time of 50 µs eliminated 95% of 
the background signal while the signal from the complex only reduced by 5%. This resulted in a 
four fold increase in signal to background when a 50 µs delay time was used. Another way of 
utilizing the long luminescent lifetime of the complex to increase signal to background is to 
increase the amount of time the detector collects the luminescent signal. This setting is called 
“integration time” on the plate reader. We found that, in comparison to a 50 µs integration time, 
the signal collected from the complex was 10 times higher when an integration time of 1000 µs 
was used. 
In summary, this method could be used for chelator quantification, but there needs to be further 
study, especially in regards to the linearity of the luminescent signal. This must be correlated to 
the standard methods of chelator quantification such as MALDI-MS and the isotopic dilution 
assay. Isotope dilution was used in determination of HOPO chelator to antibody14. 
9.4: Ru(bpy)3 Chemiluminescence imaging  
The generation of an imaging signal through chemiluminescence is fundamentally different from 
fluorescence imaging, as these chemiluminescent agents emit light without requiring an 
excitation light source. Typically, chemiluminescence imaging is based on the detection of 
photons produced as a by-product of the reduction/oxidation of a probe molecule. In biological 
systems, chemiluminescence imaging has only briefly been touched upon18. The most notable 
example is the injection of luminol into mice, which generates violet photons (424 nm) upon its 
oxidation by endogenous myeloperoxidase19. Transition-metal-mediated chemiluminescence 
has so far remained largely untapped by the molecular imaging community. Advantages of 
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Figure 9.4.1. a) Structure, reactivity and absorbance and emission spectrum of the 
chemiluminescent probe [Ru(bpy)3]2+. b) Design of the automatic nebulizer. c) Position of the 
spray device inside an IVIS Spectrum bioluminescence imaging system. d) Generation of near 
infrared light by nebulizing and spraying on an oxidizing agent. 
 
chemiluminescence over other methods include: 1) no excitation light necessary; 2) no tissue 
penetration issues for incident light; 3) unlike in Cherenkov, no radioactivity is needed, 
eliminating exposure to patients and hospital personnel; 4) there are a large number of potential 
in vivo chemiluminescence imaging agents available, ranging from small organic molecules and 
transition-metal complexes to nanoparticles20,21, spanning wavelengths from the visible to the 
near-infrared (NIR) spectrum; and 5) these imaging agents can easily be conjugated to 
biologically active targeting molecules to target specific tissues, for example, which is one of the 
fundamental requirements for a molecular imaging agent22. In conjunction with the labs of Brian 
Zeglis at Hunter College, we set out in this proof-of-principle study to show that high signal-to-
noise ratios can be achieved by detecting the NIR photon that is emitted from the 
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oxidation/reduction cycle of the reporter, that intraoperative chemiluminescence imaging 
reaches detection limits suitable for in vivo use, and that the biodistribution of a transition-metal-
based chemiluminescent reporter can be visualized in vivo. 
Figure 9.4.1a illustrates the generation and detection of a chemiluminescence signal under 
conditions suitable for chemiluminescence imaging. Because application of the required 
oxidation agent to sample tissue is essential to elicit chemiluminescence, we developed the 
nebulizing device outlined in Figure 9.4.1b. It is designed to fit into a commercially available IVIS 
Spectrum imaging system (Figure 9.4.1c) and can be operated remotely via a cable when the 
IVIS Spectrum door is closed and camera shutters are open. The spray bottle contains an 
aqueous solution of the oxidizing agent (NH3)2Ce(NO3)6 and is aimed toward the tissue sample, 
a histological slide, or any other analyte (Figure 9.4.1d). Once a spray burst is released, the 
surface of the tissue of interest is covered in (NH3)2Ce(NO3)6, which will oxidize the 
chemiluminescent reporter contained in the tissue, prompting the emission of photons. 
Alternatively, if the (NH3)2Ce(NO3)6 solution is sprayed on a region lacking any 
chemiluminescent reporters, no photons will be generated. Chemiluminescent imaging is 
therefore devoid of autofluorescence and allows the mapping of the distribution of the 
chemiluminescent reporter close to the tissue surface.  
We tested the general feasibility of chemiluminescent imaging in fresh tissues by injecting a 
solution of [Ru(bpy)3]Cl2 (8–33 nmol in 100 mL PBS) intravenously in a set of healthy mice 
(n=5); 10 min after injection, the mice were sacrificed, their body cavities were opened, kidneys 
cut, and chemiluminescence was generated by spraying (NH3)2Ce(NO3)6 onto the body cavities. 
Not surprisingly, large amounts of signal were localized to kidneys (Figure 9.4.2a) and liver, 
whereas other organs did not emit significant chemiluminescence, indicating renal clearance of 
[Ru(bpy)3]2+. Kidney chemiluminescence is far greater within the tissue than the tissue surface, 
and organs did not emit chemiluminescence if not treated with the (NH3)2Ce(NO3)6  agent 
(Figure 9.4.2b). Biodistribution of the reporter was established from a second cohort of mice 
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(n=10), which underwent similar treatment. All major organs were excised, and the 
chemiluminescence in each organ was quantified individually. Comparison with signals 
generated when the animals were injected with PBS alone yields signal-to-noise ratios of 27/1 
for kidney and 21/1 for liver (Figure 9.4.2c), and only moderate signal intensities were observed 
for other organs. This confirms the observed renal localization of the [Ru(bpy)3]2+ reporter. 
ICP-MS analyses of the mouse tissues further corroborated the chemiluminescence imaging 
data (Figure 9.4.2d). We found that ruthenium concentrations correlate well with photon flux 
rates, with the highest deposition in the kidneys (574 000 photons s-1cm-2sr-1 and 1.24 ± 0.25 
mg·g-1), followed by liver tissue (260 000 photons s-1cm-2sr-1 and 256 ± 47 ng·g-1). Overall, this 
indicates that chemiluminescence might not only be useful to detect the presence of  
 
 
Figure 9.4.2. a) White light (left), chemiluminescence (center), and overlay (right) images of a 
mouse body cavity injected with 33 nmol of [Ru(bpy)3]2+ in 100 mL PBS. The green arrows point 
toward the right kidney. b) Images of excised kidneys are clearly visible in mice injected with the 
ICI agent, but not when injected with PBS. c) Quantification of the imaging results shown in 
panel a, with imaging quantification performed on excised organs. d) Quantification of ruthenium 
metal concentrations in various tissues using ICP-MS. e) Correlation of chemiluminescent 
photon flux and ICP-MS determined ruthenium concentrations. 
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[Ru(bpy)3]2+ in vivo, but that this technique might ultimately be able to quantify concentrations 
noninvasively. 
9.5: Experimental  
9.5.1: Rucaparib Fluorescence 
Commercially available compounds were used without further purification unless otherwise 
stated. Rucaparib was purchased through SelleckChem and N-Acetyl-L-tryptophanamide 
(NATA) purchased from Sigma Aldrich (St. Louis, MO, USA).  
Sample preparation. Stock solutions of N-Acetyl-L-tryptophanamide (NATA, Sigma-Aldrich) in 
water and rucaparib (Ruc) in 1x Dulbecco’s PBS were made at 500, 400, 300, 200 and 100 µM 
concentration. Three mL of the corresponding solvents were used to obtain baseline spectra for 
UV-vis and fluorescence spectroscopy, and then 50 µL aliquots of the stock solutions were 
added to the same cuvettes used for the baselines (final concentrations: 1.64, 3.23, 4.76, 6.25 
and 7.69 µM). This procedure generated a series of 5 sets of spectra (UV-vis, fluorescence 
emission and fluorescence excitation) at varying concentrations for both compounds. For Ruc, 
fluorescence lifetime measurements were also performed at each concentration for two different 
emission wavelengths. 
UV-Vis Spectrometry. UV-visible spectra were obtained on a Perkin-Elmer Lambda 35 UV-vis 
spectrometer, scanning from 200 nm to 1000 nm, in 1 nm increments with a slit width of 1 nm. 
Solutions were mixed directly in 1 cm pathlength quartz cuvettes, and these same cuvettes 
were used for steady-state and time correlated fluorescence measurements.  
Fluorescence Spectrometry. Steady-state fluorescence emission and excitation spectra were 
obtained on a HORIBA Scientific FluoroLog-3 fluorometer. All spectra were corrected by 
dividing by the wavelength dependent lamp intensity reference signal, and further baseline 
corrected using the spectra of the pure solvents. For both the NATA and rucaparib samples, 
emission spectra were obtained using a 290 nm (1 nm slit width) excitation wavelength and 
scanning from 300 to 1000 nm (5 nm slit width). For rucaparib, additional emission spectra were 
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obtained under almost identical conditions, but using 350 nm and 395 nm excitation 
wavelengths. The NATA excitation spectra were obtained at an emission wavelength of 400 nm 
(1 nm slit width), scanning from 200 to 390 nm (5 nm slit width). Rucaparib excitation spectra 
were obtained similarly, but monitoring emission wavelengths of 450 nm and 500 nm.  
Quantum yield calculations. Gradient plots of emission intensity (at the primary peak 
wavelength) vs. absorbance (at the excitation wavelength, 290 nm) were made from data from 
the absorbance and fluorescence emission measurements. The slopes from these plots, ∇F for 
rucaparib, and ∇Fstd for NATA, along with the known quantum yield for NATA in H2O, φstd into 
the following equation: 
 





Where φ represents the quantum yield of rucaparib in PBS. 
Fluorescence Lifetimes. Time correlated single photon counting (TCSPC) measurements 
were recorded with the FluoroHub Tau-3 module for the same fluorometer, using a diode laser 
source (NanoLED-405) with a pulse duration less than 200 ps. The excitation wavelength was 
set to 395 nm (slit width 5 nm) and the emission wavelength was set to 450 nm or 500 nm (both 
with 5 nm slit widths) to obtain two separate measurements for each sample concentration. The 
recorded decay was fit to a monoexponential function using the Decay Analysis Software (v. 
6.4) provided with the instrument. 
9.5.2: Eu-HOPO Lanthanide Luminescence. 
Commercially available compounds were used without further purification unless otherwise 
stated. EuCl3 was purchased from Sigma Aldrich (St. Louis, MO, USA). 3,4,3-(LI-1,2-
hydroxypyridinone) (HOPO) was prepared as reported previously13, and provided by the labs of 
Lynn Francesconi. Water (>18.2 MΩcm-1 at 25 °C) was obtained from an Alpha-Q Ultrapure 
water system from Millipore (Bedford, MA, USA). 
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Eu-HOPO Synthesis. Eu-HOPO was first prepared as reported previously16,23,24. Briefly, 1 mg 
HOPO and 1 mg EuCl3 were combined in 1mL of pure MeOH and 2µL of pyridine were added. 
The MeOH was then removed via vacuum and the unpurified product was used for HPLC and 
LCMS analysis. Subsequently, the reaction was performed entirely in PBS. 1mg HOPO was 
combined with 5 mg EuCl3 and shaken at 500rpm at room temperature for 5-10 min. The 
product was used for the luminescence measurements without purification. 
Luminescence Measurements. Lanthanide luminescence was measured in a 96-well plate 
(Costar black clear bottom, company) with a path length of 0.3 cm for a volume of 100 µL 
respectively. Measurements were made on a SpectraMax® M5 Multi-Mode Microplate Reader. 
Samples were prepared via serial dilution to a final volume of 100 µL directly on the 96 well 
plate. All studies were performed with excitation wavelength 325 nm and emission wavelength 
610 nm. For the mass correlation study, the final concentration varied between 5 and 0.5 mM 
(5.34, 2.67, 1.34, 0.67 mM). This study was performed without a delay time (0 µs) and the 
maximum integration time (1500 µs). The delay time study was performed on the highest 
concentration (5.34 mM) and maximum integration time (1500 µs). The delay time was varied 
between 0 and 600 µs (the maximum value available). For the integration time study, again, the 
highest concentration was used, but no delay time (0 µs) was used. The integration time was 
varied from the lowest value (50 µs) to the highest value possible (1500 µs). 
9.5.3: Ru(bpy)3 Chemiluminescence imaging 
Commercially available compounds were used without further purification unless otherwise 
stated. Tris(2,2’-bipyridyl)dichloro ruthenium(II) hexahydrate ([Ru(bpy)3]Cl2·6H2O) and 
ammonium cerium(IV) nitrate (NH3)2Ce(NO3)6 were purchased from Sigma Aldrich (St. Louis, 
MO, USA). Water (>18.2 MΩcm-1 at 25 °C) was obtained from an Alpha-Q Ultrapure water 
system from Millipore (Bedford, MA, USA). High performance liquid chromatography (HPLC) 
purification and analysis was performed on a Shimadzu UFLC HPLC system equipped with a 
DGU-20A degasser, a SPD-M20A UV detector, a RF- 20Axs fluorescence detector, a LC-20AB 
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pump system, and a CBM-20A communication BUS module. HPLC solvents (Buffer A: 0.1% 
TFA in water, Buffer B: 0.1% TFA in MeCN) were filtered before use. HPLC analysis was 
performed on a reversed phase Phenomenex Gemini column (C18, 5 µm, 4.6 mm, 250 mm). 
Analysis were performed with this method: flowrate: 1 mL/min; gradient: 0-15 min 5-95% B; 15-
18 min 95% B; 18-20 min 100%-5% B). 
Mouse Models All animal experiments were done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee of MSKCC and followed National Institutes of 
Health guidelines for animal welfare. Female nude (outbred) mice at age 5 - 6 weeks and NU/J 
male mice at age 6 – 8 were purchased from Taconic Laboratories (Hudson, NY, USA) and 
Jackson Laboratories (Farmington, CT, USA) respectively. 
Nebulizer Components 1 Harmon Face Values 3oz mini sprayer (Bed, Bath and Beyond, New 
York, NY, USA); 1 Hitech HS-82MG Mirco Servo Motor, 3.4kg/cm output torque @ 6V (Hitech 
RCD USA Inc., Poway, CA, USA); 1 Energizer 9V alkaline battery (Energizer Holdings Inc., St. 
Louis, USA); 2 28 cm plastic cable ties (General Electric Inc., Fairfield, CT, USA); 1 role of duct 
tape (3M Inc., St. Paul, MN, USA); 1 copper speaker cable 1m (RCA Inc., New York, NY, USA); 
1 pencil Papermate Classic HB (Sanford L.P., Oak Brook, IL, USA); 1 littleBits w1 wire (littleBits, 
New York, NY, USA); 1 littleBits p1 power (littleBits, New York, NY, USA); 1 littleBits i2 toggle 
switch (littleBits, New York, NY, USA); 1 littleBits 011 servo (littleBits, New York, NY, USA); 3 
Wood parts: 12.5x2.5x1.8 cm (A), 11x2.5x1.8cm (B), 12.7x10.7x1.8cm (C); 3 wood cutting 
screws (4x25 mm); 1 paper clip (Staples, New York, NY, USA); 2 20 cm plastic covered wire 
twist ties (Staples, New York, NY, USA); 1 10cm of 1/16” stainless steel rod (Metals Depot Int. 
Inc., Winchester, KY, USA). 
Nebulizer Construction Wood part A was attached upright in the center of part C using two 
screws. Wood part B was attached to the middle of part A using one screw so the B can still be 
moved a bit. Two holes were drilled trough the lower tip of the spray bottle trigger. The stainless 
steel rod was pushed through to form two loops one on either side of the trigger. The spray 
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bottle was attached to wood part B using the two plastic cable ties. The littleBits 011 servo 
motor was cut off, and the cables of the littleBits servo control unit reconnected to the HS-82MG 
servo motor. The servo motor was attached to the top of wood part A using duct tape. The 
pencil was attached to the servo motor lever using the paper clip. The outermost parts of the 
pencil were connected tightly to the steel rod loops using plastic covered twist wires. The 
littleBits servo motor control units magnetic cable connector was cut off, reattached to the 
speaker cable and taped to wood part C. A littleBits w1 cable was cut in half and one part 
attached to the loose end from the speaker cable. The (magnetic) littleBits parts i2 and p1 were 
connected to the available w1. Figure A.9.1 shows a photograph of the nebulizer. 
In vivo chemiluminescence imaging after intravenous injection 
In vivo chemiluminescence imaging was performed in female nude mice. Mice received 
[Ru(bpy)3]Cl2 · 6H2O (20 µg, 27 nmol, in 100 µL, in sterile PBS) via tail vein injection after 
sterilizing the tail with an alcohol pad. For all intravenous injections, mice were gently warmed 
with a heat lamp and placed on a restrainer. The tails were sterilized with alcohol pads, and 
injection took place via the lateral tail vein. Mice were sacrificed by CO2 asphyxiation at 10 min 
p.i. The mouse abdomen were opened by a longitudinal cut and the organ of interest exposed 
superficially cut. The IVIS bioluminescence reader was set up by initializing the Live Image 4.2 
software. After signing in to the user profile the “Initialize” button was clicked in the acquisition 
control panel. In the “Imaging Mode” “Luminescent” and “Photograph” were checked, and 
“Fluorescent” was unchecked. “Exposure Time” setting for “Luminescent” was changed to 20 
seconds. Remaining settings for “Luminescent” were set to “Binning”: Medium; “F/stop”: 1; and 
“Emission Filter”: Open. Settings for “Photograph” were set to “Exposure Time”: Auto; “Binning”: 
Medium; and “F/stop”: 8. “Subject Height” was adjusted according to imaging target. In the 
“Field of View” drop down menu stage position was changed to “B”. The experiment was then 
set up by placing the mouse carcass on a sheet of black construction paper on the floor of the 
imaging chamber. The nebulizer was prepared by detaching the plastic spray bottle from the 
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wooden support and filling it with a 25mM solution of (NH3)2Ce(NO3)6 in water before 
reattachment. The nebulizer was placed inside the bioluminescence reader such that the spray 
flow was pointed towards the area of interest on the imaging subject, and also such that the 
nebulizer was not obstructing the camera’s field of view. Small black pieces of construction 
paper were placed over any potential hot spots (e.g. injection sites). At least 40 cm of the 
nebulizer remote chord were placed inside the IVIS chamber such that it did not interfere with 
the imaging subject, nebulizer, or the magnetic door latch. After closing the instrument door 
image sequences were acquired. After the camera shutter opened, three bursts of a solution of 
(NH3)2Ce(NO3)6 in water were sprayed by remotely switching the nebulizer on/off three times 
(0.24 ± 0.04 mL per spray burst). Quantification was performed the same way as for the 
determination of the detection limit using Live Image 4.3 software. Control animals were injected 
with PBS and treated the same way. 
In vivo biodistribution Biodistribution studies were performed in female nude mice (n = 5). 
Mice administered with [Ru(bpy)3]Cl2 · 6H2O (20 µg, in 100 µL, in sterile PBS) via tail vein 
injection. Mice were sacrificed by CO2 asphyxiation at 10 min p.i. and major organs were 
collected, sliced in half and sprayed with a solution of (NH3)2Ce(NO3)6 in water (25mM), using 
the same protocol and settings as described in the in vivo ICI section. All images were 
quantified using Live Image 4.3 software. ROIs were drawn over regions of interest and the 
average flux was reported. For background determination PBS injected control animals were 
used. 
ICP-MS quantification Female athymic mice (n = 3) at 10 weeks of age (Taconic, Hudson, NY, 
USA) were injected with [Ru(bpy)3]Cl2 · 6H2O (20 µg, in 100 µL, in sterile PBS) through tail 
veins. One mouse was injected with 100 µl PBS. Mice were sacrificed by CO2 asphyxiation at 
10 min p.i. and perfused with 20 ml PBS. Kidneys, liver, lungs, spleen, brain, heart, and femur 
muscle were collected from each animal, weighed, and preserved at -20 °C before ICP-MS 
analysis. Ruthenium (Ru) analysis and quantification was performed using inductively coupled 
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plasma-mass spectrometry (ICP-MS). Tissues were weighed and acid digested before ICP-MS 
analysis. For each gram of tissue, 2 mL of nitric acid and 1 mL of hydrogen peroxide was 
added. Samples were left at room temperature for 2 days and vortexed to aid tissue breakdown 
before the addition of hydrogen peroxide. After dilution in Milli-Q water, samples were 
centrifuged and then analyzed using an Agilent Technologies 8800 ICP-MS. Indium was used 
as an internal standard, added via t-piece before the nebulizer. Calibration standards were 
prepared from a 1000 µg/mL Ru certified reference material (Inorganic Ventures, 
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HPLC chromatograms of crude compound (Figure A.3.1) 
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PARPi-FL stability and formulation (Figure A.3.5) 
Blood half life and bio distribution tumor/organ ratios (Figure A.3.6) 





Figure A.3.1. Analytical HPLC trace of (a) absorbance and (b) radioactivity for the crude 


















Figure A.3.4. 18F-PARPi-FL fluorescence and emission spectra. Synthesized 18F-PARPi-FL was 
injected onto a HPLC equipped with a fluorescence detector and excitation/emission spectra 




Figure A.3.5. PARPi-FL stability and formulation. (b) Stability of 19F-PARPi-FL was checked by 
HPLC. Chromatograms were acquired at 0 minutes and 24 hours after formulation and 
compared with 19F-PARPi-FL QC. (b) 30% PEG300, 10% Captisol and 0.1M HCl were tested 
as formulations for PARPi-FL. HPLC chromatograms were obtained at different time points (0, 
1, 2, 4, 8, 12, 16, 24 h respectively) and PARPi-FL fraction collected and plotted as % of the 





Figure A.3.6. Blood half life and bio distribution tumor/organ ratios. (a) Ex-vivo blood half-life of 
18F-PARPi-FL (n=4). Blood was collected at different time points (5, 15, 30, 60, and 120 min), 
weighed, and γ-counted. Results expressed as percent injected activity/gram (%ID/g); (b) 
selected tumor to non-target tissues ratio of 18F-PARPi-FL.  
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Organ Non Blocked Blocked 
  %ID/g S.D. %ID/g S.D. 
Tumor 0.79 0.09 0.15 0.05 
Heart 0.23 0.04 0.22 0.10 
Lung 0.43 0.11 0.42 0.18 
Blood 0.42 0.19 1.03 1.20 
Liver 3.80 0.39 2.33 0.56 
Spleen 3.31 0.24 1.38 1.14 
Pancreas 0.62 0.13 0.27 0.16 
Kidney 0.76 0.13 0.49 0.15 
S I 1.70 0.95 3.17 2.51 
L I 2.19 3.03 0.35 0.16 
Stomach 0.43 0.18 0.44 0.17 
Bone 12.08 5.14 13.48 3.68 
Muscle 0.20 0.04 0.24 0.07 
Brain 0.07 0.00 0.09 0.01 
 
Table A.3.1. Values for the biodistribution studies in Figure 3.5.1 
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HPLC chromatograms for crude [18F]PARPi (Figure A.4.1) 
HPLC chromatogram for purified 19F-PARPi (Figure A.4.2) 
MS data for 19F-PARPi (Figure A.4.3) 
1H-NMR for 19F-PARPi  (Figure A.4.4) 


























Figure A.4.4. 1H-NMR (500 MHz) for 19F-PARPi. In CDCl3 
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Organ Non Blocked Blocked 
 %ID/g S.D. %ID/g S.D. 
Tumor 1.82 0.21 0.23 0.09 
Heart 0.30 0.08 0.12 0.03 
Lung 0.44 0.11 0.38 0.07 
Blood 0.41 0.09 0.45 0.36 
Liver 3.98 0.56 3.61 2.04 
Spleen 4.04 1.23 0.26 0.09 
Pancreas 1.71 0.41 0.48 0.25 
Kidney 1.17 0.46 0.47 0.22 
S I 2.94 0.91 2.35 0.70 
L I 2.24 0.59 1.73 0.80 
Stomach 0.73 0.30 1.05 0.58 
Bone 1.21 0.24 0.21 0.10 
Muscle 0.37 0.09 0.19 0.08 
Brain 0.04 0.01 0.04 0.03 
Lymph 
Nodes 
2.80 0.51 0.13 0.03 
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PARP1 IHC staining (Figure A.5.1) 
Histological characterization of GEMM tumor model and PARPi-FL localization (Figure A.5.2) 
PET/CT whole body image of [18F]PARPi 2 h p.i. (Figure A.5.3) 
PARP1 IHC of brain areas and relevant tissues and organs of ntv-a;p53fl/fl mice (Figure A.5.4) 
Biodistribution of [18F]PARPi in healthy ntv-a;p53fl/fl mice 2 h p.i. (Figure A.5.5) 
Values for the biodistribution studies (Table A.7.1) 





Figure A.5.1. PARP1 IHC staining.! (a) PARP1 staining of frontal cortex autopsy tissue of a 
diffuse midline glioma patient. The corresponding H&E is from the same area as the PARP1 
stained image. (b) Physiological, non-tumor related PARP1 expression was observed in the 
brain of ntv-a;p53fl/fl mice in the Purkinje cell layer in the cerebellum and the dentate gyrus. (c) 
Example of PARP1 and H&E staining of tumor bearing ntv-a; p53fl/fl mice injected with DF1 cells 





Figure A.5.2. Histological characterization of GEMM tumor model and PARPi-FL localization.!
(a) The GEMM model showed heterogenous morphological characteristics, representing high 
grade areas (with necrotic features, high cellularity, microvascular proliferation) and lower grade 
areas (less cellular, no necrosis). PARP1 expression was more pronounced in high grade areas 
compared to low grade areas and very low in normal pons. (b) Immunofluorescent 
characterization of high grade and low grade tumor areas and healthy brain. Tissues were 

















Figure A.5.5. Biodistribution of [18F]PARPi in healthy ntv-a;p53fl/fl mice 2 h p.i. Animals were 
injected with [18F]PARPi 2 hours prior to the biodistribution study (n=4). One group (n=4) was 




Organ Non Blocked Blocked 
  %ID/g S.D %ID/g S.D 
Heart 0.14 0.02 0.14 0.06 
Lung 0.40 0.05 0.34 0.10 
Blood 0.22 0.12 0.20 0.05 
Liver 2.61 0.24 2.51 0.54 
Spleen 2.92 0.40 0.35 0.05 
Pancreas 0.54 0.13 0.12 0.04 
Kidney 0.53 0.04 0.45 0.10 
S I 1.07 0.98 2.72 2.48 
L I 0.98 0.24 1.35 0.54 
Stomach 0.66 0.50 1.11 0.58 
Bone 0.60 0.17 0.10 0.04 
Muscle 0.13 0.05 0.07 0.01 
Brain 0.03 0.00 0.06 0.07 
Lymph 1.73 0.37 0.21 0.06 
Salivary 0.61 0.13 0.19 0.06 
 






Figure A.5.6. Monitoring tumor growth using [18F]PARPi. (a) Adult animals were imaged weekly 
after DF1 cell injection. Animals were sacrificed after week 6 and tumor presence was 
confirmed histologically. (b) One animal showed no increase in [18F]PARPi uptake over the 
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Additional PARP family assays (Figure A.6.1) 
Quantification of PARP expression from tissue microaarays (Figure A.6.2) 
Additional biodistribution studies for different genetically modified mice (Figure A.6.3) 
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Verification of DLBCL model (Figure A.7.1) 
Additional quantification for PET imaging studies (Figure A.7.1) 
Additional data for biodistribution studies (Figure A.7.1) 
Additional data for inflammation studies (Figure A.7.1) 




Figure A.7.1. Verification of DLBCL model. (a) Weights of various organs, white blood cell 
counts and platelet counts. n = 5/group. (b) Western blot of DLBCL cells from mouse spleens 
and normal B cells from B6 mouse spleens. (c) Representative flow cytometry graphs show that 
most immune cells (CD45+) in DLBCL mice express RFP and therefore derive from the 
transplanted hematopoietic precursor cells (HPCs). (d) Representative H&E of superficial 







Figure A.7.2. Additional quantification for PET imaging studies. (a) Correlation of radioactivity 
measurement between in vivo PET imaging and ex vivo γ-counting (n = 7). (b) Accumulation of 





Figure A.7.3. Additional data for biodistribution studies. (a) Biodistribution in B6 mice showing 
PARP1-specific accumulation in the lymph nodes, spleens, and salivary glands. B6 mice were 
injected with [18F]PARPi (n = 4 ) or pre-blocked with olaparib (n = 3). (b) Representative 
autoradiograms show [18F]PARPi uptake in the selected tissues in DLBCL and B6 mice injected 
with [18F]PARPi and with olaparib blocking. (c) Representative histological images of the 5 
tissues from DLBCL (n = 5) and B6 mice (n = 5). Consecutive sections were stained with 




Figure A.7.4. Additional data for inflammation studies. (a) (b) (c) Biodistribution of [18F]FDG in 5 
selected tissues from DLBCL mice (n = 5), B6 mice with inflamed lymph nodes (LN) (n = 5), and 
normal B6 mice (n = 5). (d) Biodistribution of [18F]PARPi in the same tissues from DLBCL mice 




Organ Non Blocked DLBCL Blocked DLBCL Healthy B6 
  %ID/g S.D %ID/g S.D %ID/g S.D 
Heart 0.75 0.32 0.04 0.01 0.07 0.01 
Lung 3.38 2.89 0.08 0.02 0.07 0.01 
Blood 1.55 0.95 0.13 0.05 0.12 0.03 
Liver 8.48 3.64 1.41 0.28 1.59 0.53 
Spleen 8.89 2.96 0.11 0.08 2.07 0.34 
Pancreas 3.45 1.04 0.18 0.19 0.26 0.07 
Kidney 4.54 2.56 0.24 0.09 0.30 0.06 
S I 11.87 3.81 4.69 1.39 2.70 2.22 
L I 3.07 1.57 0.28 0.05 2.17 1.39 
Stomach 1.47 0.97 0.33 0.12 1.13 1.09 
Bone 1.73 0.47 0.08 0.04 0.32 0.11 
Muscle 0.49 0.15 0.04 0.01 0.19 0.17 
Brain 0.10 0.03 0.02 0.00 0.02 0.01 
Lymph 6.32 3.84 0.07 0.03 1.11 0.30 
Salivary 3.67 0.90 0.05 0.02 0.29 0.07 
 
Table A.7.1. Values for the biodistribution studies in Figure 5.7.1. 
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Photograph of the Nebulizer (Figure A.9.1)  
! 174!
 
Figure A.9.1: Photograph of the Nebulizer. Parts used: Wooden structure parts (A, B, C), spray 
bottle (D), bent steel rod (E), duct tape (F), plastic cable ties (G), 011 servo connector part (H), 
servo motor (I), pencil (J) held by bent paper clip (K), plastic covered wire twist ties (L) w1 wire 







1. Wahlberg, E. et al. Family-wide chemical profiling and structural analysis of PARP and 
tankyrase inhibitors. Nat Biotechnol 30, 283-288 (2012). 
2. Curtin, N. J. & Sharma, R. A. PARP Inhibitors for Cancer Therapy. Cancer Drug Discovery 
and Development 83, (2015). 
3. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: 
PARP1 and beyond. Nat Rev Cancer 10, 293-301 (2010). 
4. Héberlé, E., Amé, J.-C., Illuzzi, G., Dantzer, F. & Schreiber, V. in PARP Inhibitors for 
Cancer Therapy (eds Curtin, N. J. & Sharma, R. A.) 15-46 (Springer International 
Publishing, Cham, 2015). 
5. Ménissier de Murcia, J. et al. Functional interaction between PARP-1 and PARP-2 in 
chromosome stability and embryonic development in mouse. EMBO J 22, 2255-2263 
(2003). 
6. Chiang, Y. J. et al. Tankyrase 1 and tankyrase 2 are essential but redundant for mouse 
embryonic development. PLoS One 3, e2639 (2008). 
7. Ossovskaya, V., Koo, I. C., Kaldjian, E. P., Alvares, C. & Sherman, B. M. Upregulation of 
Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other 
Primary Human Tumor Types. Genes Cancer 1, 812-821 (2010). 
8. Fisher, A. E., Hochegger, H., Takeda, S. & Caldecott, K. W. Poly(ADP-ribose) polymerase 
1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. 
Mol Cell Biol 27, 5597-5605 (2007). 
9. Velic, D. et al. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After 
Achilles’ Heel of Cancer. Biomolecules 5, 3204-3259 (2015). 
10. Schultz, N. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous 
recombination. Nucleic Acids Research 31, 4959-4964 (2003). 
11. Audebert, M., Salles, B. & Calsou, P. Involvement of poly(ADP-ribose) polymerase-1 and 
XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J 
Biol Chem 279, 55117-55126 (2004). 
12. Maltseva, E. A., Rechkunova, N. I., Sukhanova, M. V. & Lavrik, O. I. Poly(ADP-ribose) 
Polymerase 1 Modulates Interaction of the Nucleotide Excision Repair Factor XPC-
RAD23B with DNA via Poly(ADP-ribosyl)ation. J Biol Chem 290, 21811-21820 (2015). 
13. Poirier, G. G., de Murcia, G., Jongstra-Bilen, J., Niedergang, C. & Mandel, P. Poly(ADP-
ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad 
Sci U S A 79, 3423-3427 (1982). 
14. Rouleau, M., Aubin, R. A. & Poirier, G. G. Poly(ADP-ribosyl)ated chromatin domains: 
access granted. J Cell Sci 117, 815-825 (2004). 
15. Das, B. B. et al. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA 
damage. Nucleic Acids Res 42, 4435-4449 (2014). 
16. Masson, M. et al. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and 
negatively regulates its activity following DNA damage. Mol Cell Biol 18, 3563-3571 
(1998). 
17. Satoh, M. S. & Lindahl, T. Role of poly(ADP-ribose) formation in DNA repair. Nature 356, 
356-358 (1992). 
18. Pommier, Y., O’Connor, M. J. & de Bono, J. Laying a trap to kill cancer cells: PARP 
inhibitors and their mechanisms of action. Sci Transl Med 8, 362ps17 (2016). 
19. Ali, A. A. E. et al. The zinc-finger domains of PARP1 cooperate to recognize DNA strand 
breaks. Nat Struct Mol Biol 19, 685-692 (2012). 
! 176!
20. Lilyestrom, W., van der Woerd, M. J., Clark, N. & Luger, K. Structural and biophysical 
studies of human PARP-1 in complex with damaged DNA. J Mol Biol 395, 983-994 (2010). 
21. Langelier, M. F., Planck, J. L., Roy, S. & Pascal, J. M. Structural basis for DNA damage-
dependent poly(ADP-ribosyl)ation by human PARP-1. Science 336, 728-732 (2012). 
22. Ruf, A., De Murcia, J. M., De Murcia, G. & Schulz, G. E. Structure of the catalytic fragment 
of poly (AD-ribose) polymerase from chicken. Proceedings of the National Academy of 
Sciences 93, 7481-7485 (1996). 
23. Ruf, A., de Murcia, G. & Schulz, G. E. Inhibitor and NAD+ binding to poly(ADP-ribose) 
polymerase as derived from crystal structures and homology modeling. Biochemistry 37, 
3893-3900 (1998). 
24. Langelier, M. F. & Pascal, J. M. PARP-1 mechanism for coupling DNA damage detection 
to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 23, 134-143 (2013). 
25. Edmonds, C. E. et al. [18F]FluorThanatrace uptake as a marker of PARP1 expression and 
activity in breast cancer. Am J Nucl Med Mol Imaging 6, 94-101 (2016). 
26. Makvandi, M. et al. A radiotracer strategy to quantify PARP-1 expression in vivo provides 
a biomarker that can enable patient selection for PARP inhibitor therapy. Cancer Res 76, 
4516-4524 (2016). 
27. Brightwell, M. D., Leech, C. E., O’Farrell, M. K., Whish, W. J. & Shall, S. Poly(adenosine 
diphosphate ribose) polymerase in Physarum polycephalum. Biochem J 147, 119-129 
(1975). 
28. Curtin, N. J., Wang, L. Z., Yiakouvaki, A., Kyle, S. & Arris…, C. A. Novel poly (ADP-ribose) 
polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-
deficient cells. Clinical Cancer … (2004). 
29. Tutt, A. et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with< i> 
BRCA1 or< i> BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. 
The Lancet 376, 235-244 (2010). 
30. Purnell, M. R. & Whish, W. J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J 
185, 775-777 (1980). 
31. Suto, M. J., Turner, W. R., Arundel-Suto, C. M., Werbel, L. M. & Sebolt-Leopold, J. S. 
Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of 
poly(ADP-ribose) polymerase. Anticancer Drug Des 6, 107-117 (1991). 
32. Griffin, R. J. et al. Novel potent inhibitors of the DNA repair enzyme poly(ADP-
ribose)polymerase (PARP). Anticancer Drug Des 10, 507-514 (1995). 
33. Ferraris, D. V. Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From 
Concept to Clinic. J Med Chem 53, 4561-4584 (2010). 
34. O’Shaughnessy, J. et al. Iniparib plus chemotherapy in metastatic triple-negative breast 
cancer. N Engl J Med 364, 205-214 (2011). 
35. O’Shaughnessy, J. et al. Phase III study of iniparib plus gemcitabine and carboplatin 
versus gemcitabine and carboplatin in patients with metastatic triple-negative breast 
cancer. J Clin Oncol 32, 3840-3847 (2014). 
36. Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G. & Kaufmann, S. H. Failure of 
iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 18, 1655-1662 
(2012). 
37. Mateo, J., Ong, M., Tan, D. S., Gonzalez, M. A. & de Bono, J. S. Appraising iniparib, the 
PARP inhibitor that never was--what must we learn. Nat Rev Clin Oncol 10, 688-696 
(2013). 
38. Deeks, E. D. Olaparib: first global approval. Drugs 75, 231-240 (2015). 
39. Syed, Y. Y. Rucaparib: First Global Approval. Drugs 77, 585-592 (2017). 
40. Scott, L. J. Niraparib: First Global Approval. Drugs 77, 1029-1034 (2017). 
41. White, A. W. et al. Resistance-modifying agents. 9. Synthesis and biological properties of 
benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J Med 
! 177!
Chem 43, 4084-4097 (2000). 
42. Canan Koch, S. S. et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with 
potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal 
structure. J Med Chem 45, 4961-4974 (2002). 
43. Thomas, H. D. et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor 
for clinical trial. Mol Cancer Ther 6, 945-956 (2007). 
44. Banasik, M., Komura, H., Shimoyama, M. & Ueda, K. Specific inhibitors of poly(ADP-
ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267, 1569-1575 
(1992). 
45. Loh, V. M. et al. Phthalazinones. Part 1: The design and synthesis of a novel series of 
potent inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 15, 2235-2238 
(2005). 
46. Cockcroft, X. L. et al. Phthalazinones 2: Optimisation and synthesis of novel potent 
inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 16, 1040-1044 (2006). 
47. Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP 
inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 
105, 17079-17084 (2008). 
48. Lawlor, D. et al. PARP Inhibitors as P-glyoprotein Substrates. J Pharm Sci 103, 1913-1920 
(2014). 
49. Jaspers, J. E. et al. Loss of 53BP1 Causes PARP Inhibitor Resistance in -Mutated Mouse 
Mammary Tumors. Cancer Discovery 3, 68-81 (2013). 
50. Oplustil O’Connor, L. et al. The PARP Inhibitor AZD2461 Provides Insights into the Role of 
PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in 
Preclinical Models. Cancer Res 76, 6084-6094 (2016). 
51. Lok, B. H. et al. PARP Inhibitor Activity Correlates with SLFN11 Expression and 
Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin Cancer Res 
(2016). 
52. Murai, J. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 
72, 5588-5599 (2012). 
53. Murai, J. et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib 
and rucaparib. Mol Cancer Ther 13, 433-443 (2014). 
54. Murai, J. & Pommier, Y. (eds Curtin, N. J. & Sharma, R. A.) 261-274 (Springer 
International Publishing, Cham, 2015). 
55. Shen, Y. et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of 
human cancers with DNA repair deficiency. Clin Cancer Res 19, 5003-5015 (2013). 




1. Agasti, S. S., Laughney, A. M., Kohler, R. H. & Weissleder, R. A photoactivatable drug-
caged fluorophore conjugate allows direct quantification of intracellular drug transport. 
Chem Commun (Camb) 49, 11050-11052 (2013). 
2. Carney, B. et al. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma 
Models. Mol Imaging Biol 18, 386-392 (2016). 
3. Dubach, J. M. et al. In vivo imaging of specific drug-target binding at subcellular resolution. 
Nat Commun 5, 3946 (2014). 
4. Dubach, J. M. et al. Quantitating drug-target engagement in single cells in vitro and in vivo. 
Nat Chem Biol 13, 168-173 (2017). 
5. Irwin, C. P. et al. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging. 
Neoplasia 16, 432-440 (2014). 
! 178!
6. Kossatz, S., Weber, W. A. & Reiner, T. Optical Imaging of PARP1 in response to radiation 
in oral squamous cell carcinoma. PloS one 11, e0147752 (2016). 
7. Kossatz, S. et al. Detection and delineation of oral cancer with a PARP1 targeted optical 
imaging agent. Sci Rep 6, 21371 (2016). 
8. Kossatz, S. et al. Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in 
Mouse Models. Cancer Res 77, 2112-2123 (2017). 
9. Reiner, T. et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally 
developed companion imaging agents. Neoplasia 14, 169-177 (2012). 
10. Salinas, B. et al. Radioiodinated PARP1 tracers for glioblastoma imaging. EJNMMI Res 5, 
123 (2015). 
11. Thurber, G. M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight 
into drug action in vivo. Nat Commun 4, 1504 (2013). 
12. Thurber, G. M., Reiner, T., Yang, K. S., Kohler, R. H. & Weissleder, R. Effect of small-
molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer 
Ther 13, 986-995 (2014). 
13. Deeks, E. D. Olaparib: first global approval. Drugs 75, 231-240 (2015). 
14. Menear, K. A. et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-
2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J 
Med Chem 51, 6581-6591 (2008). 
15. Kim, E., Yang, K. S., Giedt, R. J. & Weissleder, R. Red Si-rhodamine drug conjugates 
enable imaging in GFP cells. Chem Commun (Camb) 50, 4504-4507 (2014). 
16. Reiner, T., Earley, S., Turetsky, A. & Weissleder, R. Bioorthogonal small-molecule ligands 
for PARP1 imaging in living cells. Chembiochem 11, 2374-2377 (2010). 
17. Rutkowska, A. et al. A Modular Probe Strategy for Drug Localization, Target Identification 
and Target Occupancy Measurement on Single Cell Level. ACS Chem Biol 11, 2541-2550 
(2016). 
18. Tu, Z. et al. Synthesis and in vivo evaluation of [11C]PJ34, a potential radiotracer for 
imaging the role of PARP-1 in necrosis. Nucl Med Biol 32, 437-443 (2005). 
19. Zhou, D. et al. Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) 
polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission 
tomography. Bioorg Med Chem 22, 1700-1707 (2014). 
20. Garcia Soriano, F. et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) 
polymerase activation. Nat Med 7, 108-113 (2001). 
21. Riss, P. J., Soskic, V., Schrattenholz, A. & Roesch, F. Synthesis and radiosynthesis of N5-
[18F]fluoroethyl-pirenzepine and its metabolite N5-[18F]fluoroethyl-LS 75. J Label Compd 
Radiopharm 52, 576-579 (2009). 
22. Keliher, E. J., Reiner, T., Turetsky, A., Hilderbrand, S. A. & Weissleder, R. High-yielding, 
two-step 18F labeling strategy for 18F-PARP1 inhibitors. ChemMedChem 6, 424-427 
(2011). 
23. Reiner, T., Keliher, E. J., Earley, S., Marinelli, B. & Weissleder, R. Synthesis and in vivo 
imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-
assisted high-performance method. Angew Chem Int Ed Engl 50, 1922-1925 (2011). 
24. Keliher, E. J., Klubnick, J. A., Reiner, T., Mazitschek, R. & Weissleder, R. Efficient acid-
catalyzed 18F/19F fluoride exchange of BODIPY dyes. ChemMedChem 9, 1368-1373 
(2014). 
25. Carlucci, G. et al. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. Mol 
Imaging Biol 17, 848-855 (2015). 
26. Warren, K. E. Diffuse intrinsic pontine glioma: poised for progress. Front Oncol 2, 205 
(2012). 
27. Zmuda, F. et al. Synthesis and evaluation of a radioiodinated tracer with specificity for 
poly(ADP-ribose) polymerase-1 (PARP-1) in vivo. J Med Chem 58, 8683-8693 (2015). 
! 179!
28. Calabrese, C. R. et al. Anticancer chemosensitization and radiosensitization by the novel 
poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96, 56-67 (2004). 
29. Edmonds, C. E. et al. [18F]FluorThanatrace uptake as a marker of PARP1 expression and 
activity in breast cancer. Am J Nucl Med Mol Imaging 6, 94-101 (2016). 
30. Sander Effron, S. et al. PARP-1 expression quantified by [18F]FluorThanatrace: a 
biomarker of response to PARP inhibition adjuvant to radiation therapy. Cancer Biother 
Radiopharm 32, 9-15 (2017). 
31. Michel, L. S. et al. PET of poly (ADP-ribose) polymerase activity in cancer: preclinical 
assessment and first in-human studies. Radiology 282, 453-463 (2017). 
32. Makvandi, M. et al. A radiotracer strategy to quantify PARP-1 expression in vivo provides 
a biomarker that can enable patient selection for PARP inhibitor therapy. Cancer Res 76, 
4516-4524 (2016). 
33. Anderson, R. C. et al. Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 
expression in vitro and in vivo. Nucl Med Biol 43, 752-758 (2016). 
34. Thomas, H. D. et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor 




1. Condeelis, J. & Weissleder, R. In vivo imaging in cancer. Cold Spring Harb Perspect Biol 
2, a003848 (2010). 
2. Alford, R., Ogawa, M., Choyke, P. L. & Kobayashi, H. Molecular probes for the in vivo 
imaging of cancer. Mol Biosyst 5, 1279-1291 (2009). 
3. van Dam, G. M. et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer 
by folate receptor-α targeting: first in-human results. Nat Med 17, 1315-1319 (2011). 
4. Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of 
malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7, 392-
401 (2006). 
5. Jennings, L. E. & Long, N. J. ‘Two is better than one’--probes for dual-modality molecular 
imaging. Chem Commun (Camb) 3511-3524 (2009). 
6. Louie, A. Multimodality imaging probes: design and challenges. Chemical reviews 110, 
3146-3195 (2010). 
7. Sanai, N. & Berger, M. S. Glioma extent of resection and its impact on patient outcome. 
Neurosurgery 62, 753-64; discussion 264 (2008). 
8. Pouratian, N., Asthagiri, A., Jagannathan, J., Shaffrey, M. E. & Schiff, D. Surgery Insight: 
the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol 3, 628-
639 (2007). 
9. Roberts, D. W. et al. Glioblastoma multiforme treatment with clinical trials for surgical 
resection (aminolevulinic acid). Neurosurg Clin N Am 23, 371-377 (2012). 
10. Ossovskaya, V., Koo, I. C., Kaldjian, E. P., Alvares, C. & Sherman, B. M. Upregulation of 
Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other 
Primary Human Tumor Types. Genes Cancer 1, 812-821 (2010). 
11. Bieche, I., de Murcia, G. & Lidereau, R. Poly(ADP-ribose) polymerase gene expression 
status and genomic instability in human breast cancer. Clin Cancer Res 2, 1163-1167 
(1996). 
12. Rojo, F. et al. Nuclear PARP-1 protein overexpression is associated with poor overall 
survival in early breast cancer. Ann Oncol 23, 1156-1164 (2012). 
13. Alanazi, M., Pathan, A. A. K., Arifeen, Z. & Shaik…, J. P. Association between PARP-1 
V762A polymorphism and breast cancer susceptibility in Saudi population. PloS one 
(2013). 
! 180!
14. Galia, A. et al. PARP-1 protein expression in glioblastoma multiforme. European journal of 
histochemistry: EJH 56, (2012). 
15. Barton, V. N. et al. PARP1 expression in pediatric central nervous system tumors. Pediatr 
Blood Cancer 53, 1227-1230 (2009). 
16. Thurber, G. M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight 
into drug action in vivo. Nat Commun 4, 1504 (2013). 
17. Irwin, C. P. et al. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging. 
Neoplasia 16, 432-440 (2014). 
18. Reiner, T. et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally 
developed companion imaging agents. Neoplasia 14, 169-IN3 (2012). 
19. Liu, S. et al. Lewis acid-assisted isotopic 18F-19F exchange in BODIPY dyes: facile 
generation of positron emission tomography/fluorescence dual modality agents for tumor 
imaging. Theranostics 3, 181-189 (2013). 
20. Li, Z. et al. Rapid aqueous [18F]-labeling of a bodipy dye for positron emission 
tomography/fluorescence dual modality imaging. Chem Commun (Camb) 47, 9324-9326 
(2011). 
21. Hendricks, J. A. et al. Synthesis of [18F]BODIPY: bifunctional reporter for hybrid 
optical/positron emission tomography imaging. Angew Chem Int Ed Engl 51, 4603-4606 
(2012). 
22. Keliher, E. J., Klubnick, J. A., Reiner, T., Mazitschek, R. & Weissleder, R. Efficient acid-
catalyzed 18F/19F fluoride exchange of BODIPY dyes. ChemMedChem 9, 1368-1373 
(2014). 
23. Menear, K. A. et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-
2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J 
Med Chem 51, 6581-6591 (2008). 
24. Zhou, D. et al. Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) 
polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission 
tomography. Bioorg Med Chem 22, 1700-1707 (2014). 
25. Keliher, E. J., Reiner, T., Turetsky, A., Hilderbrand, S. A. & Weissleder, R. High-yielding, 
two-step 18F labeling strategy for 18F-PARP1 inhibitors. ChemMedChem 6, 424-427 
(2011). 
26. Liu, Z. et al. Dual mode fluorescent (18)F-PET tracers: efficient modular synthesis of 
rhodamine-[cRGD]2-[(18)F]-organotrifluoroborate, rapid, and high yielding one-step (18)F-
labeling at high specific activity, and correlated in vivo PET imaging and ex vivo 
fluorescence. Bioconjug Chem 25, 1951-1962 (2014). 
27. Hecht, M. et al. Fluorinated Boron-Dipyrromethene (BODIPY) Dyes: Bright and Versatile 
Probes for Surface Analysis. ChemistryOpen 2, 25-38 (2013). 
28. Lakshmi, V., Chatterjee, T. & Ravikanth, M. Lewis Acid Assisted Decomplexation of F‐
BODIPYs to Dipyrrins. European Journal of Organic Chemistry (2014). 
29. Kharasch, E. D. & Thummel, K. E. Identification of cytochrome P450 2E1 as the 
predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, 
isoflurane, and methoxyflurane. Anesthesiology 79, 795-807 (1993). 
30. Ryu, Y. H. et al. Disulfiram inhibits defluorination of (18)F-FCWAY, reduces bone 
radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A 
receptors in human brain. J Nucl Med 48, 1154-1161 (2007). 
31. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of 
image analysis. Nat Methods 9, 671-675 (2012). 
32. Thurber, G. M., Reiner, T., Yang, K. S., Kohler, R. H. & Weissleder, R. Effect of small-
molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer 





1. Carlucci, G. et al. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. Mol 
Imaging Biol 17, 848-855 (2015). 
2. Reiner, T. et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally 
developed companion imaging agents. Neoplasia 14, 169-IN3 (2012). 
3. Irwin, C. P. et al. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging. 
Neoplasia 16, 432-440 (2014). 
4. Keliher, E. J., Klubnick, J. A., Reiner, T., Mazitschek, R. & Weissleder, R. Efficient acid-
catalyzed 18F/19F fluoride exchange of BODIPY dyes. ChemMedChem 9, 1368-1373 
(2014). 
5. Keliher, E. J., Reiner, T., Turetsky, A., Hilderbrand, S. A. & Weissleder, R. High-yielding, 
two-step 18F labeling strategy for 18F-PARP1 inhibitors. ChemMedChem 6, 424-427 
(2011). 
6. Thurber, G. M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight 
into drug action in vivo. Nat Commun 4, 1504 (2013). 
7. Reiner, T., Keliher, E. J., Earley, S., Marinelli, B. & Weissleder, R. Synthesis and in vivo 
imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-
assisted high-performance method. Angew Chem Int Ed Engl 50, 1922-1925 (2011). 
8. Zhou, D. et al. Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) 
polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission 
tomography. Bioorg Med Chem 22, 1700-1707 (2014). 
9. Salinas, B. et al. Radioiodinated PARP1 tracers for glioblastoma imaging. EJNMMI Res 5, 
123 (2015). 
10. Menear, K. A. et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-
2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J 
Med Chem 51, 6581-6591 (2008). 
11. Reiner, T., Earley, S., Turetsky, A. & Weissleder, R. Bioorthogonal small-molecule ligands 
for PARP1 imaging in living cells. Chembiochem 11, 2374-2377 (2010). 
12. Valko, K., Bevan, C. & Reynolds, D. Chromatographic Hydrophobicity Index by Fast-
Gradient RP-HPLC: A High-Throughput Alternative to log P/log D. Anal Chem 69, 2022-
2029 (1997). 
13. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of 





1. Kohler, B. A. et al. Annual report to the nation on the status of cancer, 1975-2007, 
featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103, 714-736 
(2011). 
2. Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous 
System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol 18, v1-v75 
(2016). 
3. Smith, M. A. et al. Outcomes for children and adolescents with cancer: challenges for the 
twenty-first century. J Clin Oncol 28, 2625-2634 (2010). 
4. Patel, S. et al. Are pediatric brain tumors on the rise in the USA? Significant incidence and 
survival findings from the SEER database analysis. Childs Nerv Syst 30, 147-154 (2014). 
5. Deorah, S., Lynch, C. F., Sibenaller, Z. A. & Ryken, T. C. Trends in brain cancer incidence 
and survival in the United States: Surveillance, Epidemiology, and End Results Program, 
! 182!
1973 to 2001. Neurosurg Focus 20, E1 (2006). 
6. Cohen, K. J. et al. Temozolomide in the treatment of children with newly diagnosed diffuse 
intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol 13, 
410-416 (2011). 
7. Haas-Kogan, D. A. et al. Phase II trial of tipifarnib and radiation in children with newly 
diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol 13, 298-306 (2011). 
8. Jalali, R. et al. Prospective evaluation of radiotherapy with concurrent and adjuvant 
temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J 
Radiat Oncol Biol Phys 77, 113-118 (2010). 
9. Korones, D. N. et al. Treatment of children with diffuse intrinsic brain stem glioma with 
radiotherapy, vincristine and oral VP-16: a Children’s Oncology Group phase II study. 
Pediatr Blood Cancer 50, 227-230 (2008). 
10. Sharp, J. R. et al. A multi-centre Canadian pilot study of metronomic temozolomide 
combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J 
Cancer 46, 3271-3279 (2010). 
11. Michalski, A. et al. The addition of high-dose tamoxifen to standard radiotherapy does not 
improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol 100, 81-
88 (2010). 
12. Kretschmar, C. S. et al. Pre‐irradiation chemotherapy and hyperfractionated radiation 
therapy 66 Gy for children with brain stem tumors. A phase II study of the pediatric 
oncology group, protocol 8833. Cancer 72, 1404-1413 (1993). 
13. Hargrave, D., Bartels, U. & Bouffet, E. Diffuse brainstem glioma in children: critical review 
of clinical trials. Lancet Oncol 7, 241-248 (2006). 
14. Liu, A. K., Brandon, J., Foreman, N. K. & Fenton, L. Z. Conventional MRI at presentation 
does not predict clinical response to radiation therapy in children with diffuse pontine 
glioma. Pediatr Radiol 39, 1317-1320 (2009). 
15. Hargrave, D., Chuang, N. & Bouffet, E. Conventional MRI cannot predict survival in 
childhood diffuse intrinsic pontine glioma. J Neurooncol 86, 313-319 (2008). 
16. Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response 
assessment in neuro-oncology working group. J Clin Oncol 28, 1963-1972 (2010). 
17. Reiner, T. et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally 
developed companion imaging agents. Neoplasia 14, 169-IN3 (2012). 
18. Thurber, G. M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight 
into drug action in vivo. Nat Commun 4, 1504 (2013). 
19. Thurber, G. M., Reiner, T., Yang, K. S., Kohler, R. H. & Weissleder, R. Effect of small-
molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer 
Ther 13, 986-995 (2014). 
20. Irwin, C. P. et al. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging. 
Neoplasia 16, 432-440 (2014). 
21. Carney, B. et al. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma 
Models. Mol Imaging Biol 18, 386-392 (2016). 
22. Kossatz, S. et al. Detection and delineation of oral cancer with a PARP1 targeted optical 
imaging agent. Sci Rep 6, 21371 (2016). 
23. Becher, O. J. et al. Preclinical evaluation of radiation and perifosine in a genetically and 
histologically accurate model of brainstem glioma. Cancer Res 70, 2548-2557 (2010). 
24. Hambardzumyan, D., Amankulor, N. M., Helmy, K. Y., Becher, O. J. & Holland, E. C. 
Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol 2, 89-95 (2009). 
25. Sutinen, E. et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J 
Nucl Med Mol Imaging 31, 317-324 (2004). 
26. Tolvanen, T. et al. Biodistribution and radiation dosimetry of [(11)C]choline: a comparison 
between rat and human data. Eur J Nucl Med Mol Imaging 37, 874-883 (2010). 
! 183!
27. Oh, S. J. et al. Fully automated synthesis system of 3’-deoxy-3’-[18F]fluorothymidine. Nucl 
Med Biol 31, 803-809 (2004). 
28. Martin, S. J. et al. A new precursor for the radiosynthesis of [ 18 F]FLT. Nuclear Medicine 




1. Weissleder, R. & Pittet, M. J. Imaging in the era of molecular oncology. Nature 452, 580-
589 (2008). 
2. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: 
PARP1 and beyond. Nat Rev Cancer 10, 293-301 (2010). 
3. Engert, F., Schneider, C., Weiβ, L. M., Probst, M. & Fulda, S. PARP Inhibitors Sensitize 
Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. 
Mol Cancer Ther 14, 2818-2830 (2015). 
4. George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 
47-53 (2015). 
5. Rudin, C. M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently 
amplified gene in small-cell lung cancer. Nat Genet 44, 1111-1116 (2012). 
6. Byers, L. A. et al. Proteomic profiling identifies dysregulated pathways in small cell lung 
cancer and novel therapeutic targets including PARP1. Cancer Discov 2, 798-811 (2012). 
7. Wahlberg, E. et al. Family-wide chemical profiling and structural analysis of PARP and 
tankyrase inhibitors. Nat Biotechnol 30, 283-288 (2012). 
8. Calabrese, C. R. et al. Anticancer chemosensitization and radiosensitization by the novel 
poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96, 56-67 (2004). 
9. Moroni, F. et al. Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but 
protect cortical cells in models of post-ischaemic brain damage. Br J Pharmacol 157, 854-
862 (2009). 
10. Murai, J. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 
72, 5588-5599 (2012). 
11. Pommier, Y., O’Connor, M. J. & de Bono, J. Laying a trap to kill cancer cells: PARP 
inhibitors and their mechanisms of action. Sci Transl Med 8, 362ps17 (2016). 
12. Murai, J. & Pommier, Y. (eds Curtin, N. J. & Sharma, R. A.) 261-274 (Springer 
International Publishing, Cham, 2015). 
13. Cardnell, R. J. et al. Activation of the PI3K/mTOR Pathway following PARP Inhibition in 
Small Cell Lung Cancer. PLoS One 11, e0152584 (2016). 
14. Soret, M., Bacharach, S. L. & Buvat, I. Partial-volume effect in PET tumor imaging. J Nucl 
Med 48, 932-945 (2007). 
15. Carney, B. et al. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma 
Models. Mol Imaging Biol 18, 386-392 (2016). 
16. Carney, B., Kossatz, S. & Reiner, T. Molecular Imaging of PARP. J Nucl Med 58, 1025-
1030 (2017). 
17. Shen, Y. et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of 
human cancers with DNA repair deficiency. Clin Cancer Res 19, 5003-5015 (2013). 
18. Daniel, V. C. et al. A primary xenograft model of small-cell lung cancer reveals irreversible 
changes in gene expression imposed by culture in vitro. Cancer Res 69, 3364-3373 
(2009). 
19. Hann, C. L. et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small 






1. Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66, 
271-289 (2016). 
2. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in 
elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346, 235-242 (2002). 
3. Roschewski, M., Staudt, L. M. & Wilson, W. H. Diffuse large B-cell lymphoma-treatment 
approaches in the molecular era. Nat Rev Clin Oncol 11, 12-23 (2014). 
4. Küppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5, 251-262 
(2005). 
5. Toledano-Massiah, S. et al. Whole-Body Diffusion-weighted Imaging in Hodgkin 
Lymphoma and Diffuse Large B-Cell Lymphoma. Radiographics 35, 747-764 (2015). 
6. Moskowitz, C. H. & Schöder, H. Current status of the role of PET imaging in diffuse large 
B-cell lymphoma. Semin Hematol 52, 138-142 (2015). 
7. Juweid, M. E. & Cheson, B. D. Role of positron emission tomography in lymphoma. J Clin 
Oncol 23, 4577-4580 (2005). 
8. Juweid, M. E. et al. Response assessment of aggressive non-Hodgkin’s lymphoma by 
integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron 
emission tomography. J Clin Oncol 23, 4652-4661 (2005). 
9. Kasenda, B. et al. 18F-FDG PET is an independent outcome predictor in primary central 
nervous system lymphoma. J Nucl Med 54, 184-191 (2013). 
10. Adams, H. J. et al. FDG PET/CT for the detection of bone marrow involvement in diffuse 
large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 
41, 565-574 (2014). 
11. Purz, S. et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of 
bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. J Clin 
Oncol 29, 3523-3528 (2011). 
12. Jerusalem, G. et al. Persistent tumor 18F-FDG uptake after a few cycles of 
polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. 
Haematologica 85, 613-618 (2000). 
13. Zhang, M. J. et al. Lymph node uptake of 18F-fluorodeoxyglucose detected with positron 
emission tomography/computed tomography mimicking malignant lymphoma in a patient 
with Kikuchi disease. Clin Lymphoma Myeloma Leuk 10, 477-479 (2010). 
14. Skoura, E., Ardeshna, K., Halsey, R., Wan, S. & Kayani, I. False-Positive 18F-FDG 
PET/CT Imaging: Dramatic “Flare Response” After Rituximab Administration. Clin Nucl 
Med 41, e171-2 (2016). 
15. Lesokhin, A. M. et al. Nivolumab in Patients With Relapsed or Refractory Hematologic 
Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol 34, 2698-2704 (2016). 
16. Locke, F. L. et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 
CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther 25, 285-295 (2017). 
17. Chiou, V. L. & Burotto, M. Pseudoprogression and Immune-Related Response in Solid 
Tumors. J Clin Oncol 33, 3541-3543 (2015). 
18. Cancer, G. A. R. N. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat 
Genet 45, 1113-1120 (2013). 
19. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of 
anticancer drug sensitivity. Nature 483, 603-607 (2012). 
20. Aukema, S. M. et al. Double-hit B-cell lymphomas. Blood 117, 2319-2331 (2011). 
21. Savage, K. J. et al. MYC gene rearrangements are associated with a poor prognosis in 
diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114, 
3533-3537 (2009). 
! 185!
22. Hu, S. et al. MYC/BCL2 protein coexpression contributes to the inferior survival of 
activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene 
expression signatures: a report from The International DLBCL Rituximab-CHOP 
Consortium Program. Blood 121, 4021-31; quiz 4250 (2013). 
23. Ortega-Molina, A. et al. The histone lysine methyltransferase KMT2D sustains a gene 
expression program that represses B cell lymphoma development. Nat Med 21, 1199-
1208 (2015). 
24. Flowers, C. R., Sinha, R. & Vose, J. M. Improving outcomes for patients with diffuse large 
B-cell lymphoma. CA Cancer J Clin 60, 393-408 (2010). 
25. Barrington, S. F. et al. Role of imaging in the staging and response assessment of 
lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging 
Working Group. J Clin Oncol 32, 3048-3058 (2014). 
26. Benoist, C., Lanier, L., Merad, M., Mathis, D. & Immunological, G. P. Consortium biology 
in immunology: the perspective from the Immunological Genome Project. Nat Rev 
Immunol 12, 734-740 (2012). 
27. Maraskovsky, E. et al. Dramatic increase in the numbers of functionally mature dendritic 
cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp 
Med 184, 1953-1962 (1996). 
28. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 
480-489 (2011). 
29. Moghbel, M. C. et al. Response Assessment Criteria and Their Applications in Lymphoma: 
Part 1. J Nucl Med 57, 928-935 (2016). 
30. Moghbel, M. C. et al. Response Assessment Criteria and Their Applications in Lymphoma: 
Part 2. J Nucl Med 58, 13-22 (2017). 
31. Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and 
indolent B-cell malignancies can be effectively treated with autologous T cells expressing 
an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology 33, 540-549 (2014). 
32. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using 
the cBioPortal. Sci Signal 6, pl1 (2013). 
33. Thurber, G. M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight 
into drug action in vivo. Nat Commun 4, 1504 (2013). 
34. Carney, B., Kossatz, S. & Reiner, T. Molecular Imaging of PARP. J Nucl Med 58, 1025-
1030 (2017). 
35. Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer 
therapy. Nature 428, 332-337 (2004). 
36. Kossatz, S. et al. Detection and delineation of oral cancer with a PARP1 targeted optical 
imaging agent. Sci Rep 6, 21371 (2016). 
37. Tang, J. et al. Immune cell screening of a nanoparticle library improves atherosclerosis 




1. Reiner, T., Earley, S., Turetsky, A. & Weissleder, R. Bioorthogonal small-molecule ligands 
for PARP1 imaging in living cells. Chembiochem 11, 2374-2377 (2010). 
2. Reiner, T., Keliher, E. J., Earley, S., Marinelli, B. & Weissleder, R. Synthesis and in vivo 
imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-
assisted high-performance method. Angew Chem Int Ed Engl 50, 1922-1925 (2011). 
3. Reiner, T. et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally 
developed companion imaging agents. Neoplasia 14, 169-177 (2012). 
4. Thurber, G. M., Reiner, T., Yang, K. S., Kohler, R. H. & Weissleder, R. Effect of small-
! 186!
molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer 
Ther 13, 986-995 (2014). 
5. Keliher, E. J., Klubnick, J. A., Reiner, T., Mazitschek, R. & Weissleder, R. Efficient acid-
catalyzed 18F/19F fluoride exchange of BODIPY dyes. ChemMedChem 9, 1368-1373 
(2014). 
6. Carlucci, G. et al. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. Mol 
Imaging Biol 17, 848-855 (2015). 
7. Irwin, C. P. et al. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging. 
Neoplasia 16, 432-440 (2014). 
8. Kossatz, S. et al. Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in 
Mouse Models. Cancer Res 77, 2112-2123 (2017). 
9. Lok, B. H. et al. PARP Inhibitor Activity Correlates with SLFN11 Expression and 





1. Syed, Y. Y. Rucaparib: First Global Approval. Drugs 77, 585-592 (2017). 
2. Reiner, T. et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally 
developed companion imaging agents. Neoplasia 14, 169-177 (2012). 
3. Irwin, C. P. et al. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging. 
Neoplasia 16, 432-440 (2014). 
4. Kossatz, S. et al. Detection and delineation of oral cancer with a PARP1 targeted optical 
imaging agent. Sci Rep 6, 21371 (2016). 
5. Kossatz, S., Weber, W. A. & Reiner, T. Optical Imaging of PARP1 in response to radiation 
in oral squamous cell carcinoma. PloS one 11, e0147752 (2016). 
6. Menear, K. A. et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-
2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J 
Med Chem 51, 6581-6591 (2008). 
7. Gillmore, A. T., Badland, M. & Crook…, C. L. Multkilogram Scale-Up of a Reductive 
Alkylation Route to a Novel PARP Inhibitor. … Process Research & … (2012). 
8. Frangioni, J. V. In vivo near-infrared fluorescence imaging. Current opinion in chemical 
biology 7, 626-634 (2003). 
9. Chen, R. F. Fluorescence Quantum Yields of Tryptophan and Tyrosine. Analytical Letters 
1, 35-42 (1967). 
10. Muiño, P. L. & Callis, P. R. Solvent effects on the fluorescence quenching of tryptophan by 
amides via electron transfer. Experimental and computational studies. J Phys Chem B 
113, 2572-2577 (2009). 
11. Deri, M. A., Zeglis, B. M., Francesconi, L. C. & Lewis, J. S. PET imaging with 89Zr: from 
radiochemistry to the clinic. Nucl Med Biol 40, 3-14 (2013). 
12. Holland, J. P. et al. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane 
antigen expression in vivo. J Nucl Med 51, 1293-1300 (2010). 
13. Deri, M. A. et al. Alternative chelator for 89Zr radiopharmaceuticals: radiolabeling and 
evaluation of 3,4,3-(LI-1,2-HOPO). J Med Chem 57, 4849-4860 (2014). 
14. Deri, M. A. et al. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr 
ImmunoPET. Bioconjug Chem (2015). 
15. Gorden, A. E., Xu, J., Raymond, K. N. & Durbin, P. Rational design of sequestering agents 
for plutonium and other actinides. Chem Rev 103, 4207-4282 (2003). 
16. Abergel, R. J., D’Aléo, A., Leung, C. N., Shuh, D. K. & Raymond, K. N. Using the antenna 
effect as a spectroscopic tool: photophysics and solution thermodynamics of the model 
! 187!
luminescent hydroxypyridonate complex [Eu(III)(3,4,3-LI(1,2-HOPO))]-. Inorg Chem 48, 
10868-10870 (2009). 
17. Moore, E. G., Samuel, A. P. & Raymond, K. N. From antenna to assay: lessons learned in 
lanthanide luminescence. Acc Chem Res 42, 542-552 (2009). 
18. Lee, J. J., White, A. G., Rice, D. R. & Smith, B. D. In vivo imaging using polymeric 
nanoparticles stained with near-infrared chemiluminescent and fluorescent squaraine 
catenane endoperoxide. Chem Commun (Camb) 49, 3016-3018 (2013). 
19. Gross, S. et al. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med 15, 
455-461 (2009). 
20. McCapra, F. The chemiluminescence of organic compounds. Q. Rev., Chem. Soc. 20, 485 
(1966). 
21. Vogler, A. & Kunkely, H. Electrochemiluminescence of 
Tetrakis(diphosphonato)diplatinate(II). Angew. Chem. Int. Ed. Engl. 23, 316-317 (1984). 
22. Siraj, N. et al. Fluorescence, Phosphorescence, and Chemiluminescence. Anal Chem 88, 
170-202 (2016). 
23. Moore, E. G., D’Aléo, A., Xu, J. & Raymond, K. N. Eu(III) Complexes of Octadentate 1-
Hydroxy-2-pyridinones: Stability and Improved Photophysical Performance[]. Aust J Chem 
62, 1300-1307 (2009). 
24. Moore, E. G., Xu, J., Jocher, C. J., Corneillie, T. M. & Raymond, K. N. Eu(III) complexes of 
functionalized octadentate 1-hydroxypyridin-2-ones: stability, bioconjugation, and 
luminescence resonance energy transfer studies. Inorg Chem 49, 9928-9939 (2010). 
 
 
